Investigations of the gut innate defences of commercial broilers by Cadwell, Kevin
     
 
 
 
Investigations of the Gut Innate Defences of Commercial Broilers 
 
 
Kevin Keith Cadwell 
 
Thesis submitted for the degree of Doctor of Philosophy 
Institute for Cell and Molecular Biosciences 
Newcastle University 
September 2014 
 
ii 
 
 
Abstract 
The E.U. ban on the use of anti-microbial growth promoters in poultry feed, introduced 
to counter global problems of bacterial antibiotic resistance, has increased the risk of 
enteric disease in commercially reared broiler chickens. Development of strategies to 
prevent such diseases requires further knowledge and understanding of avian gut defences 
and particularly the innate immune defences. In collaboration with Aviagen Ltd., the 
objective of this study was to investigate, through two farm trials, the effects of bacterial 
exposure on host avian β-defensin (AvBD) expression profiles and gut health of two 
commercial broiler lines (X and Y). Furthermore, two host defense peptides, avian beta 
defensin 1 (AvBD1) and 10 (AvBD10) were analysed in vitro for their anti-microbial 
efficacies. 
 
In Trial 1, Lines X and Y, differing in their gut health, were exposed to one of three 
bacterial challenges on the day of hatch, namely a combination of Bacteroides dorei and 
Barnesiella viscericola (B/BV), Lactobacillus johnsonii (LJ) or a mixture of the two 
challenges (B/BV + LJ). At days 4, 7, 14, 21, 28 and 35, birds were scored for gut health 
using an industry approved system and digesta were sampled and analysed for 
microbiotae (pyrosequencing). The data revealed that, relative to control and LJ 
challenged birds, the B/BV challenge was associated with gut health deterioration. 
Furthermore, relative to Line X, there was a trend for the gut health of Line Y birds to be 
superior for all challenged groups. Although microbiome analyses did not reveal any clear 
differences between Lines X and Y, the data did suggest that birds with better gut health 
outcomes were associated with higher ileal Lactobacillus spp. levels at Day 4 and higher 
caecal levels of Bacteroides spp. at Day 21. 
 
Despite less optimal gut health, Line X is important to the Aviagen Ltd. breeding 
programme. To understand the roles, if any, of the AvBDs in bird gut health, a second 
trial was performed in which gut AvBD1 and 10 gene expression were assessed in Line 
X birds following B/BV challenge.  Relative to control birds, the B/BV challenge 
suppressed gene expression of AvBD1 in the duodenum/jejunum (P < 0.05) and AvBD10 
in the duodenum/caecum (P < 0.05) and AvBD1 down-regulation was confirmed at the 
cellular level by data from an in vitro challenge model (P < 0.001). Interestingly, within 
the B/BV challenged group, birds with higher AvBD1 expression were associated with 
better gut health assessments. 
 
The AvBD1 gene contains single nucleotide polymorphisms (SNP) within the region 
encoding region the mature peptide.  Three AvBD1 variants were synthesised that were 
typical to Line X (NYH), Y (SSY) and another commercial Line, Z (NYY), and were 
assessed, together with AvBD10, for in vitro anti-microbial activities (AMAs) against a 
variety of gut bacterial isolates. Despite Line X displaying the least optimal gut health, 
the ‘NYH’ variant exhibited the greatest potency against all bacterial species. The data 
for AvBD10 revealed that, although bacterial growth was inhibited, this peptide had lower 
AMA than AvBD1, indicative of additional physiological functions. An in vitro 
examination of wound healing capacity using a scratch assay was inconclusive.  
 
The in vivo data indicated that gut AvBD expression is susceptible to gene down-
regulation by bacteria and that this, in turn, may have an adverse outcome on gut health. 
However, selectively breeding for birds able to maintain high AvBD expression presents 
a strategy to protect flocks against the threat of endemic gut health problems. 
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1 Introduction 
1.1  Overview of the Poultry Industry  
The UK poultry meat industry has grown dramatically since the 1950s, from 
approximately 5 million birds produced per year to current figures of more than 900 
million (DEFRA, 2014a). Poultry meat production continues to rise and figures released 
from the Department for Environment, Food and Rural Affairs (DEFRA) revealed that 
during 2013 broiler meat production in the UK rose by 5% to 1.4 million tonnes (DEFRA, 
2014b). Increased production has been underpinned by decades of applied research, 
focussed on the genetic selection of individual birds that support a short but efficient 
production cycle. At present the typical time for a broiler chicken to go from hatchery to 
slaughter is 35- 40 days with the average weight at slaughter being over 2.25kg (DEFRA, 
2014a). To remain competitive and profitable, the primary focus of the industry is to 
improve the conversion of feed to body mass, also known as the feed conversion ratio 
(FCR), without compromising bird welfare. In 2012 the Aviagen FCR for poultry was 
reported to be as low as 1.38 using Ross broilers (Aviagen, 2012) i.e.   1.38 kg of feed is 
required to increase bird mass by 1kg. Comparison of typical FCRs across the farming 
sector demonstrates that poultry is, agriculturally, an efficient source of meat protein 
production. For example, in 2011 the FCR for beef production was 8.8 (Wilkinson, 2011), 
2.9 – 3.9 for lamb (Wilkinson, 2011) while 3 was the EU average for pigs (BPEX, 2012).  
 
Although demand for free range chicken has increased over recent years (Martinez 
Michel et al., 2011), the vast majority of broiler chickens are reared intensively in 
purposely built barns, which house large numbers of birds, typically over 10,000. 
Although this type of intensive farming meets the high customer demand, the high 
stocking densities adopted can increase the susceptibility of birds to disease and facilitate 
the spread of infection, in addition to increasing welfare-related conditions such as 
footpad dermatitis and hock burn (Buijs et al., 2009; Estevez, 2007). However, despite 
the potential for disease, knowledge about the involvement & roles of the host immune 
defences in protecting birds in low hygiene situations, more reflective of conditions in 
commercial situations, is lacking. Hence for the UK to maintain a healthy & competitive 
poultry industry there is a requirement for the industry to start genetically selecting birds 
for disease resistance (Stear et al., 2001;  Kaiser, 2010).  
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1.2  Genetic Selection in the Poultry Industry (Aviagen Ltd.) 
According to their website, Aviagen Ltd. (www.aviagen.com) are the global leaders in 
poultry genetics and supply day-old chicks to customers in 130 countries worldwide 
under the brand names Ross, Arbor Acres and Indian River. Each brand has specific 
characteristics that are tailored to specific global markets. For example, Ross broilers are 
divided into Ross 308, said to be the world’s most popular broiler with balanced and 
versatile characteristics, Ross 708 bred for high yields, and Ross PM3 suitable for farms 
in which feed and space are at a premium and uniform birds are required. More recently 
birds have been selected that are more suitable for free range and organic farming such 
as the Rowan Ranger®, a slower growing bird launched into the European market in 2013 
(www.aviagen.com). The selective breeding programme adopted by Aviagen Ltd is 
structured as a hierarchal pyramid (Figure 1.1). Genetic improvement takes place in pure 
lines at the top of the pyramid (pedigree selection) where phenotypes are measured for a 
broad range of traits which can be summarised as broiler, breeder, health and welfare 
traits. For example, breast meat yield (bird size), FCR (feed efficiency) and leg strength 
(to support heavier birds) are three important broiler traits for intensive production. For 
these traits, breeding values are estimated using statistical tools such as Best Linear 
Unbiased Prediction (BLUP) which, in turn, informs multi-trait selection (personal 
correspondence, Dr Kellie Watson, Aviagen Ltd.).  
 
As shown in Figure 1.1, it can take 4 – 5 years for the genetic improvements to be 
transmitted to the commercial broiler population. The pedigree birds are housed in tightly 
controlled high hygiene facilities to preserve the pathogen free status of the elite stock. 
However, it is vital that information is obtained on how they perform under conditions 
more reflective of commercial environments.  It is likely that birds with different 
genotypes will respond to the environmental conditions in different ways and such 
genotype-by environment (G×E) interactions have been demonstrated in broilers. For 
example, G X E interactions have been demonstrated in low and high hygiene 
environments and linked to both growth and mortality (Ye et al., 2006; Long et al., 2008). 
Therefore, to investigate the robustness of birds with different genotypes under 
commercial farming conditions, the performance of the elite-stock siblings is assessed in 
lower hygiene environments (sib-testing). 
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Figure 1.1: The selective breeding structure of the poultry industry  
Figure provided courtesy of Aviagen Ltd (K. Laughlin) and adapted. GGP = great-grandparent 
stock. 
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1.3  Enteric Diseases in Poultry  
Enteric diseases present serious health and welfare problems to the birds and are an 
economic challenge to the industry. Enteric problems in poultry can often be complex 
and are caused by pathogenic bacterial infections, parasites and viruses resulting in a 
physical, chemical or biological disturbance. Examples include necrotic enteritis 
(Timbermont et al., 2011), coccidiosis (Chapman, 2014) and more recently the syndrome 
dysbacteriosis (Teirlynck et al., 2011). 
 
Necrotic enteritis (NE) was first described in 1961 (Parish, 1961) and has been reported 
in most poultry producing countries (McDevitt et al., 2006). The condition is 
characterised by severe intestinal lesions particularly located to the jejunum (Long et al., 
1974). The disease is caused by Clostridium perfringens and the toxins produced cause 
the lesions typical with this disease. Infections by Clostridium perfringens may be acute 
(Shane et al., 1985), or subclinical resulting in decreased weight gain and reduced nutrient 
absorption leading to poor feed conversion ratios (Lovland et al., 2004). Clostridium 
perfringens is a normal part of the gut flora and, for the bacteria to cause pathogenesis, 
predisposing factors such as concurrent coccidiossis and diets high in Non Starch 
Polysaccharides (NSPs) and animal proteins such as fish meal are likely to be important 
(Kocher, 2003; Van Immerseel et al., 2004; McDevitt et al., 2006). NSPs increase the 
viscosity of the digesta leading to increased bacterial fermentation in the proximal gut 
(Choct et al., 1996), and diets that contain fish meal are high in amino acids glycine and 
methionine that stimulate C. perfringens proliferation (Kocher, 2003; Dahiya et al., 
2007).   
 
Coccidiossis is caused by Eimeria, a protozoan that infects birds via ingestion of oocysts 
found in the litter. In brief, the mechanism of action involves the attachment of sporocysts 
to the intestinal epithelium, which undergo asexual and then sexual reproduction to 
produce more oocysts that are released into the faeces. Due to the intensive nature of 
broiler production and the constant contact with litter the condition is spread rapidly. Such 
infections present as haemorrhagic diarrhoea, resulting in poor FCR and increased bird 
mortality. The first attempts at modelling the monetary costs to the broiler industry 
revealed losses due to the disease to be in excess of £38m per year in the UK (Williams, 
1999) and $800m in the U.S (Williams, 1998). A recent review has estimated the global 
impact of coccidiosis to be in excess of $3 billion per year (Blake and Tomley, 2014). 
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The poultry industry controls coccidiosis using hygiene control and pen management, and 
broad-spectrum anticoccidial drugs such as monensin (Chapman et al., 2010). 
 
Dysbacteriosis is the term used to describe a digestive condition possibly caused by 
excess growth of intestinal microbiota resulting in non-specific enteritis (McMullin, 
2004, Bailey, 2010). Interestingly, the incidence of dysbacteriosis has increased in recent 
years although the reasons are unclear. The result of this condition is a decrease in food 
absorption affecting the FCR and the production of wet litter, which is foamy and orange 
in appearance. Wet litter can lead to additional health problems including pododermatitis 
(Shepherd and Fairchild, 2010), and hock-burn (Hepworth et al., 2011). In turn these 
welfare problems impact upon the industry through increased production costs due to 
both the requirement for antibiotic treatment and decreased bird growth (Flemming, 
2008). Although diagnosis is not straightforward, the assessment criteria includes a visual 
examination of the faeces, monitoring fluctuations in water content and checking for poor 
uniformity of growth across the hatch. An early detection method uses a scoring system 
based on water content in the faeces (Mortimer, 2002). Other monitoring techniques 
based on faecal water content include using a faecal fluid finder to obtain the ratio of solid 
matter to liquid (Bailey, 2010).  
 
1.4  Antimicrobial Growth Promoters (AGPs) 
In the 1940’s the by-product of tetracycline fermentation was fed to chicks as a potential 
source of vitamin B12 but produced an additional ‘unintended’ benefit of significantly 
improving bird growth (Moore et al., 1946; Stokstad et al., 1949).  Although, the exact 
mechanism of action is controversial, one proposal is that these antimicrobial growth 
promoters (AGPs) suppress growth of the normal microflora leading to a reduction of 
microbial metabolites that would otherwise suppress growth (Visek, 1978; Knarreborg et 
al., 2004; Dibner and Richards, 2005). In the following 50 years AGPs were routinely 
added to livestock feed, a practice that helped drive and support the proliferation of 
intensive farming in the 1950s and 1960s. Indeed, although intensive farming increased 
the risk of disease and its spread, AGPs added to feed helped control outbreaks in gut 
health diseases. Examples of AGPs that were once commonly used in the E.U. are 
virginiamycin, avoparcin, tylosin, spiramycin, bacitracin, olaquindox, carbadox and 
tetracycline (Castanon, 2007) (Figure 1.2). 
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Despite the economic benefits in terms of disease control and improved FCR, opposition 
to the use of AGPs has arisen due to concerns over the proliferation of antibacterial 
resistant strains (Barton, 2000). For example, drug-resistant Enterococcus faecium strains 
have been isolated in chickens following administration of feed supplemented with sub-
therapeutic levels of virginiamycin (Donabedian et al., 2003) and it has been shown that 
antibiotic resistant genes can be transmitted from animal to human microbiota (Greko, 
2001). However, the relationship between AGP use in animal production and antibiotic-
resistant infections in humans is still debated (McDermott et al., 2002; Phillips et al., 
2004a; Phillips et al., 2004b; Walsh and Fanning, 2008). Nevertheless, following WHO 
recommendations the EU commission initiated a phased ban on many of these AGPs in 
1999, which was fully operational by 2006 (EC Regulation No. 1831/2003). Denmark 
was the first country to voluntarily ban AGPs actually prior to the enforcement by the EU 
in 2006 and provided a good case study for the consequences of the ban. Interestingly, 
poultry productivity was not significantly affected by the ban, but from 1996 to 2002, it 
was linked to a doubling in the therapeutic use of the anticoccidial salinomycin, most 
likely reflecting an attempt to reduce the incidence of necrotic enteritis (WHO, 2003). 
Since the EU ban there has been, as seen in Denmark, an increase in poultry enteric 
problems, particularly necrotic enteritis and dysbacteriosis, associated with a 
corresponding increase in therapeutic antibiotic use throughout Europe to counteract 
these diseases (Hughes et al., 2008; Van Immerseel et al., 2009). Therefore, to protect 
against enteric disease, whilst circumventing the threat of antibiotic resistance, new 
strategies/agents are required.  
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Figure 1.2: Chemical structures of a selection of antimicrobial growth promoters used in 
poultry feed prior to E.U. restrictions (EC Regulation No. 1831/2003). 
Structural information taken from PubChem (https://pubchem.ncbi.nlm.nih.gov/), DrugBank 
(http://www.drugbank.ca/) and ChemSpider 
(http://www.chemspider.com/StructureSearch.aspx). Unique ID is shown for each compound. 
Avoparcin (ChemSpider ID16736403) Bacitracin (Drugbank DB00626)
Carbadox (PubChem CID5353472) Olaquindox (PubChem CID71905)
Spiramycin (PubChem CID 5356392) Tetracycline (Drugbank DB00759)
Virginiamycin (Drugbank DB01669) Vancomycin (Drugbank DB00512)
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1.5  Gut Microbiota 
The formation of the gut microbiome, i.e. the establishment of a bacterial population 
within the host intestine, is an important step in protecting the host from gastrointestinal 
(GI) disease. Commensal bacteria can form protective biofilms, which prevent attachment 
of pathogenic bacteria to the underlying epithelia (Baranov and Hammarstrom, 2004; 
Granato et al., 2004) and facilitate mucosal immune development (Round and 
Mazmanian, 2009). Evidence from studies using germ-free (no gut flora) mice versus 
specific-pathogen free (SPF) or normal mice have illustrated the role of the normal gut 
flora in the development of a healthy and immunologically competent gut. Indeed, Germ-
Free (GF) mice exhibited broad defects in the maturation of gut associated lymphoid 
tissue (GALT) such as isolated lymphoid follicles (Bouskra et al., 2008), poorly 
functioning Peyer’s Patches, reduced numbers of IgA producing cells (Macpherson et al., 
2001) and altered intestinal gene expression profiles (Hooper et al., 2001).  Such defects 
were however, reversible by colonising GF mice with commensal bacteria from SPF mice 
(Macpherson and Harris, 2004). Although such studies were focussed in mammals it is 
possible that these data can be extrapolated to other vertebrates including birds.  
 
Intensive poultry farming is unusual in relation to other livestock production in that chicks 
are hatched in the relatively sterile environment of a hatchery and have no direct parental 
contact. Therefore, the post-hatch development of the microbiota is likely to be facilitated 
by exposure to non-parental sources such as litter, transport conditions and human 
handling and furthermore, Stanley et al., (2013) have indicated these factors contribute to 
the high variability in microbiota composition between birds. Nevertheless, the broad 
pattern is for bacterial density to increase from the proximal (duodenum, jejunal) to the 
more distal regions of the gut reaching a maximum level in the caeca of 1012 per gram of 
digesta (Gong et al., 2002a). Furthermore, each section of the chicken gut has a distinctive 
population profile. In simple terms, the caecum hosts a wide variety of microflora (Mead, 
1989) compared to the small intestine in which 98% of the bacteria is composed of 
Lactobacilli (Gong et al., 2007). In addition to the immediate post-hatch exposure, the 
composition of commensal bacteria is influenced by factors such as bird age, disease, 
antibiotic use and diet.  The latter is thought to be a critical factor in determining the 
composition of the microbiota, with for example, diets high in barley shown to enhance 
the growth of Lactobacillus, while oat-based diets have been associated with an increase 
in Escherichia spp. (Apajalahti et al., 2004).  
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Gong et al., (2002b) compared the microbial populations of the bird ilea and caeca using 
molecular analysis of 16S rRNA genes and reported a more diverse bacterial population 
in the cecum. For both tissues, the major species identified were Lactobacilli, 
Enterococcus cecorum and various types of butyrate-producing bacteria, which the 
authors suggested may be a useful target for novel probiotics (Gong et al., 2002b). In a 
similar study, an examination of 16S rRNA genes through denaturing gradient gel 
electrophoresis (DGGE), revealed that as broilers age the number of bands on the DGGE 
gel increased indicating further complexity of the microbiota (van der Wielen et al., 
2002).  
 
Antibiotic treatments have been shown to alter the types of bacteria in the GI tract. An 
early study investigating the effect of AGPs on the broiler GI demonstrated that the AGP 
zinc bacitracin, in conjunction with salinomycin, decreased numbers of C. perfringens 
and inhibited the Lactobacillus salivarius throughout the length of the GI tract (Engberg 
et al., 2000). Crucially, a significant increase in bird growth was also observed with the 
combined treatment, which infers that high levels of L. salivarius may suppress broiler 
growth. Zhou and colleagues, using PCR-DGGE, also showed that the dietary antibiotics 
virginiamycin and bacitracin methylene disalicylate affected the chicken microbiota in a 
dose and age dependent manner, with three of the groups affected identified as Klebsiella 
granulomatis, Enterococcus sp. AK61 and Lactobacillus salivarius (Zhou et al., 2007). 
Quantitative real-time PCR revealed that Lactobacillus salivarius was particularly 
sensitive to dietary virginiamycin (22 ppm), being completely inhibited relative to the 
control group at 3, 7 and 14 days (Zhou et al., 2007).  
 
Further advances in high-throughput sequencing, such as 454 pyro-sequencing, have now 
enabled the microbial populations to be phylogenetically profiled in diseased and 
challenged broilers (Stanley et al., 2012). A comparison of the microflora in birds 
challenged with C. perfringens, to induce necrotic enteritis, and non-treated control birds 
revealed distinct microbial communities populating the guts of the healthy and diseased 
birds (Stanley et al., 2012). In diseased birds, C. perfringens was increased, reducing the 
abundance of other Clostridia (P < 0.05). Significant changes were also observed within 
Lactobacillus spp., with challenged birds harbouring both higher (e.g. L. crispatus, L. 
salivarius), and lower (e.g. L. johnsonii) relative abundances compared to controls (P 
<0.05). A key finding was that Weissella confusa was only present in healthy birds, 
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suggesting that this species disappears following C. perfringens infection (Stanley et al., 
2012).  
 
Although C. perfringens has been demonstrated to be the most important microorganism 
in the aetiology of necrotic enteritis, less is known about the microbial perturbations 
associated with other disease states. However, qualitative analyses using DGGE has 
revealed that birds with dysbacteriosis have an altered caecal and small intestinal 
microbiota characterised by the presence of various members of the Bacteroidetes 
(Bacteroides dorei, Barnesiella viscericola, Bacteroides ovatus, Bacteroides vulgatus 
and Barnesiella viscericola) in the caeca, and Lactobacillus aviarius, Escherichia coli 
and Bacteroides vulgatus in the small intestine (Bailey, 2010).  
 
Such studies reveal that the composition of microbiota influences bird growth and thus, 
further exploration & knowledge of the microbiomes of different genetic lines raised in 
different environments may provide the poultry industry with new markers to select for 
robust birds with improved disease resistance.  
 
1.6  Immunity in the Chicken GI tract 
Due to the intensive rearing conditions increasing the risk of diseases, including those 
linked to the gastrointestinal tract, it is clear that a successful poultry industry relies upon 
an understanding of the chicken immune system. Of particular importance is the innate 
immune system as newly hatched chicks lack adaptive immunity (Korver, 2006).  At this 
critical stage of development, chicks are also protected by maternally-derived antibodies 
which have been transferred via the egg yolk, until the endogenous immune system 
develops (Hasselquist and Nilsson, 2009). Although humoral or antibody-mediated 
immunity starts to develop at 5 days, birds utilise the maternal immunoglobulin Y up to 
day 13 (Rose and Orlans, 1981; Apanius, 1998). Maternal antibodies have been shown to 
protect against infectious bursal disease (Goddard et al., 1994), but their efficacy can be 
affected by the diet fed to young birds (Kidd, 2003; Leandro et al., 2011).  
 
Protection against exogenous pathogens in the GI tract is conferred through the innate 
defences that are relatively non-specific and include the physical epithelial/mucosal 
barrier, mucin secretion, chemical factors such as pH and bile acids to lower pH, as well 
as innate effector molecules. As part of the innate defence system eukaryotic host cells 
express pattern-recognition receptors (PRRs) on their surface, which recognise pathogen-
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associated molecular patterns (PAMPs) specific to microbes. Toll-like receptors (TLRs) 
are key sensory PRRs that are evolutionary conserved and appear to be widespread 
throughout the animal kingdom (Roach et al., 2005). These membrane proteins contain 
an extracellular ligand-binding domain that varies in its structure, and hence ligand 
specificity, between TLR forms (Kang and Lee, 2011). Bioinformatic comparisons of 
human and chicken TLRs (chTLRs) revealed a number of orthologs but also identified 
TLRs unique to chickens namely chTLR15 and chTLR21 (Temperley et al., 2008). No 
ortholog of the mammalian DNA binding TLR9 molecule is found in the chicken, but this 
function can be performed through chTLR21 (Brownlie et al., 2009; Keestra et al., 2010). 
PAMPS that have been demonstrated to activate TLR-signalling include 
lipopolysaccharide (LPS) (ligand for chTLR4), CpG-DNA (ligand for chTLR21), 
flagellin (ligand for chTLR5) and various forms of lipopeptide (ligands for 
chTLR2t1/chTLR16/ TLR2t1/TLR1LB) (Keestra et al., 2013). In mammalian cells 
PAMP ligands activate TLR signalling by inducing TLR dimerisation, which in turn 
activates a MyD88-dependent pathway leading to the up-regulation, often through NF-
kappa B or activating protein 1 (AP-1) signalling, of pro- and anti-inflammatory 
molecules such as cytokines, chemokines and host defense peptides (HDPs) (Kawai and 
Akira, 2006; Kawai and Akira, 2007). It is probable although not proven that similar 
mechanisms exist in the chicken. A number of studies have utilised PAMP ligands to 
assess immune responses in chicken cells.  Chicken heterophils have been shown to 
express many TLR sub-sets and the TLR 4 agonist lipopolysaccharide (LPS) was shown 
to induce the expression of pro-inflammatory cytokines such as the interleukins, IL-6, IL-
8 and IL-1β (Kogut et al., 2005). This up-regulation of pro-inflammatory cytokine 
expression was also observed in vivo in the spleen (St Paul et al., 2011). These authors 
also revealed that the TLR21 agonist CpG-ODN can induce a Th1-like response 
evidenced by IL-13 suppression and interferon-gamma (IFN-ɣ) up-regulation (St Paul et 
al., 2011). In addition, TLR agonists have been investigated with the aim of priming the 
immune response against gut-related pathogens such as Salmonella enteritidis 
(Swaggerty et al., 2012) and Eimeria acervulina (Dalloul et al., 2004). 
 
Analyses of the chicken genome has now identified the majority of immune signalling 
molecules including cytokines such as ILs, chemokines, IFNs, transforming growth 
factors (TGFs) and tumor necrosis factor superfamily (TNFSF) members (Kaiser et al., 
2005). In broad terms, many of these molecules can be grouped into those that are pro-
inflammatory including IL-1β, IL-6, IL-17, TNFs and IFN-ɣ and those that are anti-
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inflammatory such as IL-10 and TGF-β. It is proposed that to maintain healthy gut host-
commensal interactions a balancing act exists between pro- and anti-inflammatory 
signalling,  (Brisbin et al., 2008), and yet is primed to respond effectively to exogenous 
pathogens (Lavric et al., 2008). For example, in response to Salmonella challenge the 
chemokines CXCLi1 and CXCLi2 were significantly up-regulated (Cheeseman et al., 
2008) and furthermore, high constitutive expression of these genes was associated with 
Salmonella resistant lines (Swaggerty et al., 2014). 
 
Many of the host-defense peptides synthesised by epithelia and antigen presenting cells 
were initially studied for their anti-microbial properties and designated as anti-microbial 
peptides (AMPs) (Boman, 2003). Following numerous studies which showed these 
peptides capable of stimulating other immune functions, the term host defense peptide 
(HDP) were adopted (Steinstraesser et al., 2011). A huge variety of HDPs have now been 
characterised across a variety of species and the majority exert a broad action against 
microbes through membrane disruption that is driven by their cationic (positively 
charged) and amphipathic nature i.e. spatially distinct regions of positively charged and 
hydrophobic residues (Ganz, 1999; Zasloff, 2002). Based on structural differences, three 
groups of AMPs or HDPs have been proposed: α-helical conformation e.g. cathelicidins; 
three disulphide bridges between cysteine residues e.g. defensins (Ganz, 2005); β-hairpin 
with one or two disulphide bonds e.g.hepcidin (Bulet et al., 2004).  
 
1.7  Host defense peptides and microbiota 
In mammalian cells it has been shown that human-defensin 5, secreted from Paneth cells 
in intestinal crypts, is able to influence the microbiota composition of the small intestine 
(Salzman et al., 2010). Using transgenic mice able to express human defensin-5 (HD-5) 
and MMP7 KO mice which lack matrix metalloproteinase 7 (MMP7) which is required 
to cleave the propeptide to produce active defensin, Salzman et al. (2010) were able to 
induce significant shifts in bacterial species. Analyses of the microbiota from mice which 
were able to express HD5 had lower percentage Firmicutes and higher percentage of 
Bacteroidetes. As part of the decrease in Firmicutes a complete loss of segmented 
filamentous bacteria (SFB) was found in the active HD5 expressing mice. SFB are unique 
in that they are in direct contact with epithelial cells (Snel et al., 1995) and have also been 
shown to stimulate Th17 cells (Ivanov et al., 2009), which have been implicated in tissue 
damage associated with autoimmune diseases (Steinman, 2007). To date this is the only 
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study on the relationship between microbiota composition and defensins and, in addition, 
this study was on human alpha-defensins which are not present in birds (van Dijk et al., 
2008). Nevertheless, the work of Salzman indicated that host defence peptides exert 
influence on commensal bacteria and are not just important in protecting against 
exogenous pathogenic bacteria. Therefore, this suggests there may be a relationship 
between avian HDP expression and the GI microbiome but, to date, no studies have been 
performed to confirm this. 
 
1.8 Avian Host defense peptides  
Avian host defense peptides can be broadly grouped into two main families: cathelicidins 
(Xiao et al., 2006) and defensins (van Dijk et al., 2008), the latter of which are sub-divided 
into the beta-defensins (van Dijk et al., 2008) and the egg white expressed ovo-defensins 
(Gong et al., 2010). In addition,  other individual peptides have also been identified and 
include the saposin-like NK-lysin (Hong et al., 2006), named due its presence in Natural 
Killer (NK) cells, and chicken liver-expressed antimicrobial peptide (cLEAP) (Townes 
et al., 2004). 
 
1.9  Cathelicidins 
Cathelicidins are alpha-helical cationic peptides that display both potent anti-microbial 
activity and a range of immunomodulatory properties (Zanetti, 2005). They exist as 
prepropeptides containing a signal peptide at the N-terminus which is cleaved prior to 
secretion, a cathelin-like domain and a C-terminal mature peptide (Figure 1.3). The 
mature peptide is activated once the pro-cathelin-like domain is cleaved. The initial 
discovery of Cathelicidin-1 in the chicken was through a bioinformatics approach that 
screened a library of chicken expressed sequence tags (ESTs) (Lynn et al., 2004). This 
was then followed by the identification of three other peptides; Cathelicidin-2 (van Dijk 
et al., 2005) Cathelicidin-3 (Xiao et al., 2006) and Cathelicidin-B1/Cathelicidin-4 
(exclusive to the bursa of Fabricus) (Goitsuka et al., 2007). With the exception of CATH-
B1/CATH-4, which is mainly expressed in the bursa of Fabricus, the cathelicidins are 
expressed across many tissues, including the GI tract (Achanta et al., 2012), although it 
was discovered that the CATH-2 peptide is located in heterophils that are recruited to the 
site of infection, rather than in intestinal epithelial cells (van Dijk et al., 2009b). CATH-
1, 2 and 3 all display potent anti-bacterial activity against both gram-negative and positive 
strains (Xiao et al., 2006), and CATH-2 was shown to be active against gut isolates of S. 
14 
 
typhimurium, S. enteritidis, E. coli and C. perfringens (van Dijk et al., 2009b). In addition, 
CATH-1 and 2 exert immunomodulatory functions such as binding lippolysaccharide 
(LPS) preventing the LPS-mediated induction of pro-inflammatory cytokine expression 
(Xiao et al., 2006) and CATH-2 can also induce the expression of monocyte chemotactic 
protein 1 (MCP-1) (van Dijk et al., 2009a). The broad-spectrum anti-microbial activity 
coupled to their immune-boosting functions suggests that cathelicidin-based peptides are 
potential candidates as a long-term replacement for conventional antibiotics and AGPs 
(van Dijk et al., 2011). 
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Figure 1.3: The 3D structures of the three chicken anti-cathelicidins 
The three-dimensional structures of A) cathelicidin-1 (Xiao et al., 2006), B) cathelicidin-2 (Herrera et al., 2007) and C) cathelicidin-3 (Bommineni et al., 2007) as 
deposited in the RCSB protein data bank (http://www.rcsb.org) 
Solution structure of Fowlicidin-1 
(CATH-1)
PDB ID: 2AMN
Solution structure of
Fowlicidin 3 (CATH-3)
PDB ID: 2HFR
NMR structure of Fowlicidin-2 (CATH-2)
PDB ID: 2GDL
B C
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1.10  Avian Defensins  
Structurally, all defensins comprise of a β sheet-fold and six conserved cysteine residues 
that form three disulphide bridges (Ganz and Lehrer, 1994) (Figures 1.4 and 1.5).  
According to their cysteine to cysteine bonding patterns, defensins are grouped as alpha 
(α) (1–6, 2–4, 3–5), beta β (1–5, 2–4, 3–6), and theta (θ) (1-6, 2-5, 3-4) (Lehrer and Ganz, 
2002). Both α and β defensins are found in mammals, θ-defensins are only active in 
primates (Tang et al., 1999) and interestingly avian species exclusively express β-
defensins. Avian beta-defensin (AvBDs) gene sequences have been identified not only in 
the chicken (Lynn et al., 2004; Xiao et al., 2004), but also in the turkey (Zhao et al., 2001), 
mallard duck (Ma et al., 2012a), quail (Wang et al., 2010), king pigeon (GenBank: 
ABI20694.1), ostrich (Sugiarto and Yu, 2006) and king penguin (Thouzeau et al., 2003). 
 
1.10.1  Chicken avian beta-defensins (AvBDs) 
The first AvBDs were isolated from leukocytes and heterophils of the chicken, and were 
initially named chicken heterophil peptides CHP1 and CHP2 (Evans et al., 1994). In that 
same year, another group reported the isolation from chicken leukocytes of AMPs that 
had homology to the bovine β-defensins, and designated the peptides as ‘gallinacins’ 
(Harwig et al., 1994). The remaining AvBD genes were later identified using an in silico 
approach that first identified AvBD3 in 2001 (Zhao et al., 2001). Later, sequences for 
AvBDs 4 – 13, were reported in two key 2004 studies (Lynn et al., 2004; Xiao et al., 
2004), closely followed by the discovery of the AvBD14 sequence (GenBank ref: 
AM402954.1)(Soulier, 2006).  In 2007, a standard nomenclature was proposed based on 
the numbering system of Xiao et al. (2004), replacing the term ‘gallinacin’ with ‘avian 
beta-defensin’ (Lynn et al., 2007). 
 
1.10.2  Ovo-defensins 
Three forms of an in ovo defensin, Gallin, were identified that exhibited homology to egg 
white proteins from other species including the turkey (meleagrin) and swan (cygnin) and 
closely resembled the AvBD family (Gong et al., 2010). Indeed, Gallin consists of a 
conserved six-cysteine motif although the number of amino acids between cysteines 
differs from the classical AvBDs. Structural studies utilising Nuclear Magnetic 
Resonance (NMR) spectroscopy confirmed that Gallin shares all the structural features 
of the AvBDs, but contains an additional two stranded beta-sheet (Herve et al., 2014). 
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Moreover, the anti-microbial activity of Gallin was confirmed against E. coli although 
not against any of the other bacterial strains tested namely S. enteritidis, S. typhimurium, 
S. aureus and L. monocytogenes (Herve et al., 2014). 
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Figure 1.4: The 3D structures of two avian beta-defensins  
The three-dimensional structures of A) chicken AvBD2 (Derache et al., 2012) and B) king 
penguin beta-defensin (spheniscin-2) (Landon et al., 2004) as deposited in the RCSB protein data 
bank (http://www.rcsb.org).  
 
 
 
 
 
 
Figure 1.5: The three- dimensional structure of ovo-defensin  
Three-dimensional structure was determined by NMR (Herve et al., 2014) and deposited in the 
RCSB protein data bank (http://www.rcsb.org)  
  
NMR structure of Chicken AvBD2
PDB ID: 2LG5 PDB ID: 1UT3
Solution structure of Spheniscin-2A B
NMR structure of hen egg beta-
defensin gallin (chicken ovo-defensin)
PDB ID: 2MJK
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1.10.3  Genomics and SNPs in the chicken AvBDs 
All the AvBDs identified to date have been located to a single 86kb cluster on 
chromosome 3 (3q3.5–q3.7), and with the exception of AvBD12, contain four exons that 
are translated to produce AvBDs as prepropeptides containing a signal peptide, a propiece 
and a mature peptide. The signal peptide sequence is encoded by exon 2, the peptide 
propiece is encoded for by exons 2 and 3, and the mature peptide is encoded by exons 3 
and 4 respectively (Figure 1.6).  
 
Despite being evolutionary conserved, natural allelic variation has been identified within 
human defensins (Jurevic et al., 2003; Prado-Montes de Oca et al., 2006), and aided by 
the sequencing of the chicken genome (Wallis et al., 2004) single nucleotide 
polymorphisms (SNPs), have also been reported in the AvBDs. An analysis of five 
candidate defensins (AvBD2, 3, 4, 5 and 7) revealed the presence of SNPs at a mean rate 
of 13.2 per kb, and moreover, SNPs in AvBD3 and 7 were associated with antibody titres 
following S. Enteritidis vaccination suggesting that SNPs in the AvBDs may be markers 
of disease susceptibility (Hasenstein et al., 2006). In addition, a genome-wide study of 
three commercial broiler lines (X, Y and Z) revealed the presence of 15 SNPs within the 
AvBD genome including three SNPs in the mature peptide of AvBD1. To date, these 
three non-synonymous SNPs have yet to be fully investigated for their effects on anti-
microbial activity, but notably were found at variable frequencies in birds that differ in 
susceptibility to enteric problems (Butler, 2010). 
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Figure 1.6: Genomic organisation of the chicken AvBDs  
A) The relative positions of each AvBD (1 – 14) on chromosome 3 (3q3.5–q3.7) are 
shown. The width of each vertical block represents the size of each gene and the 
direction of transcription is arrowed.  
B) AvBDs contain four exons that encode a signal peptide (green), pro-peptide (red) and 
mature peptide (black).  
Figure adapted from Xiao et al. (2004) and Cuperus et al. (2013).  
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1.10.4  Structure of chicken AvBDs  
A comparison of the primary structures of the 14 AvBD mature peptides reveals that they 
are 36 – 82 amino acids in length and all contain a six cysteine sequence motif: C-x2-4-G-
x1-2-C-x3-5-C-x9-10-C-x5-6-CC-xn. Typically, these peptides are enriched for positively 
charged amino acids such as arginine and lysine resulting in cationic properties i.e. a 
positive net charge at physiological pH. The primary sequences and charge at pH7 for all 
the chicken AvBDs are shown in Table 1.1. AvBD11 is unusual in that it contains a large 
post-piece comprising a six cysteine defensin-like motif, postulated to have arisen from 
gene duplication (Herve-Grepinet et al., 2010). In addition, AvBD3 and 13 also contain 
large post-pieces relative to the other AvBDs, although their functions, if any, are 
unknown. Other functional differences between the AvBDs are likely to exist due to post-
translational modifications, for example AvBD1 and 7, but not AvBD2 exhibit C-terminal 
amidation (Derache et al., 2009b). Amidation has been shown to stabilise structural 
features and enhance activity (Shalev et al., 2002) and provide resistance against 
proteolytic degradation (Stromstedt et al., 2009). The ability of defensins to form dimers 
has been revealed for hBD3 and is thought to be the reason for its increased anti-microbial 
potency against S. aureus, relative to hBD1 and 2 which are more likely to be monomeric 
(Schibli et al., 2002), although homology modelling has suggested hBD2 may also form 
dimers (Suresh and Verma, 2006). Therefore, it is likely that AvBDs, in vivo, may also 
form dimers, as shown for duck AvBD2 (Soman et al., 2009b) although, to date, 
dimerisation has not been reported for the chicken AvBDs. No X-ray crystallography 
structures have been reported for the AvBDs but Nuclear Magnetic Resonance (NMR) 
spectroscopy has allowed the tertiary structures, of AvBD103b (Landon et al., 2004), a 
king penguin defensin, and chicken AvBD2 (Derache et al., 2012) to be modelled. Both 
these peptides were revealed to form the characteristic three-stranded beta-sheet, and 
contained both hydrophobic and positive residues on the outer surface (Derache et al., 
2012).  
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Table 1.1: Amino acid sequences for the mature peptide regions of AvBD1 - 14 
 
AvBD GenBank 
Protein ID 
Amino acid sequence of the mature peptide Net charge 
at pH 7 
1 AAB30584 GRKSDCFRKSGFCAFLKCPSLTLISGKCSRFYLCCKRIWG 8 
2 AAB30585  LFCKGGSCHFGGCPSHLIKVGSCFGFRSCCKWPWNA 4 
3 Q9DG58  TQCRIRGGFCRVGSCRFPHIAIGKCATFISCCGRAYEVDALNSVRTSPWLLAPGNNPH 5 
4 AAS99318 RYHMQCGYRGTFCTPGKCPYGNAYLGLCRPKYSCCRWL 6 
5 AAS99320 GLPQDCERRGGFCSHKSCPPGIGRIGLCSKEDFCCRSRWYS 3 
6 AAS99315 SPIHACRYQRGVCIPGPCRWPYYRVGSCGSGLKSCCVRNRWA 7 
7 AAS99316 RPIDTCRLRNGICFPGICRRPYYWIGTCNNGIGSCCARGWRS 6 
8 AAU07922 NNEAQCEQAGGICSKDHCFHLHTRAFGHCQRGVPCCRTVYD 0 
9 AAS99317 ADTLACRQSHGSCSFVACRAPSVDIGTCRGGKLKCCKWAPSS 4 
10 AAS99319 DPLFPDTVACRTQGNFCRAGACPPTFTISGQCHGGLLNCCAKIPAQ 1 
11 AAT45551 LPRDTSRCVGYHGYCIRSKVCPKPFAAFGTCSWRQKTCCVDTTSDFHTCQDKGGHCVSPKIRCLEEQLGLCPLKRWTCCKEI 6 
12 AAS99321 MRNLCFVFIFISLLAHGSTHGPDSCNHDRGLSRVGNCNPGEYLAKYCFEPVILCCKPLSPTPTKT 2 
13 AAT48937 FSDSQLCRNNHGHCRRLCFHMESWAGSCMNGRLRCCRFSTKQPFSNPKHSVLHTAEQDPSPSLGGT 4 
14 AM402954 MGIFLLFLVLLAVPQAAPESDTVTCRKMKGKCSFLLCPFFKRSSGTCYNGLAKCCRPFW 6 
The conserved cysteine – cysteine disulfide bonding motif is highlighted for C1 – C5 (yellow), C2 – C4 (green) and C3 – C6 (blue). The GenBank protein I.D. is 
shown for each defensin. The net charge at pH7 was calculated using Innovagen Peptide Calculator (http://www.innovagen.com/custom-peptide-synthesis/peptide-
property-calculator/peptide-property-calculator.asp). 
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1.10.5  Anti-microbial activities of chicken AvBDs 
AvBDs have been shown to exhibit broad spectrum activity against numerous microbes 
as measured using a variety of techniques including radial diffusion assays based on zones 
of inhibition (Lehrer et al., 1991), colorimetric assays (Peck, 1985), microbroth dilution 
assays (van Dijk et al., 2007; Ma et al., 2008) and a time-kill assay based on colony counts 
at two different time-points (Townes et al., 2004). Minimum inhibitory concentrations 
(MICs) have been reported for AvBDs against various microbial strains, but generally, it 
is difficult to compare data between studies, as variations in assay methodologies exist; 
for example, information on the ratio of bacteria to peptide is often lacking and different 
AvBD preparations are often utilised including chemically synthesised, naturally 
extracted, recombinant, folded and unfolded forms. A summary of the in vitro 
investigations of chicken AvBDs against gram-positive and negative bacteria are 
summarised in Table 1.2 and these data, although sparse, show that the peptides are active 
against a wide range of organisms. 
 
1.10.6  Mechanism of action 
Due to their cationic nature (Table 1.1) it is thought that defensins, including AvBDs, 
exert their anti-microbial function by binding to negatively charged components found in 
microbial membranes, such as lipopolysaccharides (LPS) and lipoteichoic acid (LTA) 
(Ganz, 2003).  It is thought that defensins are far less active against host eukaryotic 
membranes due to the presence of zwitterionic phospholipids and sterols and this has 
been modelled in vitro using liposomes to mimic peptide-membrane interactions (Mason 
et al., 2007; Dong et al., 2012).  In addition, the hydrophobic residues, as part of the 
amphipathic surface of many AvBDs, are also thought to contribute to anti-microbial 
activity by facilitating interactions between the peptide and the microbial cell wall 
(Powers and Hancock, 2003). Following the initial electrostatic interactions, the 
membrane is disrupted via one of three potential models: the “carpet/wormhole” model 
(Figure 1.7) (Shai, 1995), the “barrel-stave” model (Figure 1.8) (Oren and Shai, 1998) or 
the “Toroidal pore” model (Figure 1.9) (Brogden, 2005). In all cases, a key target of the 
peptides is the bacterial cell membrane, although once inside the cell AMPs have been 
shown to bind to and interfere with DNA/RNA and protein function (Brogden, 2005; 
Nicolas, 2009). 
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Although the structural characteristics that govern killing capacity have not been fully 
determined, a number of structure-function studies have provided evidence for the 
importance of critical residues such as the relatively conserved C-terminal lysine 
(Derache et al., 2012) and positively selected sites (PSS), amino acid sites selected for by 
evolution (Higgs et al., 2007).  A role for increased cationicity in exerting higher AMA 
has also been established using modified versions of AvBD8 that differ by their charge 
(Higgs et al., 2007), and through comparisons of  the activities of AvBD1 (+8), AvBD7 
(+6) and AvBD2 (+2) (Derache et al., 2009b). Although studies on human defensins have 
indicated that the three dimensional structure is more important for immunomodulatory 
functions rather than AMA (Wu et al., 2003), it is interesting that a recent study has 
reported that the folded variant of AvBD2 possesses higher AMA than the linearised form 
(Derache et al., 2012).  
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Figure 1.7: The carpet model of the action of AMPs against bacterial membranes.  
A) The positively charged regions of the anti-microbial peptides form electrostatic interactions 
with negatively charged phospholipid head groups on the bacterial cell membrane leading to the 
formation of an extensive carpet-like layer.  
B) At high concentrations the membrane is disrupted via a detergent-like mechanism. 
C) The membrane is completely disrupted as micelles are formed. 
The hydrophilic regions of the defensin peptide are shown in black and the hydrophobic regions 
are shown in red. Model described by Brogden (2005) and Oren and Shai (1998). 
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Figure 1.8: The barrel-stave model of the action of AMPs against bacterial membranes.  
A) The positively charged regions of the anti-microbial peptides form electrostatic interactions 
with negatively charged phospholipid head groups on the bacterial cell membrane leading to 
peptide aggregation. 
B) Peptides insert into the membrane forming a pore. The hydrophilic regions of the peptide form 
a hydrophilic interior of the pore whilst the exterior is formed by the interaction of the 
hydrophobic peptide regions with the phospholipids. 
The hydrophilic regions of the defensin peptide are shown in black and the hydrophobic regions 
are shown in red. Model described by Brogden (2005) and Oren and Shai (1998). 
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Figure 1.9: The toroidal pore model of the action of AMPs against bacterial membranes.  
A) The positively charged regions of the anti-microbial peptides form electrostatic interactions 
with negatively charged phospholipid head groups on the bacterial cell membrane. 
B) AMPs begin to insert into the phospholipid bilayer causing the top lipid monolayer to bend as 
the pore is formed.  
C) A toroidal pore is formed as the two lipid monolayers connect resulting in a water core lined 
by phospholipid head groups in contact with the inserted AMPs. 
The hydrophilic regions of the defensin peptide are shown in black and the hydrophobic regions 
are shown in red. Model described by Brogden (2005) and Huang et al. (2004).  
c
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Table 1.2: Summary of the anti-microbial activities of the chicken AvBDs 
Bacteria  1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Gram negative 
E. coli   - -  -    -  - X - 
S. enteritidis   -   -  - - -  - - - 
S. typhimurium   -   -  X X -  -  - 
S. pullorum - - - - - - - - - - - - - - 
C. jejuni   - - - - - -  - - - - - 
P. multocida X - - - - - - - - - - - - - 
P. aeroginosa  X - - - -  - X - - - - - 
E. cloaca  XX - - - -  - - - - - - - 
K. pneumoniae   - - - -  - - - - - - - 
B. avium    - - - - - - - - - - - - 
Gram postive 
B. subtilis   - - - -  - - - - - - - 
Lactobacillus  - - - - - - - - - - - - - 
C. perfringens  - - - - - - -  - - - - - 
S. aureus   - - - -  X X -  - X - 
B. cereus   - - - -  - X - - - - - 
L. monocytogenes   - - - -   - -  -  - 
S. haemolyticus   - - - -  - - - - - - - 
S. saprophytus   - - - -  - - - - - - - 
S. suis - - - -  - - - - - - - - - 
S. pyogenes - - - - - - -   - - - X - 
 anti-bacterial, X – not anti-bacterial, - not tested.   
References: AvBD1 (Evans et al., 1994; Evans et al., 1995; Harwig et al., 1994; Derache et al., 2009b); AvBD2 (Harwig et al., 1994; Evans et al., 1995; Derache et 
al., 2009b; Derache et al., 2012); AvBD4 (Milona et al., 2007); AvBD5 (Milona et al., 2007; Ma et al., 2008); AvBD7 (Milona et al., 2007; Derache et al., 2009b); 
AvBD8 (Higgs et al., 2007); AvBD9 (van Dijk et al., 2007); AvBD10 ;  AvBD11 (Herve-Grepinet et al., 2010); AvBD13 (Higgs et al., 2005).  
Normal font – AvBD peptide extracted and purified from bird tissues/cells; underlined – AvBD synthetic peptide; italic – AvBD recombinant peptide.
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1.10.7  Other immune functions 
A number of studies have shown that human defensins possess many immune-modulatory 
activities including functioning as chemoattractants (Yang et al., 1999), anti-toxins 
(Wang et al., 2006), facilitating wound repair (Yang et al., 2004), and suppressing the 
production of pro-inflammatory cytokines (Semple et al., 2011). Despite the likelihood 
of a role for immune regulation, few studies have investigated novel non-killing 
properties in the AvBDs. Duck T and B cell lymphocytes have been shown to exhibit 
chemotaxis towards AvBD2-containing media (Soman et al., 2009b) but no comparable 
experiments have been reported using chicken AvBDs. There are strong suggestions, 
however, from in vivo work, of immunomodulatory roles. A large-scale in vivo trial 
revealed that birds fed chicken AvBD13 immediately post-hatch produced significantly 
higher IgG,  IgM and infectious bursal disease virus (IBDV) antibody titres, relative to 
control birds, following administration of the infectious bursal disease vaccine (Yang et 
al., 2007). In addition, AvBD1 has also been shown to be able to boost antibody titres 
when used as a vaccine adjuvant for IBDV (Zhang et al., 2010). The potential of AvBDs 
to link the innate and adaptive immune responses was shown in another study by Yang et 
al., who showed that the addition of AvBD13 to murine peripheral blood mononuclear 
cells activated NF-κB pathways and up-regulated IL-12 and IFNα through TLR-4 
signalling (Yang et al., 2010).  
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1.10.8  Chicken AvBD gene expression 
Discovery of the AvBD genes using a bioinformatics approach was supported by tissue 
expression studies that employed small numbers of birds and endpoint RT-PCR 
techniques that are, at best, semi-quantitative. Therefore, although the relative expression 
of each AvBD gene in chicken tissues has been reported, the data has to be viewed 
cautiously until large sample studies utilising quantitative real-time PCR have been 
performed. Nonetheless, the data so far does imply that the AvBD expression pattern in 
each tissue is unique and these data are shown in Table 1.3.  
 
In relation to the GI tract expression has been revealed for all 14 AvBDs in the small 
intestine and also many AvBDs have been found expressed in the large intestine/caeca 
indicating that these peptides are important innate immune effectors which protect the gut 
from both exogenous pathogens and may also may have roles in modifying the host 
microbiota (Salzman, 2010). In the oesophagus, proventriculus and gizzard, fewer 
defensins appear to be expressed than in other regions although only a small number of 
studies have been performed (Lynn et al., 2004; Xiao et al., 2006). The crop has been 
shown to express AvBD1 – 7, 9 and 11 with increased AvBD9 expression reported in the 
crop in comparison with the small and large intestine (van Dijk et al., 2007).  
 
1.10.9  Developmental chicken AvBD expression  
Temporal and tissue specific differences in AvBD have been reported to occur prior to 
hatch during chicken embryogenesis (Meade et al., 2009a). Similarly, evidence exists for 
high levels of AvBD expression in the first few days post-hatch, which then decrease with 
increasing bird age (Bar-Shira and Friedman, 2006; Milona et al., 2007; Butler, 2010). 
This supports the hypothesis that AvBDs are of importance in the early innate immune 
response of young birds that are, as yet, unable to mount an effective antibody response 
(Bar-Shira et al., 2003).  
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Table 1.3: Chicken AvBD tissue expression 
 
Tissues 
Defensin 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Skin X X  X X X X X    X X - 
Reproductive               - 
Spleen               
Kidney X X   X  X X      - 
Liver X  X  X  X    X X  - 
Lung   X     X   X X  - 
Tongue X X    X X X   X X  - 
Esophagus X X   X  X X  X X X X - 
Crop        X  X  X X X 
Proventriculus X X  X  X X X  X X X  - 
Gizzard X X X  X X X X  X X X X - 
S. Intestine               
L. Intestine     X   X  X X  X - 
Caeca     X  X X  X X X X - 
Colon - - - X X X X X  X X X  - 
Caecal tonsil   -  -  - -  - - - - - 
 Present, X Not detected, - not tested.  
 
References: AvBD1 (Lynn et al., 2004; Sadeyen et al., 2004; Sadeyen et al., 2006; Akbari et al., 
2008; Mageed et al., 2008; Crhanova et al., 2011; Hong et al., 2012); AvBD2 (Lynn et al., 2004; 
Sadeyen et al., 2004; Sadeyen et al., 2006; Akbari et al., 2008; Mageed et al., 2008; Crhanova et 
al., 2011; Hong et al., 2012) AvBD3 (Zhao et al., 2001; Lynn et al., 2004; Mageed et al., 2008; 
Hong et al., 2012; Rodriguez-Lecompte et al., 2012) AvBD4 (Lynn et al., 2004; Xiao et al., 2004; 
Milona et al., 2007; Akbari et al., 2008; Mageed et al., 2008; Crhanova et al., 2011; Hong et al., 
2012); AvBD5 (Lynn et al., 2004; Xiao et al., 2004; Milona et al., 2007; Ma et al., 2008; Mageed 
et al., 2008; Hong et al., 2012); AvBD6 (Lynn et al., 2004; Xiao et al., 2004; Milona et al., 2007; 
Mageed et al., 2008; Crhanova et al., 2011; Hong et al., 2012; Rodriguez-Lecompte et al., 2012); 
AvBD7 (Lynn et al., 2004; Xiao et al., 2004; Mageed et al., 2008; Hong et al., 2012); AvBD8 
(Xiao et al., 2004; Mageed et al., 2008; Hong et al., 2012) AvBD9 (Lynn et al., 2004; Xiao et al., 
2004; van Dijk et al., 2007; Mageed et al., 2008; Hong et al., 2012); AvBD10 (Lynn et al., 2004; 
Xiao et al., 2004; Ma et al., 2008; Mageed et al., 2008; Hong et al., 2012); AvBD11 (Xiao et al., 
2004; Mageed et al., 2008; Hong et al., 2012)  AvBD12 (Xiao et al., 2004; Mageed et al., 2008; 
Hong et al., 2012); AvBD13 (Xiao et al., 2004; Mageed et al., 2008; Hong et al., 2012); AvBD14 
(Hong et al., 2012). 
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1.10.10 AvBD regulation following bacterial challenge 
A number of in vivo and in vitro studies have investigated the expression of AvBDs 
generally in GI and reproductive tract tissues following bacterial challenges, most 
commonly Salmonella spp, or bacterial PAMPs such as LPS. Table 1.4 summarises the 
findings from the in vivo challenges reported in the literature. The observed responses are 
variable with both up and down-regulation of AvBD expression reported, and generally 
related to the age of the bird, tissues analysed and microbial agents employed.  
 
For example two day old birds challenged with Salmonella enterica serovar 
Typhimurium expressed AvBD1, 2, 4 and 6 at higher levels in the caecal tonsils (major 
lymphoid tissues in the avian caecum) relative to unchallenged birds and, interestingly, 
this up-regulation was suppressed via the delivery of a probiotic one day prior to infection 
(Akbari et al., 2008). In the small intestine, however, AvBD4 was not inducible by oral 
challenge with either S. typhimurium or S. enteritidis (Milona et al., 2007), and AvBD2 
expression, similarly, was not affected in the caeca following S. enteritidis challenge 
(Cheeseman et al., 2008). These data suggest that defensin expression in the caecal tonsils 
is more sensitive to regulation. Comparison of the expression of all 14 AvBDs in the GI 
tract (duodenum, jejunum, ileum and caecum) of 3 day-old broilers following S. pullorum 
challenge revealed that groups of defensins were either up-regulated (AvBD3, 4, 5, 6 and 
12), down-regulated (AvBD10, 11, 13 and 14) or unchanged (AvBD1, 2, 7, 8 and 9) 
(Ramasamy et al., 2012).  Differential patterns of AvBD regulation have also been 
revealed between two commercial breeds (Cobb and Ross) in a necrotic enteritis model 
induced by co-infection with C. perfringens and Eimeria maxima (Hong et al., 2012).  
 
The lack of a commercially available epithelial cell line to model the chicken gut has 
meant that most of the bacterial challenge studies in broilers have been performed using 
live birds. While more limited in number, in vitro experiments have also been performed 
on isolated primary cells and the data have generally supported the in vivo studies. 
Researchers using primary intestinal epithelial cells showed that AvBD1 is unchanged 
following S. enteritidis challenge while AvBD2 is up-regulated, although only in cells 
expanded from a Salmonella susceptible breed (Derache et al., 2009a). Using a chicken 
microarray, Chiang and colleagues discovered that following Salmonella enteritidis 
infection more immune genes were down-regulated in chicken heterophils expanded from 
a Salmonella susceptible line, including AvBD5, compared to birds from a resistant line 
(Chiang et al., 2008). Both the studies of Chiang et al. (2008) and Derache et al. (2009a) 
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indicate that regulation differs between the AvBD genes and is influenced, strongly, by 
host genetics.  
 
1.10.11  Dietary supplementation to enhance AvBD expression 
Comparison of AvBD expression in birds that are either susceptible or resistant to 
Salmonella spp. colonisation has indicated that enhanced constitutive AvBD expression 
is associated with a lower susceptibility to bacterial colonisation (Derache et al., 2009a). 
Therefore it is possible that enhanced AvBD expression could confer enhanced protection 
against potential gastro-intestinal pathogens and disease states. One possible strategy of 
inducing endogenous AMP expression has been to provide birds with dietary 
supplements. For example, vitamin D3 supplementation was shown to boost AvBD1 
expression in the bursa of Fabricus, although the GI tract was not examined (Zhang et al., 
2011). Butyrate is an important short chain fatty acid (SCFA) produced by the 
fermentation of undigested carbohydrate by numerous caecal bacteria including species 
belonging to the phylum Firmicutes such as Butyricicoccus spp. (Eeckhaut et al., 2008). 
Butyrate, when used as an in-feed additive, was shown to reduce Salmonella titres (Van 
Immerseel et al., 2005). It was later revealed that this beneficial effect was caused, at least 
in part, due to a significant up-regulation of the AvBDs, particularly AvBD9 (Sunkara et 
al., 2011).  Furthermore, synergistic up-regulation of AvBD9 was observed in vitro using 
the cAMP agonist forskolin (Sunkara et al., 2014), which suggests that feeding both 
butyrate in conjunction with cAMP agonists may have potential benefits in protecting 
poultry against enteric disease, although further in vivo trials are necessary to confirm 
this. 
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Table 1.4: Regulation of AvBD expression following bacterial challenge 
 S.T References S.E References S.P References EM/CP  
AvBD1 ↑ (Akbari et al., 2008) -  NC (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD2 ↑ (Akbari et al., 2008) NC (Cheeseman et al., 
2008) 
NC (Ramasamy et al., 2012) NC (Hong et al., 2012) 
AvBD3 -  -  ↑ (Ramasamy et al., 2012) ↓ (Hong et al., 2012) 
AvBD4 NC, ↑ (Milona et al., 2007; Akbari et al., 2008) NC (Milona et al., 2007) ↑ (Ramasamy et al., 2012) ↓ (Hong et al., 2012) 
AvBD5 NC, ↑ (Milona et al., 2007; Akbari et al., 2008) NC (Milona et al., 2007) ↑ (Ramasamy et al., 2012) NC (Hong et al., 2012) 
AvBD6 NC, ↑ (Milona et al., 2007; Akbari et al., 2008) NC (Milona et al., 2007) ↑ (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD7 -  -  NC (Ramasamy et al., 2012) NC (Hong et al., 2012) 
AvBD8 -  -  NC (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD9 -  -  NC (Ramasamy et al., 2012) NC (Hong et al., 2012) 
AvBD10 -  -  ↓ (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD11 -  -  ↓ (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD12 -  -  ↑ (Ramasamy et al., 2012) ↓ (Hong et al., 2012) 
AvBD13 -  -  ↓ (Ramasamy et al., 2012) ↑ (Hong et al., 2012) 
AvBD14 -  -  ↓ (Ramasamy et al., 2012) NC (Hong et al., 2012) 
S.T – Salmonella typhimurium, S.E – Salmonella enteritidis, S.P - Salmonella pullorum, EM/CP - Eimeria maxima/Clostridium perfringens 
↑ up-regulation, ↓ down-regulation, NC no change, - not assessed. AvBD expression was compared between control and challenged birds determined by endpoint 
RT-PCR or real-time quantitative real-time PCR.   
Experimental conditions: 
Akbari et al. (2008): Real-time qPCR; broiler chickens challenged on day of hatch; gene expression 1, 3 and 5 days-post challenge. 
Cheeseman et al. (2008): Real-time qPCR; challenged at 2 days of age; gene expression 7 days-post challenge. 
Hong et al. (2012): Real-time qPCR; challenged at 14 days (E. maxima) and 18 days (C. perfringens); gene expression 2 days-post challenge. 
Milona et al. (2007): semi-quantitative RT-PCR; challenged at 5 days; gene expression 4 days-post challenge. 
Ramasamy et al. (2012): Real-time qPCR; challenged at 3 days; gene expression 1 day-post challenge. 
35 
 
1.11 Aims of the study  
This study focussed on investigating potential links between bird gut health, microbial 
profile and AvBD expression. The project was performed in collaboration with Aviagen 
Ltd. and centred on two commercial broiler lines (Line X and Y) that differ in their gut 
health. The goals were first to assess and understand differences at the physiological, 
genetic and microbiome level, second to provide insight into why individual, and groups 
of birds, may be more prone to enteric disease and third to identify if innate immune 
genes, particularly the AvBDs, are useful biomarkers of gut health deterioration. 
 
The first studies assessed and compared the gut health and microbiota (ileal/caecal) of 
bird Lines X and Y following environmental exposure to either Bacteroides 
dorei/Barnesiella viscericola (B/BV), or Lactobacillus johnsonii (LJ), or a mixture 
(B/BV + LJ). The objectives were to determine if changes in gut health were associated 
with shifts in the composition of the ileal and caecal microbiome. 
 
The second studies examined AvBD expression in the GI tract of Line X birds, with the 
least robust gut health, following environmental exposure to a mix of Bacteroides dorei 
& Barnesiella viscericola (B/BV).  The objectives were to determine the tissue expression 
of AvBD1 and 10 with particular focus on GI tract tissues, and to examine the regulation 
of expression following the B/BV challenge. In addition, AvBD expression was 
examined in relation to gut health at the individual bird and group level with the purpose 
of evaluating if AvBDs are useful biomarkers of gut health and/or if they have potential 
as candidate genes to include in the genetic selection of innate immune traits. 
 
The final studies used an in vitro approach to further explore the AvBDs. The objectives 
were (i) to perform in vitro bacterial challenges to model AvBD gene regulation at the 
cellular level and evaluate the data in the context of the in vivo bird trials (ii) to assess the 
anti-microbial activity of peptides encoded by three SNP variants of AvBD1, that differ 
in their prevalence within the commercial breeding lines, and AvBD10 against chicken 
bacteria isolated from the gut of a bird with poor enteric health, and (iii) to explore novel 
properties for the AvBDs including wound healing and cell proliferation. 
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2.  Materials and Methods 
2.1  Consumables 
Unless stated, acids and solvents were from Fisher Scientific (Loughborough, U.K.), all 
other reagents were supplied from Sigma-Aldrich (Poole, U.K.) and all plastics were 
purchased from Starlab (Milton Keynes, U.K.). 
 
2.2  Farm Trials 
2.2.1  Overview 
 In collaboration with Aviagen Ltd., two farm trials were performed at a site in Ayrshire, 
Scotland which reflected poultry rearing in commercial environments (Kapell et al., 
2012). Trial 1 was performed during April – May 2011 and Trial 2 was performed during 
January – March 2012.  
 
Two different genetic lines of broilers were used in this study (Lines X and Y), chosen 
due to their differing gut health. Compared to Line X, Line Y birds exhibit a more robust 
gut health and thus suffer a lower incidence of enteric health problems (Butler, 2010). 
Bird numbers, bacterial challenges and sampling protocols are reported in the appropriate 
Chapters. For each trial, three hatches of birds were reared in physically separate locations 
(either different barns or compartments within the barn). All birds were euthanized 
humanely by trained Aviagen Ltd. employees using cervical dislocation.  
2.2.2  Bird rearing conditions 
In Farm Trial 1, each hatch of birds was reared on fresh bedding. However, in Farm Trial 
2, birds were reared on litter consisting of a 50% fresh bedding (top layer) and 50% litter 
from the previous hatch that had been mechanically conditioned. Where litter was re-
used, appropriate management strategies were employed to ensure that litter was kept dry 
and friable on the surface at all times including de-caking between hatches, adding a fresh 
top layer of litter and monitoring ammonia levels (see Aviagen Brief: Reused Litter 
Treatments for Improved Bird Health,  
http://www.aviagen.com/assets/Tech_Center/Broiler_Breeder_Tech_Articles/English/A
viagenBrief_LitterTreatment_Aug08.pdf). Each pen contained 100 birds reaching a 
maximum stocking density of 33kg per m2. 
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All birds were provided ad libitum the same diet which consisted of ‘crumble’ containing 
a relatively low dietary content of maize, similar in quality to that used in commercial 
rearing environments. During the starter period (hatch - day 10) the diet contained 195g 
of crude protein (CPr)/kg providing 12 MJ of metabolisable energy (ME)/kg whilst 
during the  grower period (day 11 - slaughter) contained 170 g of CP/kg providing 12.7 
MJ of ME/kg. All birds underwent normal vaccination protocols such as that for 
infectious bursal disease (Appendix B). Environmental temperature was controlled at all 
times and reduced steadily from 35 to 24°C as birds aged. During the first week birds 
were reared in 23h light and 1h dark and from day 8 onwards the photoperiod was altered 
to 20h light and 4 h dark.  
2.2.3  Bird weights 
For Farm Trial 1, 100 birds were weighed per pen at 4, 7, 14, 21 and 28 days post-hatch 
and for Farm Trial 2, only the sampled birds were weighed prior to the gut health 
assessments and tissue sampling. 
2.2.4  Tissue sampling 
For Farm Trial 1, birds were sampled by Dr Richard Bailey (Aviagen Ltd.) at 4, 7, 14, 21 
and 28 days and for Farm Trial 2, birds were sampled by myself and Dr Vanessa 
Armstrong at 0, 7, 14, 21 and 28 days. For each bird, a 5 – 10 cm section of jejunum was 
excised starting from the end of the folded duodenum, cut longitudinally and washed in 
PBS. The exposed mucosal surface was collected by scraping with a microscope slide 
and the contents placed in aluminium foil. The samples were snap-frozen in liquid 
nitrogen, transported to Newcastle and stored long-term at -80°C. Digesta was taken from 
the ileum and caecum and stored in 1.5ml microfuge tubes.  
 
In Farm Trial 2, GI tissue sections (approximately 1 – 2cm in length) including 
duodenum, jejunum, ileum, caecum and caecal tonsil, plus the liver, kidney, thymus, 
spleen and bursa of Fabricus, were collected, placed in 1ml of RNA later solution, prior 
to long-term storage at -80°C. 
 
2.2.5  Gut health assessments 
The gut health assessment was performed by Dr Richard Bailey (Aviagen Ltd.) and is 
shown in Appendix A. The gut was analysed for redness of the gut surface, gut tone and 
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consistency of gut contents (water content) using scoring numbers 0 (normal), 1 (mildly 
abnormal) and 2 (severely abnormal).  
 
2.2.6  DNA extraction from digesta and sequencing of the microbiota 
DNA extraction from ileal and caecal digesta samples was performed by Dr Richard 
Bailey, (Aviagen Ltd.) using a protocol that was optimised for extracting DNA from 
chicken faeces using the DNAzol™ kit (Life Technologies Ltd, Paisley, UK).  
 
Aliquots of 1g of faecal material were washed by placing in a centrifuge tube containing 
150 µl of acid washed glass beads (Sigma-Aldrich, Poole, U.K.) and 5ml H2O, vortexed 
for 5 min and then centrifuged (3000 x g). The supernatant was removed and the pellet 
was again washed as before. The faecal pellet was weighed and 200mg was added to a 
1.5ml microfuge tube containing an equal volume of glass beads and 400 µl DNAzol™ 
mix. To facilitate lysis, the tubes were left overnight on a rotating box mixer. The next 
day the lysate was centrifuged (10 min 10,000 x g) and 400 µl of supernatant was mixed 
with 200 µl of 100% ethanol in a fresh microfuge tube. After leaving for 5 min the mixture 
was centrifuged as before and the supernatant removed to leave a pellet containing the 
DNA. The pellet was washed in 1ml of 80% ethanol, centrifuged as before and the 
supernatant discarded. The pellet was left to dry in air for 10 min and then re-suspended 
in 200 µl of TE elution buffer (Qiagen, UK). DNA concentration and purity was assessed 
by Nanodrop spectrophotometer (Fisher Scientific, Loughborough, U.K.) 
 
The DNA samples were analysed commercially by the Animal Health and Veterinary 
Laboratories Agency (AHVLA) (Weybridge, U.K). Bacterial DNA was sequenced by 
454-pyro sequencing (Roche, Indianapolis, U.S.A) at the V4-V5 region of the 16S 
ribosomal gene.  The data was formatted commercially and sent to Aviagen Ltd. as 
percentage abundance of the overall microbiome for each identified species. 
 
2.3  Analysis of jejunal gut scrapes 
2.3.1  Total protein extraction and quantification 
Gut samples were stored on ice during the extraction procedure. Each sample was placed 
in a 15ml Falcon tube containing 1ml of 10% acetic acid and homogenised using a 
TissueRupter® (Qiagen, Crawley, UK). The TissueRupter probes were carefully washed 
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between samples using 70% ethanol and 0.1M PBS. After homogenisation the samples 
were transferred to 1.5ml microfuge tubes and centrifuged at room temperature, 13000 x 
g for 10 min. Following centrifugation, the supernatant was removed from each sample, 
placed in a new microfuge tube and the sample was dried in a heat block at 56°C until all 
the acetic acid had evaporated leaving behind a dried pellet of protein.  The pellet was 
reconstituted with 0.3ml – 1ml 0.1M PBS (depending on approximate size of gut scrape) 
and vortexed. Centrifugation was repeated at 13000 x g for 10 min to remove insoluble 
material and the supernatant was pipetted into a clean microfuge tube.  Total protein 
concentration was measured using NanoDrop (Fisher Scientific, Loughborough, U.K.) 
and samples were diluted with 0.1M PBS to give a concentration of 4µg/µl. (Butler, 
2010). 
2.3.2  Thin layer chromatography 
A pencil line was drawn 1cm from the end of a 10cm x 12cm siliconised aluminium plate 
(Millipore U.K. Limited, Hertfordshire, U.K.)  and marked at 1cm intervals for sample 
spotting. On the left side of the plate 2µl of 10mM sugar standard (Megazyme, Co. 
Wicklow, Ireland) was spotted and dried with a hairdryer. Six microlitres of each sample 
was analysed (3µl spotted, dried and further 3µl was spotted). Plates were placed in a 
tank containing solvent (2:1:1, butanol:acetic acid:H20) at 1cm depth for 1.5 h. Plates 
were dried, placed again in the solvent again for 1.5 h and re-dried.  Plates were covered 
in developer (32.3ml sulphuric acid : 752.7ml ethanol: 215ml water : 1g orcinol) for 30 
s, dried, placed in a drying oven at 70°C and monitored until bands were distinguishable 
(approx. 5min). Samples were assessed by comparing sample bands to the sugar 
standards. 
2.3.3  High Pressure Liquid Chromatography (HPLC) 
Prior to running samples and standards on HPLC, four sets of running buffer were 
prepared. Buffer A contained 3.5ml NaOH (46/51% soln. HPLC electrochemical grade) 
in 1L H20; buffer B contained 3.5ml NaOH and 68g NaAc in 1l H20; buffer C contained 
1L H20 and buffer D contained 28.4ml NaOH in 1L H20. Buffers were filtered to remove 
impurities and de-gassed for 1hr. A series of sugar standards (mannose, arabinose, 
galactose) were diluted from 10mM stock to 0.3mM in a total volume of 200µl. The gut 
scrape samples were diluted 1:10 to a total volume of 200µl and 3 sets of standard + 
sample were prepared (6µl sugar standard + 20µl sample + 174µl H20). In addition, three 
sets of 300µl water samples were prepared and all samples were placed in glass vials 
(Chromacol, Hertfordshire U.K) for HPLC analysis (UltiMate® 3000 HPLC, Dionex, 
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Thermo, Hemel Hempstead, U.K.). A water sample was injected onto the HPLC column, 
followed by the gut samples and two water samples to finish. The HPLC data was 
analysed using Chromeleon® software (Dionex, Thermo, Hemel Hempstead, U.K.). 
 
2.4  Bacterial culture 
2.4.1  Bacterial strains  
Chicken isolates were sampled from a commercial Ross 308 broiler showing symptoms 
of enteric upset that resembled dysbacteriosis. The strains isolated and used for the 
microbial growth assays were from Escherichia coli, Bacteroides dorei (strain 1 and 2), 
Barnesiella viscericola and Lactobacillus johnsonii. In addition, a chicken isolate of 
Enterococcus faecalis, obtained in 2007 from the post-mortem of an Aviagen Ltd. bird, 
was used (Butler (2010).  
 
The Salmonella strain utilized was Salmonella enterica serovar Typhimurium 1344 and 
was provided from Dr A. Khan, Newcastle University, U.K.      
 
Competent cells (Promega, Southampton, U.K.) used for cloning, transformation, 
plasmid propagation and hyperexpression were: E. coli DH5α, E. coli JM109 and E. coli 
BL21(DE3)pLysS (protein hyperexpression only). 
2.4.2  Growth media and agar 
All media was purchased from Sigma-Aldrich and prepared using the manufacturer’s 
instructions prior to sterilisation at 121ºC using an autoclave. 
 
Luria-Bertani (LB) broth and agar was prepared from reagents from BD Biosciences 
(Oxford, UK). For each litre of broth, NaCl (10g), Bacto-tryptone (10g) and Bacto-yeast 
(5g) was dissolved in 1L of de-ionised water and the pH was adjusted to 7.4 with 1M 
NaOH. LB agar was prepared using the same method with the addition of 15g agar/1L 
LB.  
 
Super optimal broth (SOC medium) was used for bacterial transformation. 
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Blood agar was used without the addition of heparinised horse blood and was used in E. 
coli and E. faecalis growth assays. Tryptic soy broth (TSB) and agar (TSA) were used to 
culture S. typhimurium.  
 
Brain heart infusion (BHI) broth was used for the growth of B. viscericola and BHI agar 
used for plating out colonies of B. viscericola and B. dorei.  De Man, Rogosa and Sharpe 
(MRS) broth and agar was used for culturing L. johnsonii.   
 
B. dorei strains were grown in Tryptone Yeast Glucose (TYG) broth which was prepared 
in 100ml aliquots containing tryptone peptone (1g), bacto yeast extract 
(0.5g), glucose (0.2g), cysteine (free base) (0.05g), 1 M KPO4 pH 7.2 (10ml), Vitamin K 
solution, 1mg/ml (1ml), TYG salts (4ml), 0.8% CaCl2 (0.1ml), FeSO4, 0.4 mg/ml (0.1ml), 
resazurin, 0.25 mg/ml (0.4ml) and H2O (85ml).  Prior to culturing, haematin (w/v %) was 
added to a final concentration of 0.1 % w/v.  
 
For plating bacteria, E. coli, E. faecalis and S. typhimurium were grown overnight 
aerobically while B. dorei, L. johnsonii and B. viscericola were cultivated overnight on 
plates in an anaerobic jar (Anaerocult® system, VWR International, Leicestershire, U.K.). 
 
2.4.3  Growth curves 
For all bacterial species, growth curves were plotted to determine the optical density 
(OD600nm) at which the bacteria enter the exponential growing phase. To ensure all 
bacteria tested were in the same growth phase, cultures were grown to mid-log phase 
prior to dilution and anti-microbial testing using either the colony counting, microbroth 
dilution or radial diffusion assays. 
 
To prepare E. coli and E faecalis prior to their use in the anti-microbial assays a loop of 
bacteria was taken from a glycerol stock (50% glycerol stored at -80°C), streaked onto a 
blood agar plate and grown overnight. From this plate a single colony was selected and 
added to 5ml of LB broth. The bacteria were grown overnight (approx. 16 h) in an orbital 
shaker set at 200 rpm and 37°C. A sterile 30ml universal container containing 10ml LB 
and 100mM glucose was inoculated with 200µl of the overnight culture and the bacteria 
grown in the orbital shaker under the same conditions. The OD600nm of the culture was 
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monitored using a spectrophotometer (Amersham Biosciences, Ultraspec 43000 pro, 
High Wycombe, UK) until the culture reached mid-log (OD600nm 0.3 – 0.6).  
 
For B. dorei, B. viscericola and L. johnsonii overnight cultures were prepared first by 
adding 50µl of glycerol stock to 5ml of the appropriate media. Once in liquid culture 
these bacteria were plated under the appropriate conditions.  
 
2.4.4  Preparation of heat-killed bacteria for cell challenges 
Bacteria were grown to exponential phase as previously described. At mid-log stage 
bacteria were centrifuged (1000 x g) for 10 min, the growth media removed, the cell pellet 
washed in PBS, re-centrifuged and pellets resuspended in 1ml of fresh PBS in a 1.5ml 
microfuge tube. A dilution series was performed and colonies were plated overnight prior 
to counting to provide the bacterial concentration in colony forming units per ml 
(CFU/ml). For heat inactivation the bacterial suspension was boiled for 5 min and to 
confirm cell death 50µl plated onto a selective medium and incubated overnight as 
appropriate.  
 
2.4.5  Colony counting assay 
Bacteria were grown to exponential phase as previously described (Section 2.4.3) and a 
working stock of bacteria was prepared by diluting the culture 1 in 1000 with 0.1M PBS 
(10µl of culture added to 4990µl of 0.1M PBS). The colony counting assays were 
modified from Milona et al. (2007). A series of tubes were prepared in triplicate for each 
sample containing 90µl of the diluted bacterial culture and either 10µl of gut scrape to a 
final concentration of 0.4µg/µl (gut scrape growth assays) or 10µl of AvBD peptide to a 
final concentration 0.1 - 50µg/ml (anti-microbial assay).   
 
These test samples were analysed for bacterial growth by performing a dilution series at 
two time-points (0 h and 2 h) in 96-well microtitre plates and then plating out the colonies. 
At time-point 0h, 10µl was removed from the 1/1000 bacteria + AvBD/gut scrape sample 
and serially diluted four times to give final dilutions relative to the mid-log bacterial 
culture of 10-5 (dilution 1), 10-6 (dilution 2), 10-7 (dilution 3) and 10-8 (dilution 4). 
Aliquots of 10µl from each of these serial dilutions were plated onto individually labelled 
quarters on blood agar plates. After the AvBD/gut scrape and bacteria had been incubated 
for 2 h the serial dilutions and plating procedures were repeated. Following 16 - 18 h of 
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incubation, the C.F.U. were counted for each plate quarter, multiplied according to the 
dilution factor (105 – 108) and an average C.F.U/ml was calculated across the dilution 
series. The value at time 0 h was subtracted from the value at 2 h, to represent the extent 
of bacterial growth. As performed by Townes et al. (2004), the bacterial growth inhibited 
by each sample was presented relative to the PBS control, which was assigned a growth 
value of 100%. Therefore, a value of more than 100% indicated excess bacterial growth, 
i.e. a pro-microbial effect, values of 0 - 99% represented inhibition of bacterial growth 
and a value < 0% indicated that less colonies were found at 2 h than at 0 h i.e. bacterial 
killing.  
2.4.6  Microbroth dilution assay 
For each anti-microbial peptide or control (PBS), a single row of a 96-well microtitre 
plate was utilized. Each well contained 100µl of anti-microbial peptide serially diluted 1 
in 2 with PBS across the row and starting at 125µg/ml. To each well, 100µl of diluted 
mid-log bacteria (1 in 20,000) was added and the plate was incubated for 3 h. At 3 h, 
100µl of  LB growth media was added and the plate was incubated for further 16 h in a 
plate reader (FluoSTAR Omega, BMG Labtech, Ortenberg, Germany) using a  custom 
program that maintained the temperature at 37ºC, provided shaking at 200rpm every 20 
min and measured the optical density at 600nm every 20 min. From these data, growth 
curves were plotted and the minimum inhibitory concentration (MIC) was determined. 
To confirm complete killing the contents of each well was plated out on an appropriate 
medium and checked for bacterial colonies. 
2.4.7  Radial diffusion assay 
The radial diffusion assay was performed as outlined by Schroeder and Wehkamp, 
(2011). A low nutrient ‘underlay’ gel was prepared to a volume of 50ml (5 petri dishes) 
by dissolving 0.5g low EEO-agarose in a solution containing 0.5ml TSB, 5ml 100mM 
phosphate buffer (mixture of 47.5 ml of monobasic sodium phosphate with 202.5 ml 
dibasic sodium phosphate) and 45ml dH2O. Similarly, a higher nutrient ‘overlay’ gel was 
prepared by dissolving 0.5g EEO and 3g TSB powder in a solution containing 5ml 
100mM phosphate buffer and 45ml dH2O. Both ‘underlay’ and ‘overlay’ gel were 
autoclaved and left to cool. Bacteria was grown to mid-log from an overnight culture and 
pelleted by centrifugation (1000g) for 10 min. The media was removed, the pellet was 
washed with cold 10mM phosphate buffer, re-centrifuged, re-suspended to an OD600nm of 
0.1nm (against a buffer control) and kept on ice until required. Whilst bacteria were 
growing, both underlay and overlay gel were kept at 50ºC in a waterbath.  
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For each petri-dish, a 10ml aliquot of liquid ‘underlay’ gel was left to cool to 45 ºC and 
150µl of diluted bacterial suspension (OD600nm 0.1nm) was added. The aliquot was gently 
mixed and poured into a petri-dish and allowed to set. Holes measuring 3mm were 
punched into the gel and removed by suction to ensure the holes were clean. Peptide was 
applied at the required amounts eg 4, 2 and 1μg and appropriate controls were used (PBS 
– negative control, Cecropin/Lysozyme – positive controls). The plates were incubated 
for 3 h, 5ml of melted overlay was added to each plate, allowed to dry and then incubated 
overnight. The following day, zones of bacterial inhibition were photographed using a 
spImager (S&P Robotics Inc, Chennai, Tamil Nadu, India) and the relative size of each 
zone of inhibition was measured using ImageJ software (imagej.nih.gov/ij/, National 
Institutes of Health, Maryland, U.S.A.). 
 
For the assessment of peptide activities against anaerobic bacteria (B. dorei, B. viscericola 
and L. johnsonii), the underlay and overlay aliquots also contained a reducing agent, 
namely dithiothreitol (DTT) (1mM), and a redox-indicator namely, resazurine (1µg/ml). 
Anaerobic bacteria were cultured under anaerobic conditions using the Anaerocult® 
system (VWR International, U.K.). In addition, the overlay gel contained 3g of the 
appropriate growth media i.e. BHI for B. dorei and B. viscericola and MRS for L. 
johnsonii. 
 
2.5  Cell Culture 
2.5.1  Overview 
Chicken CHCC-OU2 (OU2) cells were donated by Professor Pete Kaiser and Dr Lisa 
Rothwell from the National Avian Research Centre, Roslin Institute, Edinburgh.  Unless 
otherwise stated all plastics were supplied from Corning (Massachusetts, USA) and 
reagents were supplied from Sigma (Dorset, UK). Cells were grown and passaged using 
high glucose DMEM media containing 5% fetal calf serum, 1% chicken serum, 1% 
penicillin/streptomycin and 10% tryptose buffered phosphate. For challenge experiments, 
the media was prepared as stated but without the addition of the antibiotics. For 
maintenance and passaging, cells were seeded at 1 x 106 for 25 cm2, 2 x 106 for 75cm2, 
and 4 x 106 for 175cm2 flasks. All experiments were performed under sterile conditions 
in a class ІІ laminar flow cabinet (S@feflow 1.2, BIOAIR, Italy) and cells were cultured 
at 41ºC in 5% CO2.  
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2.5.2  Bacterial challenge experiments 
Cells were seeded at 2 x 105 in 12-well plates and grown overnight. At 24 h media was 
removed and replaced with challenge media (no antibiotics). At 48 h cells were 
challenged with heat-killed bacteria (102, 103, 104, 105, 2 x 106 C.F.U. per well) for up to 
24 h. After the appropriate incubation time the media was removed, the cells washed 
twice in 1 x PBS and 125µl of RNA lysis solution (Promega, Southampton, U.K.) was 
added. The cells were then scraped off the wells with a cell scraper and stored at -20ºC 
prior to RNA extraction. 
 
2.5.3  Wound healing assay 
CHCC-OU2 cells were seeded into 6 well plates at a density of 1 x 106/well and cultured 
for up to 48 h or until confluent (cell to cell contact visable throughout). The media was 
removed and a straight vertical line was scratched in each well using a 200µl pipette tip. 
The cells were washed twice in PBS to remove debris and 1ml of media was added. To 
triplicate wells recombinant AvBD10 was added to a final concentration of 0.1, 0.5 or 
1nM. In addition, three wells were set-up containing basic fibroblast growth factor 
(bFGF) (Life Technologies Ltd, Paisley, UK) at 1ng/ml as a positive control or PBS as a 
negative control. Images were recorded at 0, 24, 48 and 72 h of the same wound area, 
outlined originally using a china pencil. At 48 h, media was replaced containing the 
appropriate concentration of AvBD10 or control reagent.  Images were analysed using 
ImageJ software (http://imagej.nih.gov/ij/) and percentage wound healing was calculated 
using pixel measurements as the total wound area (black pixels) minus the number of 
cells (represented by white pixels) that had migrated into the wound area.  
 
2.5.4  Cell proliferation assays 
The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay was used to measure 
the number of metabolically active cells following challenge with heat-killed Bacteroides 
dorei, whilst the CellTiter-Blue® Assay was used to assess the number of viable cells 
relative to a PBS control following incubation with recombinant AvBD10. For both 
assays, reagents were supplied by Promega (Southampton, U.K.) and the assays were 
performed according to the manufacturer’s protocol. 
 
The CellTiter 96® AQeuos Non-Radioactive Cell Proliferation Assay utilises the 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
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sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS) reagent. The 
MTS (20ml) and PMS (1ml) reagents were thawed and then mixed together prior to 
storing at -20ºC in 1ml aliquots. For the assessment of cell viability, CHCC-OU2 cells 
were seeded in wells in a 96-well plate at a density of 2 x 104 in 200µl of media. Cells 
were cultured to confluence (48 – 72 h) and then challenged with killed bacteria at a final 
concentration of 102 – 2 x 106 C.F.U/ml for 24 h. After challenge, the media was removed 
and cells were washed three times in warm PBS (41ºC) and allowed to equilibrate for 15 
min in 100µl PBS. To each well, 20µl MTS/PMS solution was added, the plate was 
incubated for 4 h and the absorbance was read at 490nm using a micro-titre plate reader 
(FLUOstar Omega, BMG LabTech, Germany). The percentage viability of the 
challenged wells was compared to unchallenged CHCC-OU2 cells in PBS using standard 
curves. 
 
For the CellTiter-Blue Reagent® Assay, cells were seeded in 24-well plates at a density 
of 1 x 105 and cultured for 48 h. At this time-point the media was replaced with antibiotic-
free media and the cells were challenged with recombinant AvBD10, bFGF, mytomycin 
C, Bovine serum albumin (BSA) or PBS at a final concentration of 1, 5 and 10nM for 48 
h. After 48 h of incubation, the media was removed and 100% methanol was added to 
two wells per plate and left for 2 – 3 min to kill the cells. Next the methanol was removed 
and to all wells 500µl of warm serum-free media was added together with 100µl of 
CellTiter-Blue® reagent. The plates were incubated for 2 – 4 h until a colour change from 
blue to pink was observable, indicating that the cells are metabolically active. Into a 96-
well plate, a standard curve was set up in duplicate using the media from the methanol-
killed cells (blue) and the media from the 100% viable PBS treated cells (pink). The 
standard curve covered the viability range 100%, 75%, 50%, 25% and 0%. For the 
remaining treated wells, 100µl of media was transferred to the 96-well plate. The 96 well 
plate containing media from both the standards and treated cells was read for absorbance 
at 570 and 600nm (FLUOstar Omega, BMG LabTech, Germany). The value at 600nm 
was subtracted from the value at 570nm and a standard curve plotted which was used to 
calculate the relative number of metabolically active cells relative to the PBS control.  
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2.6  Molecular Analyses 
2.6.1  DNA extraction from CHCC-OU2 cells 
Genomic DNA was extracted from bird tissues using the DNeasy® Blood & Tissue Kit 
(Qiagen, Crawley, UK) according to the manufacturers’ instructions. Briefly, three 
triplicate wells from a 6 well plate containing 80 – 100% confluent cells (~ 5 x 106 cells 
in total) were removed by scraping, the cells were centrifuged for 5 min at 300 x g, the 
pellet re-suspended in 200µl of PBS, and 20µl proteinase K was added. To ensure RNA-
free genomic DNA, 4 µl of RNase A (100mg/ml) was added. To this, 200 µl Buffer AL 
was added, the suspension vortexed and incubated at 56°C for 10 min. After incubation, 
200µl ethanol was added, the sample mixed and transferred into a DNeasy Mini spin 
column. Following centrifugation for 1 min at 6000 x g, the flow-through was discarded, 
500µl Buffer AW1 was added and the spin column re-centrifuged as described 
previously. To the spin column, 500µl Buffer AW2 was added and centrifuged for 3 min 
at 14,000 x g. Finally, 200µl of Buffer AE was pipetted onto the DNeasy membrane and, 
following 1 min of incubation, the column was centrifuged for 1 min at 6000 x g to elute 
the DNA.  
 
2.6.2  Sequencing and analysis 
Prior to sequencing, DNA concentration and purity (260/280 ratio ~1.8 – 2) was 
confirmed using a Nanodrop 2000 spectrophotometer (Fisher Scientific, Loughborough, 
U.K.). All gene sequencing was performed by Genevision, (Newcastle-Upon-Tyne, UK), 
using customised forward and reverse primers supplied with the sample. Sequence 
analysis was performed using FinchTV software (Geospiza, Seattle, USA), 
(http://www.geospiza.com/Products/finchtv.shtml). Query and subject sequences were 
manually aligned or the nucleotide sequences were searched for matches against the 
chicken genome (Gallus gallus) using BLASTn (http://www.ncbi.nlm.nih.gov/).  
 
2.6.3  RNA extraction and quantification 
RNA extraction from tissue samples was performed by Dr Catherine Mowbray using the 
SV Total RNA Isolation System (Promega, Southampton, U.K.) and according to the 
manufacturer’s instructions. The tissue samples were removed from the -80°C freezer 
and a sample of 10 - 20mg homogenized in liquid nitrogen using a pestle and mortar. The 
homogenised sample was added to a microfuge tube containing 175µl lysis buffer, the 
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sample mixed by inversion and 350μl of RNA Dilution Buffer added. The tubes were 
inverted, heated for 3 min at 70°C using a hotblock and centrifuged for 10 min at 13,000 
x g. The cleared lysate was transferred to a fresh tube, 200μl of ethanol (95%) added and, 
following mixing, the suspension transferred into a spin basket assembly. To the mixture, 
600μl of RNA Wash Solution was added, the spin column centrifuged for 1 minute as 
previously described and the eluate discarded. To remove contaminating DNA, the spin 
column membrane was incubated with 50μl of DNAse mix (80% Yellow Core Buffer, 
10% MnCl2, 10% 0.09M DNase I) for 15 min. To stop any further DNase activity, 200μl 
of DNase Stop Solution was added and the column re-centrifuged for 1 min. The 
membrane was washed twice in RNA Wash Solution and the RNA eluted in 50 - 100μl 
of nuclease-free water. For the extraction of RNA from CHCC-OU2 cells, the above 
method was followed except cells were homogenised by repeatedly passing them through 
a 0.8mm gauge needle (BD Microlance™ 3, VWR International, U.K).  The quantity and 
purity of the RNA was determined using the Nanodrop 2000 spectrophotometer (Fisher 
Scientific, Loughborough, U.K.).  
 
2.6.4  Reverse transcription 
Reverse transcription was performed using a Px2 Thermal Cycler (Fisher Scientific, 
Loughborough, U.K.). Table 2.1 shows the reagents required for each RT reaction.  All 
reagents were from Promega unless stated. For each sample, a PCR tube containing a 
total of 0.5µg of RNA was mixed with Milli-Q pure water (Millipore U.K. Limited, 
Hertfordshire, U.K.) to a total volume of 12.5µl. To each tube 1µl of random hexamers 
(0.5mg/ml) (Roche, Indianapolis, U.S.A) was added, the samples incubated at 65°C for 
5 min and placed on ice for 2 min. To each tube, 12µl of mastermix was added containing 
5µl MMLV buffer, 6.25µl dNTPs (Bioline, London, U.K.), and 0.25µl RNasin and 0.5µl 
MMLV RT enzyme. The samples were mixed by pipetting and incubated at 42°C for 2 
h.  
Table 2.1: Reagents required per tube for each reverse transcription reaction  
Reagent Volume 
(µl) 
Supplier 
RNA (0.5µg) 12.5  
Random hexamers (0.5mg/ml) 1 Roche, U.S.A 
M-MLV Buffer 5 Promega, UK 
dNTPs (2mM) 6.25 Bioline, UK 
RNasin 0.25 Promega, UK 
M-MLV reverse transcriptase 0.5 Promega, UK 
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2.6.5  Primer design for polymerase chain reaction (PCR) 
Real-time qPCR primers for AvBD1 and 10 were designed and optimised by Dr Catherine 
Mowbray. All primers were designed to amplify across at least two exons. Primers were 
supplied by Integrated DNA Technologies (Leuven, Belgium). To confirm optimum 
primer annealing temperatures for both AvBD1 and 10 primers, a repeated set of PCR 
reactions were set up over a temperature gradient (57 - 62°C)  and the annealing 
temperature was selected based on the presence of a strong single band with low levels 
of primer dimerisation. The same sets of primers were used for both the endpoint and 
quantitative real-time PCR reactions, as shown in Table 2.2.  
 
Table 2.2: Primers, expected gene product sizes and annealing temperatures (Tm°C) for 
AvBD1, AvBD10, IL-6 and IL-1β 
Gene Forward  5’  to   3’ Reverse 5’   to   3’ cDNA 
Product 
Size 
(bp) 
Tm  
°C 
AvBD1 
Genomic 
GCGGATCGTGTACCTGCTC TTGTGAAACCAGCAAGCCAG 911 60 
AvBD1 TACCTCTGCTGCAAAAGAATATGG GAGAAGCCAGGGTGATGTCC 70 60 
AvBD10 CTGTTAAACTGCTGTGCCAAGATTC TGTTGCTGGTACAAGGGCAAT 77 58 
IL-6 CTTCGACGAGGAGAAATGCCT ACTCGACGTTCTGCTTTTCG 110 58 
IL-1β CTCCAGCCAGAAAGTGAGGC CTTGTAGCCCTTGATGCCCA 109 58 
 
 
2.6.6  Endpoint RT-PCR  
The reagents required for each endpoint reverse-transcriptase (RT) PCR reaction are 
shown in Table 2.3. The amplification protocol was performed using a thermal cycler 
(Techne, Bibby Scientific Limited, UK) and the following program was applied: 95°C 
for 2 min followed by 35 cycles consisting of 95°C for 30 s, 58/60°C for 30 s (annealing 
temperatures), 72°C for 30 s. To complete the reaction, a final extension step was 
performed at 72°C for 10 min followed by a hold step at 4°C.  
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Table 2.3: PCR reagents, suppliers and volumes per reaction (total volume 20µl)  
Reagent Volume (µl) Supplier 
cDNA 1.5  
5X Green GoTaq® Reaction Buffer 5 Promega, UK 
GoTaq® G2 DNA Polymerase 0.2 Promega, UK 
dNTPs (2mM) 2.5 Bioline, UK 
F + R Primer Mix [10µM] 2.5 IDT, Belgium 
Water  8.3  
 
2.6.7  Gel Electrophoresis 
PCR products were electrophoresed using 1.5% w/v TBE-agarose gels at 70V for ~1 h. 
For each gel, 1.5g of agarose was dissolved in 1 X TBE buffer (54g Tris, 27.5g boric 
acid, 20ml 0.5M EDTA per 1L de-ionised water) by heating in a microwave. Gels were 
allowed to cool, ethidium bromide was added (5µg/ml) and gels were poured into a gel 
electrophoresis tank. The PCR reaction products were loaded to a volume of 15µl and the 
outside lanes flanking the samples were loaded with 10µl 100bp DNA Ladder. 
 
2.6.8  Gel extraction and purification of cDNA bands 
Gels were visualized on a U.V. illuminator and cDNA bands excised using a scalpel. The 
gel section was placed in a microfuge tube and the DNA purified using a QIAquick® Gel 
extraction kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. 
Following extraction, the gel slice was weighed and dissolved in Buffer QG (300µl of 
Buffer QG:100mg of gel) by incubating at 50°C.  For each 100mg of gel, 100µl of 
isopropanol (100%) was added to the sample, and after mixing, transferred to a QIAquick 
spin column. The sample was centrifuged 1 min at 13,000 x g twice, discarding the eluate 
between each spin. To the spin column 500μl of Buffer QG was added and the column 
re-centrifuged. To wash the membrane, 750μl of buffer PE was added to the column, 
allowed to incubate for 2 min and the column re-centrifuged. Finally, 50μl of H2O was 
added to the membrane and left to stand for 2 min prior to DNA elution by centrifugation 
for 2 min.  
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2.7  Cloning of cDNAs and screening 
2.7.1  Competent cells 
For transformation using plasmids for real-time PCR, the E. coli strain DH5α (fhuA2 
Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR1) was used (Promega, Southampton, U.K). 
2.7.2  Preparation of ampicillin/IPTG/X-gal plates 
LB agar was prepared and autoclaved as described in Section 2.4.2. Once the LB had 
cooled to ~50°C, ampicillin was added to a final concentration of 0.05mg/ml. Isopropyl 
thiogalactoside (IPTG) was prepared as a 0.1M solution and 5-bromo-4-chloro-3-indolyl-
beta-D-galactopyranoside (X-gal) was prepared as a 20mg/ml solution in dimethyl 
sulfoxide (DMSO). After the plates had cooled, 40µl of both X-gal and IPTG were spread 
evenly over each plate. Plates were then allowed to dry prior to colony plating. 
2.7.3  Vector ligation and transformation 
For the production of plasmids for use in real-time qPCR standard curves, all cDNA 
sequences for the AvBDs (AvBD1, AvBD10), cytokines (IL-6, IL-1β), and housekeeping 
genes were cloned using the pGEM-T® easy vector according to the manufacturer’s 
protocol (Promega, Southampton, U.K.). The ligation reagents were set up as outlined in 
Table 2.4, vortexed and incubated overnight at 4°C. The following day, competent cells 
were thawed for 5 minutes on ice, while 2µl of each ligation reaction was added to a 
microfuge tube. In another tube 0.1ng of uncut plasmid was added as a negative control. 
To each sample, 50µl of competent cell suspension was added and the microfuge tubes 
were gently flicked and then incubated on ice for 20min. The samples were then heat 
shocked for 45 s at 42°C and immediately returned to ice for a further 2 min. To each 
tube 950μl of SOC media was added and the samples were incubated for 1.5 h at 37°C 
with shaking. To screen for recombinant colonies, 100μl of culture was plated onto 
ampicillin/IPTG/X-gal plates (10μl for the uncut plasmid control) and the white colonies 
were selected after 24 h.  
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Table 2.4: Reagents for pGEM-T® easy ligation reactions for cDNA genes, positive control 
and background control.  
Reagents cDNA 
Reaction 
Positive 
Control 
Background 
Control 
 Volume (µl) 
pGEM®-T Easy Vector (50ng) 1 1 1 
2X Rapid Ligation Buffer, T4 DNA Ligase 5 5 5 
T4 DNA Ligase (3 Weiss units/µl) 1 1 1 
PCR product 3 - - 
Control Insert DNA - 2 - 
Milli-Q pure water to a final volume of 10 10 10 
 
2.7.4  Colony PCR 
As an additional screening method, white coloured colonies were selected and amplified 
using the primers of interest to confirm the presence of the gene insert. Up to four single 
colonies were picked using a sterile pipette tip for each colony and re-plated by lightly 
touching onto LB/ampicillin/IPTG/X-gal plates for colony preservation.  Using the same 
pipette tip for each colony, an overnight culture was prepared in LB/ampicillin media and 
the following day a colony lysate was prepared by boiling the culture and centrifuging at 
14,000 x g for 10 min. Using 2.5μl of supernatant, PCR reactions were set up as outlined 
in Table 2.5 and amplified using the usual endpoint PCR parameters (Section 2.6.6). 
 
Table 2.5: Colony PCR reagents, suppliers and volumes per reaction (total volume 25µl)  
Reagent Volume (µl) Supplier 
Colony lysate (supernatant) 2.5  
5X Green GoTaq® Reaction Buffer 5 Promega, UK 
GoTaq® G2 DNA Polymerase 0.2 Promega, UK 
dNTPs (2mM) 2.5 Bioline, UK 
F + R Primer Mix [10µM] 2 IDT, Belgium 
Water  12.8  
 
2.7.5  Plasmid mini-prep 
Following confirmation of the correct insert using colony PCR, each re-plated colony was 
grown overnight at 37°C with shaking in 5ml of LB broth supplemented with 5µl 
ampicillin (50µg/µl). After >16 h of growth each 5ml culture was centrifuged and the 
plasmid DNA extracted using QIAprep® Miniprep according to the manufacturers’ 
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instructions. The DNA was eluted in 30µl of Milli-Q pure H20. Plasmids were sent for 
sequencing (Genevision, Newcastle-Upon-Tyne, U.K.) prior to use in real-time PCR 
assays. 
 
2.8  Quantitative real-time PCR (qRT-PCR) 
2.8.1  Selection of reference genes using GeNorm Kit 
The MIQE guidelines state that the selection of reference genes for qRT-PCR should be 
experimentally validated and that, in most cases, a minimum of two are required (Bustin 
et al., 2009; Bustin, 2010). The chicken GeNorm kit (Primerdesign Ltd, Southampton, 
U.K.) was used to select two appropriate reference genes to correct for variation in the 
amount of genetic material between samples. The kit allows the gene expression of 6 
potential reference genes were selected in a representative set of samples to be 
determined. The reference genes were GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase 
Activation Protein Zeta), ACTB (Beta-actin), UBC (ubiquitin C), SDHA (Succinate 
dehydrogenase complex, subunit A, flavoprotein variant) and SF3A1 (Splicing factor 3 
subunit 1). For this study the reference genes were analysed alongside cDNA from both 
representative tissue samples (from challenge and unchallenged birds) and CHCC-OU2 
cells. GeNorm software (PrimerDesign, Southampton, U.K.) was used to rank the 
stability of the reference genes and also select the minimum number of reference genes 
required. The most suitable genes for the in vivo tissue experiments were SDHA and 
SF3A1, and for the in vitro cell culture experiments were GAPDH and YWHAZ. 
 
2.8.2  Real-time PCR reactions 
The reaction mixtures were set up in 96-well plates (Roche, Basel, Switzerland) each in 
a total volume of 10µl (Table 2.6). Each sample was prepared in duplicate and each plate 
contained two plasmid dilutions to enable the relative quantification of the samples. The 
amplification program was performed using a Roche LightCycler 480 (Roche, Basel, 
Switzerland) and is shown in Table 2.7. 
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Table 2.6: Quantitative real-time PCR reagents, suppliers and volumes per reaction  
Reagent Volume 
(µl) 
Suplier 
Sybr green master mix  5 Roche, Basel, Switzerland 
Diluted plasmid/RT product 2  
Molecular grade water 2.5  
F + R Primer Mix [10µM] 0.5 IDT, Belgium 
 
 
Table 2.7: Quantitative real-time PCR protocol (Roche LightCycler 480) 
Programme Number of cycles Time (min:sec) Temperature °C 
Pre-incubation 1 10:00 95 
Amplification 45 
00:10 95 
00:20 60 (AvBD1) 
60 (SDHA) 
60 (SF3A1) 
60 (GAPDH) 
60 (YWHAZ) 
58 (AvBD 10) 
58 (IL-6) 
58 (IL-1β) 
00:01 72 
Melting curve  00:05 95 
  00:01 70 
   97 
Cooling 1 00:10 40 
 
 
2.8.3  Relative quantification and analysis  
Relative quantification was performed against a standard curve produced from a series of 
1/10 dilutions of each plasmid-gene construct. Diluted plasmids were analysed together 
with sample cDNA to ensure the sample values fell within the range of the standard curve. 
A number of standard curves were completed for each gene of interest. In addition, the 
reference genes and standard curves were selected with an amplification efficiency of ~2 
and an error rate of <0.05. Based on these standard curves, the crossing point (CP) value 
for each sample was assigned an arbitrary unit value (A.U). Relative quantification was 
performed by dividing the A.U. value for each sample by the A.U. geometric mean of the 
two appropriate reference genes. 
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2.9  Engineering of recombinant AvBD  
2.9.1  Plasmids for hyperexpression 
Engineering of the plasmids for hyperexpression was performed in collaboration with Dr 
Vanessa Armstrong, Newcastle University. Partial sequences of AvBD1 and 10 genes 
were cloned into the vector PGEX-6P-1 (GE Healthcare Life Sciences, Buckinghamshire, 
U.K.) using BamHI and EcoRI (Fisher Scientific UK Ltd, Loughborough, U.K.). The 
resulting plasmid constructs used for hyperexpression were PGEX-6P-1-AvBD10 and 
PGEX-6P-1-AvBD10.  
  
2.9.2  Competent Cells and Transformation 
For the initial cloning of the AvBD1 and 10 cDNAs, the PGEX-6P-1-AvBD constructs 
were transformed into JM109 (Promega, Southampton, U.K.), recombinants selected 
using blue-white colony screening (as described in Section 2.7.3) and sent for sequencing. 
However, the E.coli strain utilized for hyperexpression was BL21 Origami B (DE3):: 
plySs (Novagen, Darmstaft, Germany). BL21 strains, although efficient for 
hyperexpression, do not transform well and hence were not used for the initial cloning 
and propagation of the PGEX-6P-1-AvBD constructs. Moreover, the BL21 Origami B 
(DE3):: plySs cells were prepared fresh each time prior to transformation. 
 
2.9.3 Preparation of fresh BL21 Origami B (DE3):: plySs competent cells 
An overnight culture was set up by inoculating 10ml of LB broth containing 
chloramphenicol (0.03mg/ml dissolved in 100% ethanol) with 50μl of BL21 Origami B 
(DE3):: plySs from a glycerol stock and gently shaking overnight at 37°C in an orbital 
shaker. A two ml aliquot was taken and sub-cultured into 100ml of LB containing 
chloramphenicol until an OD600nm of ~0.3 was reached. The 100ml culture was 
centrifuged at 3000 x g for 5min at 4°C, the supernatant removed and the pellet re-
suspended in 4ml 0.1 M MgCl2.  The suspension was centrifuged as before, the 
supernatant removed and the pellet re-suspended in 4ml of 0.1M CaCl2. The cells were 
left to incubate on ice for 2 h prior to transformation.  
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2.9.4  Transformation of BL21 Origami B (DE3):: plySs cells and screening 
Transformation of BL21 Origami B (DE3):: plySs was carried out as described in Section 
2.7.3. To screen for recombinants BL21 Origami B (DE3):: plySs cells were  plated onto 
LB plates containing chloramphenicol (0.03mg/ml) and ampicillin (0.05mg/ml).  
 
2.9.5  Sequencing of PGEX-6P-1-AvBD constructs 
Prior to the hyperexpression experiments, the plasmid DNA was checked by sequencing 
using primers PGEX F and R at 3.4μM (GE Healthcare Life Sciences, Buckinghamshire, 
U.K.).  
 
2.9.6  Hyperexpression 
For hyperexpression, a single colony containing the plasmid-gene construct of interest 
was selected and grown overnight in 10 ml LB together with chloramphenicol 
(0.03mg/ml) and ampicillin (0.05mg/ml) in a shaking incubator at 37°C. For each colony, 
1L of LB media (with appropriate antibiotics) was prepared and 10ml of overnight culture 
was added. Cells were cultured at 37°C to an OD600nm of 0.8 and hyperexpression induced 
by the addition of 0.8M ITPG (isopropyl-beta-D-thiogalactopyranoside) to a final 
concentration of 0.08M. The cultures were grown for 3 h at 25°C then centrifuged at 5000 
x g for 10 min (Avanti J centrifuge, Beckmann Coulter Inc, High Wycombe, U.K.). The 
supernatant was discarded and the pellets were stored at -80°C for up to 3 months until 
needed.  
 
2.9.7  Sonication 
Each bacterial pellet was thawed on ice, reconstituted in 20ml 1 x PBS, transferred to a 
30ml centrifuge tube and the cell suspension was sonicated for 3 – 4 min on ice in 30 s 
bursts. Following sonication, the samples were centrifuged at 15,000 x g (Avanti J 
centrifuge, Beckmann Coulter Inc, High Wycombe, U.K.) and the supernatant containing 
the cytoplasmic proteins stored on ice prior to purification.  
 
2.9.8 Protein Purification 
Poly-Prep® Chromatography Columns (BioRad, Hertfordshire, U.K.) were rinsed with 
alcohol and 2ml of Amintra® glutathione sepharose (Expedeon, Cambridge, U.K.) loaded 
onto the column. The column was left to equilibrate for 1 – 2 min and 10ml of PBS was 
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added. The supernatant containing the cell free extract (C.F.E) was added slowly to 
maintain a flow rate of 0.2–1 ml/min until all the C.F.E had passed through the column. 
At every step in the purification process, a small aliquot was removed and analysed by 
NuPAGE to confirm the success of each purification step. The column was re-washed 
with up to 10ml of 1 x PBS. To remove the GST-tag from the AvBD peptide an on-
column cleavage approach was adopted. The column was washed with 10ml of cleavage 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol DTT, pH 
7.5). For each 1ml of glutathione sepharose, an enzymatic cleavage mix was prepared 
containing 80μl (160 units) of PreScission Protease (GE Healthcare Life Sciences, 
Buckinghamshire, U.K.) with 920μl of cleavage buffer. This enzymatic cleavage mix was 
loaded onto the column and left to incubate overnight at 4°C. The next day the column 
was eluted using 5-10ml of cleavage buffer and 1ml aliquots were collected. The majority 
of the GST and PreScission Protease attached to the column. To separate the cleaved 
AvBD peptides (~5kDA) from the remaining GST (26kDa)  and PreScission Protease 
(46kDa), the eluate was passed through a Centrifugal concentrator with a molecular 
weight cut-off of 10kDa (Vivaspin 6, Fisher Scientific UK Ltd, Loughborough, U.K.).  
The flow-through containing the cleaved peptide was collected and buffer exchanged in 
PBS using a PD-10 Desalting Column (Sigma-Aldrich, Poole, U.K.). The AvBD peptide 
was passed through a centrifugal concentrator with a molecular weight cut-off of 5kDa 
(Vivaspin 6, Fisher Scientific UK Ltd, Loughborough, U.K.) and the flow-through 
discarded. The remaining liquid in the top of the column was recovered. 
 
2.9.9  Determination of peptide concentration 
AvBD peptide concentrations were determined using the Novagen® BCA Protein Assay 
Kit (Millipore U.K. Limited, Hertfordshire, U.K.) according to the manufacturers’ 
instructions. In summary, a series of bovine serum albumin (BSA) standards were 
prepared at 0 - 1000μg/ml. Twenty-five μl of each BSA standard or AvBD sample were 
pipetted, in duplicate, into wells of a 96 well  plate and 200μl of BCA working reagent 
(80µl 4% Cupric Sulfate + 4ml BCA solution) was added to each well. After a short mix, 
the plate was incubated for 30 min at 37°C and the absorbance measured at 562nm 
(FLUOstar Omega, BMG LabTech, Germany). Using the BSA concentrations, a standard 
curve was plotted and the peptide concentrations calculated.  
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2.9.10  Identification of peptides using polyacrylamide gel electrophoresis 
Proteins were separated using the NuPAGE® system (Life Technologies Ltd, Paisley, 
U.K.). All running buffers and reagents required for electrophoresis were supplied by 
Life Technologies Ltd unless otherwise stated. To prepare the samples, a mixture 
containing 10.4μl of sample, 4μl of 4x buffer and 1.6μl of reducing reagent was heated 
to 70°C for 5 min. Running buffer (x1) was prepared by diluting 42.5ml of 20x buffer to 
850ml using dH20. From this running buffer, 200ml was dispensed into a separate 
measuring cylinder and 0.5ml anti-oxidant was added. The comb was removed from a 4-
12 % Bis-Tris Pre-Cast gel which was placed into the XCell SureLock® Mini-cell gel 
running tank. The upper chamber, containing the inward facing wells, was filled with the 
200ml 1 x running buffer containing the anti-oxidant. To each well, 15μl of sample was 
added and 10μl of Novex® Sharp standard was used as a size marker. The remainder of 
the chamber was filled with the 1 x running buffer and the gel was electrophoresed at 
200V for 45 min. The gels were stained with InstantBlue (Expedeon, Cambridge, U.K.), 
a ready to use Coomassie® stain, for 30 min and photographed.  
 
2.10  Synthesis of AvBD1 variants 
Three variants of AvBD1 were synthesised by PeptideSynthetics (Hampshire, UK) 
termed ‘NYH’, ‘SSY’ and ‘NYY’ based on their corresponding primary sequence and 
shown in Table 2.8. The purity was >95% for all peptides (checked by RP-HPLC and 
electrospray mass spectrometry). For each AvBD1 variant 5 x 1mg lyophilised aliquots 
were prepared. The lyophilised aliquots were stored at -20°C and dissolved in 20µl of 
10% acetic acid and the volume made up to 1ml using Milli-Q pure H2O to give a working 
stock at a concentration of 1mg/ml. 
 
 
Table 2.8: Primary sequences synthesised by PeptideSynthetics for three AvBD1 variants 
termed ‘NYH’, ‘SSY’ and ‘NYY’. 
AvBD Variant Sequence 
‘NYH’ GRKSDCFRKNGFCAFLKCPYLTLISGKCSRFHLCCKRIWG 
‘SSY’ GRKSDCFRKSGFCAFLKCPSLTLISGKCSRFYLCCKRIWG 
‘NYY’ GRKSDCFRKNGFCAFLKCPYLTLISGKCSRFYLCCKRIWG 
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2.11 Circular dichroism (CD) spectrometry 
Circular dichroism experiments and analyses were performed by Sherko Subhan, 
Newcastle University PhD student. The three synthetic AvBD1 peptides were 
reconstituted in either Sodium Phosphate buffer (50mM pH 7.4 or sodium dodecyl 
sulphate (1% SDS) to a final concentration of 0.25mg/ml, as determined by A280nm 
(Nanodrop). For CD analysis, 80 μl of peptide or control (Sodium Phosphate buffer 50 
mM or 1% SDS) were added into a 0.2 mm cuvette. Far-UV was recorded over the range 
250 – 185 nm (Jasco-810 CD spectropolarimeter) with settings of band width 0.2 nm, 
data pitch 0.5 nm, scanning speed 100 nm/min, response 10 sec and accumulation 10. 
Absorption units were calculated using Spectra Manager (JASCO UK, Ltd, Essex, U.K.) 
software and analysed in Microsoft Excel. 
2.12  Generation of custom antibodies 
Custom antibodies for AvBD1 and AvBD9 were produced by Cambridge Research 
Biochemicals (CRB) (Cleveland, U.K.). The primary amino acid sequences of the AvBDs 
were sent to CRB for antigenic prediction, to ensure no cross reactivity between defensins 
and to ensure good anti-genticity. A unique peptide antigen for AvBD1, 
GRKSDSFRKNGFC-amide, determined by the Company was used to raise rabbit 
polyclonal antibody to AvBD1.  
2.13  Tissue immunohistochemistry (IHC) 
All IHC developmental and staining work was performed by Dr Catherine Mowbray.  
Avian tissue was harvested and fixed in 4% buffered formalin and subsequently stored in 
70% ethanol before being processed into paraffin blocks. Tissue was sectioned at a 
thickness of 4 µm onto SuperFrost Plus slides (Fisher Scientific, Loughborough, U.K.)  
and allowed to dry for 24 to 48 hours before staining. For immunohistochemical staining, 
slides were de-waxed in xylene, rehydrated through graded alcohols to water and 
subjected to a hydrogen peroxide block (1.5% in water) for 10 minutes. All antibodies 
were assessed independently to determine the appropriate antigen retrieval method for 
use with each stain. Methods assessed were pressure cooking with citrate buffer (pH6.0), 
pressure cooking with EDTA (pH8.0), enzymatic digest with trypsin (pH7.8 at 38oC) and 
no antigen retrieval. For the AvBD1 antibody, pressure cooking with EDTA worked most 
effectively. After antigen retrieval, staining was carried out using the Vectastain Elite 
ABC peroxidase kit (rabbit) (Vector Laboratories, Peterborough, U.K.) as per 
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manufacturers’ instructions. Antibodies were used at dilutions of 1/250 in TBS (pH7.6) 
for 1 hour at room temperature for AvBD1. The reaction was developed using the 
peroxidase chromogen DAB (3,3-diaminobenzedine tetrahydrochloride) as per 
manufacturer’s instructions, then the nuclei counterstained using Mayer’s Haematoxylin 
and Scot’s tapwater substitute. Sections were then dehydrated through graded alcohols 
and cleared in xylene before mounting using DPX.  
2.14  Statistical Methods 
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad 
Software Inc, La Jolla, California, USA). Median values between two groups were 
compared using Mann-Whitney U test and median values between three or more groups 
were compared using Kruskal-Wallis test followed by Dunn’s post test. Means were 
compared using one-way ANOVA followed by Dunn’s multiple comparison post-test   or 
two-way ANOVA followed by Bonferroni post-tests. The significance level was set at 
5% (P < 0.05). To check for a normal distribution of data, the D'Agostino & Pearson 
(1973) omnibus normality test was performed. 
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Chapter 3: Farm Trial 1  
 
3.1 Farm Trial 1 Overview 
This trial was set up in collaboration Aviagen Ltd, and the aim was to explore and 
compare the effects of exposure to different residents of the normal chicken microbiota 
on the gastrointestinal health of two commercial breeding lines of Aviagen broilers. The 
two genetic lines, X and Y, differed in their gut function, with Line Y characterized by 
its increased gut efficiency. Other details about the genotype of these Lines cannot be 
provided for reasons of commercial confidentiality. The objectives of this trial was to 
identify potential factors that determine the differing gut function.  
 
It is common practice within the poultry industry to administer probiotics (generally <5 
species of defined bacteria) or competitive exclusion products (undefined bacterial 
composition >200 species) to growing broilers.  This trial aimed to mimic the widespread 
commercial application of direct-fed microbials to aid the colonisation of the gut flora.  
Most probiotic products available contain members of the genus lactobacillus, such as L. 
johnsonii, due to their well-documented benefits to gut health (La Ragione et al., 2004; 
Van Coillie et al., 2007; Wegmann et al., 2009). Furthermore, since lactobacilli are the 
major component of the small intestine microbiome of the chicken, administration of a 
probiotic lactobacillus strain with proven benefits to intestinal health was expected to 
improve gut health.  Competitive exclusion products are produced from mass culture of 
healthy chicken caecal contents clear of known pathogens.  Administration of competitive 
exclusion products aims to not only prevent the colonisation of pathogens such as E. coli 
but also to aid the maturation of the caecal microbiota.  Due to the undefined nature of 
competitive exclusion products containing hundreds of bacterial species, pure cultures of 
two bacterial species known to be residents of the adult chicken caeca were chosen as a 
means to aid colonisation of the caeca.  Bacteroides dorei and Barnesiella viscericola 
were chosen as they had previously been isolated from healthy chicken caeca and 
represent normal residents of the adult chicken caecal microbiota (Sakamoto et al., 2007; 
Sergeant et al., 2014).  A mixture of the lactobacillus with the BD and BV aimed to assist 
the colonisation and maturation of both the large and small intestine.   
 
The trial was performed during April – May 2011 on an Aviagen commercial sib-testing 
farm in Scotland, UK, which is designed to represent the lower quartile of commercial 
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UK broiler farms in terms of standards of hygiene. Line X and Y birds were administered 
with either Lactobacillus johnsonii (LJ), Bacteroides dorei/Barnesiella viscericola 
(B/BV), or a mixture of both. Following arrival from the hatchery (Day 0), Line X and Y 
birds were assigned to one of four pens in which they were administered bacteria (treated) 
or just water (control) (Figure 3.1). In the three treated pens, birds were administered 
either LJ at a concentration of 1012 CFU/ml, B/BV spp. at 109 CFU/ml or a mixture of the 
two (total 1012 CFU/ml).  Following hatch the intestinal tract of a chicken undergoes rapid 
development which includes colonisation and succession of the microbiota along with 
maturation of the intestinal tissues (Yadav et al., 2010) and immune system (Crhanova et 
al., 2011).  Therefore birds were sampled at multiple ages in order to map the temporal 
changes in the development of the gut environment.  At 4, 7, 14, 21, 28 and 35 days post-
hatch respectively, a random sample of five birds per pen were sacrificed and visually 
assessed for gut health using criteria designed and implemented by Aviagen Ltd. (see 
Appendix A). To determine the microbiome the gut contents were sampled and analysed 
using 454 pyrosequencing. To assess the ability of the gut to promote or inhibit microbial 
growth a mucosal jejunal scrape was taken from each of the five sampled birds. As a more 
general assessment of growth, each bird was weighed and an average weight for each pen 
(n = 100) was calculated. The entire process was repeated for a total of three hatches, 
each hatch in separate locations (either different barns or compartments of the same barn).  
 
63 
 
 
 
Figure 3.1: Flow-chart of Farm Trial and analyses performed. 
Microbiome sampling and gut assessments were performed by Dr Richard Bailey (Aviagen Ltd).  Jejunal gut scrapes were sent to Newcastle 
University for use in the E. coli growth assay.
Microbiome Analyses performed
Gut Health 
Assessment
E. coli growth 
assays
X Y Bird Line
Lactobacillus
Johnsonii (LJ)
Bacteroides Dorei + 
Barnesiella Viscericola
Mixture
(LJ + B/BV)
Water
Bacterial challenge
(Day of Hatch)
Day 35Day 28Day 21Day 14Day 7Day 4
Bird age at sampling
x 3 hatches
(B/BV)
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3.2 Results 
3.2.1 Overview of Gut Health Assessments 
Figure 3.2 A-D illustrates the total gut health per challenged pen over six sampling 
timepoints for Hatches 1 and 2, respectively. This figure provides a simple overview of 
how the gut health varied with time, genetic line and bacterial challenge. Data for 
individual birds are shown in Figures 3.3 – 3.16 alongside mean bird weight and the 
caecal microbiota. Hatch 3 birds were affected by a low level coccidiosis outbreak thus 
the data relating to these birds was excluded from the final analyses. 
 
For each pen at each time-point, five individual birds were assessed for gut health and 
assigned a score of 0 (normal), 1 (some abnormalities) or two (very abnormal) across 
three criteria (redness, water content and gut tone). These scores were summed for each 
group of five birds. For example, the worst possible gut health score per bird was 6, 
whereas a completely healthy bird was scored 0.  These data revealed a trend for gut 
health to deteriorate over time with the worst gut health observed at 28 days post-hatch 
followed by recovery at 35 days. In general, Hatch 2 had worse gut health than Hatch 1, 
with an overall total gut score for all sampling time-points of 101 compared to 77, 
respectively. 
 
Relative to the water  control group, the  B/BV challenged group displayed worse gut 
health, with the effects clearly observable at the later sampling time-points (Day 21 – 28), 
particularly in the Line X birds.  In contrast, the LJ challenge was associated with 
beneficial effects in both lines and in both hatches. At 28 days post-hatch the total gut 
score per group was lower for the LJ challenge than for all other challenges, including the 
water control. In general, the trend was for the ‘mix’ challenge not to adversely affect gut 
health. 
 
The total gut health data indicated that relative to Line X birds, Line Y birds were resistant 
to potentially adverse bacterial challenges such as B/BV. For example, in Hatch 1 at 28 
days post-hatch the gut health of the Line X B/BV challenged birds had deteriorated 
markedly (water = 6, B/BV = 16) whereas this was not observed in Line Y (water = 4, 
B/BV = 5).  
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Figure 3.2: Total gut score per pen for Line X and Y birds.   
Line X (A and C) and Y (B and D) birds were sampled at 4, 7, 14, 21, 28 and 35 days in Hatch 1 (A and B) and Hatch 2 (C and D) (n = 5 birds). Pens were challenged 
with water, Lactobacillus johnsonii (LJ), Bacteroides/Barnesiella viscericola (B/BV) or a mixture (B/BV + LJ). Each bird was assessed for redness, watery digesta 
and gut tone and assigned a score of 0 (normal), 1 (some abnormalities) or 2 (very abnormal) for each criteria. The total scores comprised of summed gut scores across 
the three gut health criteria for 5 birds. 
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3.2.2 Gut health, bird weight and caecal microbiota in Line X and Y birds  
Figures 3.3 and 3.4 illustrate individual bird gut health at each sampling timepoint (A), 
the mean weight per bird (B) and the caecal microbiome in Line X (C) and Line Y control 
birds (D). 
 
A comparison of the median gut health scores revealed no significant differences in gut 
health between Line X and Y birds at any of the sampling time-points for either hatch (P 
> 0.05, Dunn’s multiple comparison test). However, the total gut health scores per group 
do show worse gut health in Line X birds (Hatch 1: 6 and Hatch 2: 16) compared to Y 
(Hatch 1: 4 and Hatch 2: 10). A significant age-dependent effect was observed in Hatch 
2 only with bird gut health deteriorating over time for both Line X (P < 0.01) and Line Y 
(P < 0.05). Interestingly, Figures 3.4B and 3.5B highlight that Line X birds are 
significantly heavier than Line Y at all sampling time-points apart from 4 days post-hatch 
(P <0.001).  
 
The caecal microbiota reveals that the most abundant bacterial genera at 4 days post-hatch 
are Lactobacillus spp. (Hatch 1: Line X, Hatches 1 and 2: Line Y) and Faecalibacterium 
spp. (Hatch 2: Line X). By 28 days post-hatch Barnesiella spp. were the dominant species 
(> 25%) in three of the four pens; the exception was Hatch 1: Line X in which 
Lactobacillus spp. remained dominant. Differences were observed between lines, 
although no obvious bacterial markers of adverse gut health were identified. In Hatch 1, 
Line Y had a higher abundance of Lactobacillus spp. (Day 4), Bacteroides spp. (Day 21), 
and Barnesiella spp. (Day 28) than Line X, but in Hatch 2 the differences were less 
obvious with similar levels of Bacteroides spp. and Barnesiella spp. identified. 
  
Differences in gut health observed between hatches were however reflected by different 
microbiota compositions. The caecal digesta from the Hatch 2 water control pens, which 
had worse gut health than in Hatch 1, contained higher abundances of Barnesiella spp. at 
Day 28 compared to Hatch 1. This pattern was observed for both Line X (11% vs. 32%) 
and Line Y (21% vs. 27%). In addition, at Day 4 higher abundances of Butyricicoccus 
spp, Coprococcus spp. and Faecalibacterium spp. were found in Hatch 2 compared to 
Hatch 1. It is of interest that the guts of Line X: Hatch 2 birds were healthier at this early 
sampling time-point (all 5 birds normal), supporting these bacterial species to be 
associated with beneficial effects. Furthermore, it was revealed that Bacteroides spp. form 
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part of the Day 4 microbiota in Hatch 1 (figure 3.3) but are not present in Hatch 2 at this 
timepoint (Figure 3.4). In Line Y, the most notable difference in the Hatch 2 pens was a 
much lower abundance of Lactobacillus spp. at Day 4 (30% lower than Hatch 1).  
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Figure 3.3: Gut health, caecal microbiota and bird weight analysis for Hatch 1 water control LX and LY birds. 
Birds were sampled at  4, 21 and 28 days post-hatch.  A: Gut health assessments for individual LX and LY birds (n = 5 birds per pen), filled circles = Line X birds, 
open circles = Line Y birds. B: Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = Line X birds, open columns = Line Y birds. C 
& D: Relative abundance of bacterial genus (% population) in caecal digesta of Hatch 1 Line X birds (C) and  Hatch 1 Line Y birds (D) (n = 5 birds per pen). 
Corresponding total gut health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.4: Gut health, caecal microbiota and bird weight analysis for Hatch 2 water control LX and LY birds.  
Birds were sampled at 4, 14, 21 and 28 days post-hatch.  A: Gut health assessments for individual LX and LY birds (n = 5 birds per pen), filled circles = Line X birds, 
open circles = Line Y birds. B: Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = Line X birds, open columns = Line Y birds. C 
& D: Relative abundance of bacterial genus (% population) in caecal digesta of Hatch 1 Line X birds (C) and  Hatch 1 Line Y birds (D) (n = 5 birds per pen). 
Corresponding total gut health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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3.2.3 The effects of Lactobacillus johnsonii challenge on gut health, bird weight and 
caecal microbiota 
 
3.2.3.1 Line X 
Figures 3.5 and 3.6 illustrate individual Line X bird gut health (A), the mean weight per 
bird (B) and the caecal microbiome of control birds (C), and LJ challenged birds (D) at 
each sampling time-point. 
 
When individual bird gut scores for Hatch 1 (Figure 3.5 A) and Hatch 2 (Figure 3.5 B), 
were plotted and median values compared no significant differences in gut health were 
observed between control and LJ challenge pens (P > 0.05, Dunn’s multiple comparison 
test). However, if birds were grouped and the total gut scores per pen calculated then a 
beneficial effect of the LJ challenge was evident.  For example, the water control pens 
had scores of 6 and 16 and the LJ challenge pens had scores of 3 and 8, for Hatch 1 and 
2 respectively. The median gut score of the Line X: LJ challenged pen in Hatch 2 differed 
significantly between sampling time-points highlighting that gut health worsened with 
age (P < 0.05).  In Hatch 2, the mean weight of the water control birds was significantly 
lighter than the LJ challenged birds at Days 14, 21 and 28 (P < 0.01, Bonferroni post-
tests) though no differences in bird weight were observed in Hatch 1.  
 
 
The caecal microbiota data showed that in both hatches the relative abundance of 
Lactobacillus spp. at Day 28 was lower in the LJ challenged pens i.e. 15% compared to 
6% in Hatch 1 and 24% compared to 11% in Hatch 2.  
 
3.2.3.2 Line Y 
Figures 3.7 (Hatch 1) and 3.8 (Hatch 2) illustrate individual Line X bird gut health (A), 
the mean weight per bird (B) and the caecal microbiome of control birds (C) and LJ 
challenged birds (D) at each sampling time-point. 
 
Comparison of median gut health in Hatch 1, shown in Figure 3.7A, revealed no 
significant effects of the LJ challenge on gut health (P > 0.05, Two-way ANOVA). 
However in Hatch 2, the LJ challenged birds had significantly lower gut scores at 28 days 
post-hatch than the water control group (P < 0.05, Dunn’s multiple comparison test). 
Moreover, in Hatch 2 only 1/5 LJ challenged birds had an abnormal gut score in 
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comparison with 5/5 in the water control pen indicating that the Line Y birds respond to 
probiotic LJ intervention , at least in this sampled hatch.  
 
In Hatch 1, the mean weight of the water control birds was significantly heavier than the 
LJ challenged birds by Day 28 (P < 0.01, Bonferroni post-tests) though no differences in 
bird weight were observed in Hatch 2.  
 
Analysis of the caecal microbiota revealed that compared to the water control group the 
LJ challenged group had higher percentage abundances of Butyriccoccus spp. at Day 4 
and Bacteroides spp. at Day 21. Another notable effect of LJ challenge was that the 
sampled microbiome from the LJ challenged birds in Hatch 2 contained a higher 
percentage of Barnesiella spp. at 21 days post-hatch compared to the water control birds 
(8% in the water control group compared to 34% in the LJ challenged group).  
 
As observed in the Line X birds, the caecal microbiome of the LJ challenged birds 
contained a lower percentage of Lactobacillus spp. at Day 28 than the water control birds.  
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Figure 3.5: The effects of Lactobacillus johnsonii (LJ) challenge on Line X birds in Hatch 1 
Line X birds were challenged with water or Lactobacillus johnsonii (LJ) at Day 0 and sampled at 4, 21 and 28 days post-hatch.  A: Gut health assessments for individual 
LX birds (n = 5 birds per pen), black circles = water challenge, blue circles = LJ challenged birds. B: Average bird weight per pen ± co-efficient of Variation % (n = 
100); filled columns = water challenged, blue columns = LJ challenged birds (*** P < 0.001, Bonferroni post-test following Two-way ANOVA). C & D: Relative 
abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and LJ challenged birds (D) (n = 5 birds per pen). Corresponding total gut health 
score per sampled group (n = 5) at each timepoint is shown above each column. 
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Figure 3.6: The effects of Lactobacillus johnsonii (LJ) challenge on Line X birds in Hatch 2 
Line X birds were challenged with water or Lactobacillus johnsonii (LJ) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.  A: Gut health assessments for 
individual LX birds (n = 5 birds per pen), black circles = water challenge, blue circles = LJ challenged birds. (* P < 0.05, ** P < 0.01 Kruskal-Wallis test). B: 
Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, blue columns = LJ challenged birds (*** P < 0.001, Bonferroni 
post-test following Two-way ANOVA). C & D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and LJ challenged 
birds (D) (n = 5 birds per pen). Corresponding total gut health score per sampled group (n = 5) at each timepoint is shown above each column. 
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.  
Figure 3.7: The effects of Lactobacillus johnsonii (LJ) challenge on Line Y birds in Hatch 1 
Line Y birds were challenged with water or Lactobacillus johnsonii (LJ) at Day 0 and sampled at 4, 21 and 28 days post-hatch.    A: Gut health assessments for 
individual LY birds (n = 5 birds per pen), black circles = water challenge, blue circles = LJ challenged birds. B: Average bird weight per pen ± co-efficient of Variation 
% (n = 100); filled columns = water challenged, blue columns = LJ challenged birds (** P < 0.01, Bonferroni post-test following Two-way ANOVA). C & D: Relative 
abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and LJ challenged birds (D) (n = 5 birds per pen). Corresponding total gut health 
score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.8: The effects of Lactobacillus johnsonii (LJ) challenge on Line Y birds in Hatch 2. 
Line Y birds were challenged with water or Lactobacillus johnsonii (LJ) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.  A: Gut health assessments for 
individual LYbirds (n = 5 birds per pen), black circles = water challenge, blue circles = LJ challenged birds. . (* P < 0.05, Kruskal-Wallis test). B: Average bird weight 
per pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, blue columns = LJ challenged birds. C & D: Relative abundance of bacterial genus 
(% population) in caecal digesta of water challenged (C) and LJ challenged birds (D) (n = 5 birds per pen). Corresponding total gut health score per sampled group (n 
= 5) at each sampling timepoint is shown above each column. 
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3.2.4 Effects of Bacteroides spp. /Barnesiella viscericola spp. challenge (B/BV) on gut 
health, bird weight and caecal microbiota 
3.2.4.1 Line X 
Figures 3.9 and 3.10 illustrate individual Line X bird gut health at each sampling 
timepoint (A), the mean weight per bird (B), the caecal microbiome of water control birds 
(C) and B/BV challenged birds (D) for hatches 1 and 2, respectively. 
 
For both hatches, higher median gut score values were observed in the B/BV challenged 
groups at 21 and 28 days-post hatch, suggesting an adverse effect of B/BV challenge on 
gut health although no statistically significant differences were revealed  (P > 0.05; 
Dunn’s multiple comparison test) (Figures 3.9A and 3.10A). Significantly different gut 
scores were observed between sampling time-points for the B/BV challenged group in 
Hatch 1 (P < 0.05) and Hatch 2 (P < 0.01) indicating a deterioration in gut health up to 
Day 28.  
 
In Hatch 1, the water control birds aged 21 days were significantly heavier than the B/BV 
challenge groups (P <0.05, Bonferroni post-tests), although there were no differences 
observed in this pen 1 week later at Day 28. No weight differences were observed in 
Hatch 2. 
 
In Hatch 2 the Day 4 caecal microbiome in the B/BV challenged group contained 
Bacteroides spp. at a relative abundance of 40%, but this was not replicated in the water 
control pen. Relative to the water control birds, the microbiota from the Line X B/BV 
challenged groups contained higher abundances of Butyricicoccus spp. at Day 4 (Hatch 
1: 3% vs. 8%; Hatch 2: 6% vs. 11%), Lactobacillus spp. at Day 21 (Hatch 1: 7% vs. 16%; 
Hatch 2: 10% vs. 16%) and Alistipes spp. at Day 28 (Hatch 1: 6% vs. 11%; Hatch 2: 3% 
vs. 9%). Relative to the water control birds the B/BV challenged group had lower 
abundances at Day 4 of Blautia spp. (Hatch 1: 7% vs 4%; Hatch 2 5% vs. 3%) and 
Faecalibacterium spp. (Hatch 1: 6% vs. 5%; Hatch 2: 13% vs. 7%) and at Day 28 lower 
relative abundances of Lactobacillus spp. were found (Hatch 1: 24% vs. 12%; Hatch 2: 
15% vs. 8%).  
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3.2.4.2 Line Y 
Figures 3.11 and 3.12 illustrate the individual gut health scores of Line Y birds at each 
sampling time-point (A), the mean weight per bird (B), the caecal microbiome of water 
control birds (C) and the B/BV challenge birds (D) for hatches 1 and 2, respectively. 
There were no significant differences in gut scores between the B/BV challenged pens 
and the water pens at any of the sampling time-points in either hatch 1 or 2 (P > 0.05; 
Dunn’s multiple comparison test). This was reflected in the total gut scores per sampling 
group i.e. the gut scores for the water control birds were 4 and 10 compared to 5 and 8 
for the B/BV challenged birds for hatch 1 and 2, respectively. In addition, no significant 
differences were found in mean bird weight for the water and the B/BV challenged groups 
for either hatch. 
 
A significant age effect was found in Hatch 2 for both the B/BV and the water challenge 
pen (P <0.05; Kruskal-Wallis test), indicating that the gut health was worse at the later 
sampling time-points, irrespective of challenge. 
 
In general, the Line Y birds were resistant to the B/BV challenge in that their gut health 
was robust and not adversely affected. At Day 4 the microbiota of the B/BV challenged 
pens differed to their corresponding control pen by showing reduced levels of 
Lactobacillus spp. (Hatch 1: 41% vs. 3%; Hatch 2: 10% vs. 3%). The abundance of 
Bacteroides spp. was higher in the B/BV challenged group in Hatch 1 at Day 21 (24% 
vs. 33%) and at Day 14 in Hatch 2 (30% vs. 37%). At Day 21 in Hatch 2 a much larger 
proportion of the microbiota in the B/BV challenged group consisted of Barnesiella spp. 
in comparison with the control pen (8% vs. 48%) but no obvious differences in 
Barnesiella spp. were seen in Hatch 1.  
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Figure 3.9:  The effects of Bacteroides dorei + Barnesiella viscericola challenge on Line X birds in Hatch 1. 
Line X birds were challenged with water or Bacteroides dorei + Barnesiella viscericola (B/BV) at Day 0 and sampled at 4, 21 and 28 days post-hatch.      A: Gut 
health assessments for individual LX birds (n = 5 birds per pen), black circles = water challenge, red circles = B/BV challenged birds, (* P < 0.05, Kruskal-Wallis 
test). B: Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, red columns = B/BV challenged birds (*P < 0.001, 
Bonferroni post-test following Two-way ANOVA). C & D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and B/BV 
challenged birds (D) (n = 5 birds per pen). Corresponding total gut health score per sampled group (n = 5) at each sampling time-point is shown above each column. 
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Figure 3.10: The effects of Bacteroides dorei + Barnesiella viscericola challenge on Line X birds in Hatch 2. 
Line X birds were challenged with water or Bacteroides dorei + Barnesiella viscericola (B/BV) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.      A: Gut 
health assessments for individual LX birds (n = 5 birds per pen), black circles = water challenge, red circles = B/BV challenged birds, (* P < 0.05, ** P < 0.01; Kruskal-
Wallis test). B: Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, red columns = B/BV challenged birds.C & 
D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and B/BV challenged birds (D) (n = 5 birds per pen). Corresponding 
total gut health score per sampled group (n = 5) at each sampling time-point is shown above each column. 
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Figure 3.11: The effects of Bacteroides dorei + Barnesiella viscericola challenge on Line Y birds in Hatch 1. 
Line Y birds were challenged with water or Bacteroides dorei + Barnesiella viscericola (B/BV) at Day 0 and sampled at 4, 21 and 28 days post-hatch. A: Gut health 
assessments for individual LY birds (n = 5 birds per pen), black circles = water challenge, red circles = B/BV challenged birds, (* P < 0.05, Kruskal-Wallis test). B: 
Average bird weight per pen ± co-efficient of variation % (n = 100); filled columns = water challenged, red columns = B/BV challenged birds. C & D: Relative 
abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and B/BV challenged birds (D) (n = 5 birds per pen). Corresponding total gut 
health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.12: The effects of Bacteroides dorei + Barnesiella viscericola challenge on Line Y birds in Hatch 2. 
Line Y birds were challenged with water or Bacteroides dorei + Barnesiella viscericola (B/BV) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.  A: Gut 
health assessments for individual LYbirds (n = 5 birds per pen), black circles = water challenge, red circles = B/BV challenged birds, (* P < 0.05, Kruskal-Wallis test). 
B: Average bird weight per pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, red columns = B/BV challenged birds. C & D: Relative 
abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and B/BV challenged birds (D) (n = 5 birds per pen). Corresponding total gut 
health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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3.2.5 Effects of mix challenge (B/BV + LJ) on gut health, bird weight and caecal 
microbiota 
3.2.5.1 Line X 
Figures 3.13 and 3.14 illustrate individual Line X bird gut health scores at each sampling 
timepoint (A), the mean weight per bird (B), the caecal microbiome of water control birds 
(C) and mix challenged birds (D) for hatches 1 and 2, respectively. 
 
For Hatches 1 and 2, no significant differences in gut health were observed between the 
water and mix challenge pens (P > 0.05, Dunn’s multiple comparison test), although at 
Day 28 for Hatch 1, the median gut health for the mix challenge was two compared to 
one in the water control group. For Hatch 1, a significant effect of sampling age on gut 
health was observed in the mix challenged group indicating that gut health worsens at the 
later sampling time-points; this did not reach statistical significance in the water 
challenged pens (P < 0.05, Kruskal-Wallis test). Despite the gut health worsening over 
time, seeding the pens with mixed bacteria had no significant effect on mean Line X bird 
weight for either hatch. 
 
In comparison to the water control birds , the caecal microbiome of the Line X mix 
challenge birds had a higher abundance of Barnesiella spp. at Day 4 (Hatch 2: 0% vs. 
18%), Day 21 (Hatch 2: 15% vs. 23%) and Day 28 (Hatch 1: 11% vs. 23%). The relative 
abundance of Lactobacillus spp. at Day 4 was higher in the ‘mix’ challenged birds 
compared to the water control birds (Hatch 1: 10% vs. 18%; Hatch 2: 9% vs. 16%). In 
contrast, Lactobacillus spp. was less abundant in the ‘mix’ challenge pens at Day 28 
(Hatch 1: 24% and 10%; Hatch 2: 15% vs. 9%).  
 
3.2.5.2 Line Y 
Figures 3.15 and 3.16 illustrate individual Line Y bird gut health at each sampling 
timepoint (A), the mean weight per bird (B), the caecal microbiome of water control birds 
(C) and B/BV challenged birds (D) for hatches 1 and 2, respectively. 
 
No significant differences in gut health scores were observed between the water controls 
and ‘mix’ challenge birds (P > 0.05, Dunn’s multiple comparison test). Consistent to both 
hatches was that the ‘mix’ challenge appeared to result in lighter birds than the water 
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challenge pen (Hatch 1: mean weight 1016g vs. 982g; Hatch 2: 1044g vs. 1029g)(P < 
0.01 and P < 0.001, Bonferroni post-tests following Two-way ANOVA).  
 
Compared to the water control pens the caecal microbiome of the ‘mix’ challenged birds 
contained higher relative abundances of Bacteroides spp. at Day 21 (Hatch 1: 24% vs. 
39%; Hatch 2: 2% vs. 14%)  and Day 28 (Hatch 1: 4% vs. 6%; Hatch 2: 2% vs. 12%). 
Lower abundances of Barnesiella spp. were found in the ‘mix’ challenged birds at Day 
28 (Hatch 1: 21% vs. 14%; Hatch 2: 27% vs. 22%). Noteworthy differences found in 
single hatches were that relatively high levels of Escherichia/shigella spp. were found in 
Hatch 1 mix challenged birds (17%), and, as described earlier, high Lactobacillus spp. 
levels were also found in the water control pen in this hatch (40%).  
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Figure 3.13: The effects of mix challenge (B/BV + LJ) on Line X birds in Hatch 1. 
Line X birds were challenged with water or mixture (B/BV + LJ) at Day 0 and sampled at 4, 21 and 28 days post-hatch. A: Gut health assessments for individual LX 
birds (n = 5 birds per pen), black circles = water challenge, orange circles = Mix challenged birds, (* P < 0.05, Kruskal-Wallis test). B: Average bird weight per pen ± 
co-efficient of Variation % (n = 100); filled columns = water challenged, orange columns = B/BV challenged birds. C & D: Relative abundance of bacterial genus (% 
population) in caecal digesta of water challenged (C) and Mix challenged birds (D) (n = 5 birds per pen). Corresponding total gut health score per sampled group (n = 
5) at each sampling timepoint is shown above each column. 
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Figure 3.14: The effects of mix challenge (B/BV + LJ) on Line X birds in Hatch 2. 
 Line X birds were challenged with water or mixture (B/BV + LJ) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.   A: Gut health assessments for individual 
LX birds (n = 5 birds per pen), black circles = water challenge, orange circles = Mix challenged birds, (* P < 0.05, Kruskal-Wallis test). B: Average bird weight per 
pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, orange columns = Mix challenged birds (*** P < 0.001, Bonferroni post-test following 
Two-way ANOVA). C & D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and Mix challenged birds (D) (n = 5 birds 
per pen). Corresponding total gut health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.15: The effects of mix challenge (B/BV + LJ) on Line Y birds in Hatch 1. 
Line Y birds were challenged with water or mixture (B/BV + LJ) at Day 0 and sampled at 4, 21 and 28 days post-hatch.    A: Gut health assessments for individual 
LY birds (n = 5 birds per pen), black circles = water challenge, orange circles = Mix challenged birds, (* P < 0.05, Kruskal-Wallis test). B: Average bird weight per 
pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, orange columns = B/BV challenged birds (* P < 0.05, ** P < 0.01, Bonferroni post-
test following Two-way ANOVA). C & D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and Mix challenged birds 
(D) (n = 5 birds per pen). Corresponding total gut health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.16: The effects of mix challenge (B/BV + LJ) on Line Y birds in Hatch 2. 
Line Y birds were challenged with water or mixture (B/BV + LJ) at Day 0 and sampled at 4, 14, 21 and 28 days post-hatch.  A: Gut health assessments for individual 
LY birds (n = 5 birds per pen), black circles = water challenge, orange circles = Mix challenged birds, (* P < 0.05, Kruskal-Wallis test). B: Average bird weight per 
pen ± co-efficient of Variation % (n = 100); filled columns = water challenged, orange columns = Mix challenged birds (* P < 0.05, Bonferroni post-test following 
Two-way ANOVA). C & D: Relative abundance of bacterial genus (% population) in caecal digesta of water challenged (C) and Mix challenged birds (D) (n = 5 birds 
per pen). Corresponding total gut health score per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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3.2.6 Summary of caecal microbiotae at the phylum level 
Although a relatively large percentage of bacterial species could not be identified, the 
composition of the caecal microbiota for all groups of birds could be broadly categorised 
at the phylum level into Firmicutes (predominantly Lactobacillus spp., Faecalibacterium, 
Blautia, Butyricicoccus and Coprobacillus) and Bacteroidetes (predominantly Alistipes 
spp, Bacteroides spp. and Barnesiella spp.). Figure 3.17 summarises the composition of 
the caecal microbiotae at the phylum level and shows the effect of bird age and the type 
of bacterial challenge. In brief, at 4 days following challenge there were few trends that 
were consistent across Hatches 1 and 2, although the Hatch 2 B/BV challenge did result 
in a large increase (>40%) in species belonging to the Bacteroidetes phyla for both Lines 
X and Y. The microbiotae data at Day 28 showed no obvious effect of bacterial challenge 
although the microbiotae had shifted away from the Firmicutes found at Day 4 to 
Bacteroidetes particularly Barnesiella (as shown in Figures 3.3 – 3.16). 
 
3.2.7 The relationship between gut health score and caecal microbiome composition 
Taking both Lines X and Y into account, no single microbial shift could be identified that 
was linked to deterioration of gut health. Analysis of all healthy/normal pens at the Day 
4 sampling timepoint (Line Y LJ challenged pens in both hatches and Line X Hatch 2 
control) revealed no consistent composition of microbiota that was different to pens 
containing abnormal birds. At Day 28, although large differences in gut health between 
pens was observed (total pen score 1 – 23), the microbiotas at this time-point were similar 
with Barnesiella spp. as the dominant species. However, a significant correlation was 
found between the relative abundance of Bacteroides spp. at Day 21 and the gut health 
of these birds at Day 21 and Day 28 (Figure 3.18A and B). 
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Figure 3.17: The effect of bird age and species of bacterial challenge on caecal microbiotae 
at the phylum level 
 
The relative bacterial abundances (%), taking into account only Firmicutes (black) and 
Bacteroidetes (grey), are shown for groups of birds (n = 5) challenged with water (control), 
Lactobacillus johnsonii (LJ), Bacteroides dorei/Barnesiella viscericola (B/BV) and mixture (LJ 
+ B/BV) at hatch and sampled at Day 4 (A, C, E and G) and Day 28. LX – Line X, LY – Line Y, 
H1 – hatch 1, H2 – hatch 2.  
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Figure 3.18: The correlation between relative abundance of Bacteroides spp. in the caecal 
digesta and total gut score.   
The data shows the abundance of Bacteroides spp. (%) in the digesta from birds sampled at 21 
days post-hatch and the total gut score per pen at 21 days (A) and 28 days post-hatch (B) (*** P 
< 0.001; ** P < 0.01; Spearman Rank correlation).  
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3.2.7 Ileal microbiome of challenged broilers  
The relative abundance of bacterial genera from ileal digesta for Line X and Y birds are 
shown in Figures 3.19 – 3.22, respectively. 
 
Lactobacillus was the most abundant species found in all sampled groups apart from the 
Line X mix challenged pen sampled at Day 14 (Hatch 2) in which Escherichia/shigella 
spp. were found to dominate at 69% (Figure 3.21D). This high level of 
Escherichia/shigella spp. appeared to have no detrimental effect on gut health (group gut 
score 2) compared to other Line X Hatch 2 pens. This unusual microbiome appeared to 
be short-lived as no Escherichia/shigella spp. were found in the ileal digesta of birds 
sampled seven days later at 21 days post-hatch.  
 
For both hatches, Line Y birds had increased bacterial diversity compared to Line X birds. 
The highest number of bacterial genera was found in digesta from 21 day-old birds and 
diversity was highest in Line Y Lactobacillus johnsonii challenged birds. For example, 
digesta from Line Y Lactobacillus johnsonii challenged birds (Hatch 1) contained 
bacteria from 8 genera at low abundances of 1 – 4% (Weissella spp., Streptococcus spp., 
Staphylococcus spp., Corynebacterium spp., Brevibacterium spp., Brachybacterium spp. 
and Atopostipes spp.) in contrast to the equivalent Line X group in which Lactobacillus 
spp. were the only bacterial species identified. However, by 28 days-post hatch little 
variation in the microbiome was observed and Lactobacillus spp. levels had increased to 
over 89% for all pens.  
 
The Line X: B/BV challenged group in Hatch 2 displayed the worst gut health and 
contained lower levels of Lactobacillus spp. and higher levels of Enterococcus spp. than 
the LJ and mix challenged pens, which had better gut health. Plotting the relative 
abundance of Lactobacillus spp. found in digesta at 4 days post-hatch in Line X birds 
against total gut health per pen at Day 28 identified a significant inverse correlation (P < 
0.05) (Figure 3.23). However, no relationship between early Lactobacillus spp. 
colonisation and gut health was found in Line Y birds (P > 0.05). Irrespective of line, a 
comparison of the pen with the worst gut health (Line X H2: B/BV challenge, Figure 
3.21C) and the best gut health (Line Y H2: LJ challenge, Figure 3.22B ) revealed no 
differences in Lactobacillus spp. levels at Day 4 with relative abundance levels of 75% 
for both pens.   
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Figure 3.19: The ileal microbiome of Line X birds in Hatch 1. 
Relative abundance of bacterial genus (% population)  in ileal digesta of Hatch 1 Line X birds (n = 5) sampled at 4, 21 and 28 days post-hatch from pens challenged 
with A) water, B) Lactobacillus johnsonii (LJ), C) Bacteroides dorei/Barnesiella viscericola (B/BV), D) Mixture (B/BV + LJ). Corresponding total gut health score 
per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.20: The ileal microbiome of Line Y birds in Hatch 1. 
Relative abundance of bacterial genus (% population)  in ileal digesta of Hatch 1 Line Y birds (n = 5) sampled at 4, 21 and 28 days post-hatch from pens challenged 
with A) water, B) Lactobacillus johnsonii (LJ), C) Bacteroides dorei/Barnesiella viscericola (B/BV), D) Mixture (B/BV + LJ). Corresponding total gut health score 
per sampled group (n = 5) at each sampling timepoint is shown above each column. 
4 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 21 28
0
20
40
60
80
100
Acetivibrio
Atopostipes
Barnesiella
Brachybacterium
Brevibacterium
Coprobacillus
Corynebacterium
Enterococcus
Escherichia/Shigella
Faecalibacterium
Gemella
Nocardiopsis
Propionibacterium
Sphingomonas
Staphylococcus
Streptococcus
Weissella
Yaniella
Weeksella
Lactobacillus
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
1 3 4 0 1 2
2 2 5 2 1 2
A B
C D
94 
 
 
Figure 3.21: The ileal microbiome of Line X birds in Hatch 2. 
Relative abundance of bacterial genus (% population)  in ileal digesta of Hatch 2 Line X birds (n = 5) sampled at 4, 21 and 28 days post-hatch from pens challenged 
with A) water, B) Lactobacillus johnsonii (LJ),C) Bacteroides dorei/Barnesiella viscericola (B/BV), D) Mixture (B/BV + LJ). Corresponding total gut health score 
per sampled group (n = 5) at each sampling timepoint is shown above each column. 
4 14 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 14 21 28
0
20
40
60
80
100
Other
Unclassified
Bordetella
Corynebacterium
Enterococcus
Lactobacillus
Staphylococcus
Escherichia/Shigella
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 14 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
4 14 21 28
0
20
40
60
80
100
Bird age at sampling (days)
%
 P
o
p
u
la
ti
o
n
0 1 5 16 1 3 8 8
1 2 5 102 10 17 23
A
C
B
D
95 
 
 
Figure 3.22: The ileal microbiome of Line Y birds in Hatch 2. 
Relative abundance of bacterial genus (% population)  in ileal digesta of Hatch 2 Line Y birds (n = 5) sampled at 4, 21 and 28 days post-hatch from pens challenged 
with A) water, B) Lactobacillus johnsonii (LJ),C) Bacteroides dorei/Barnesiella viscericola (B/BV), D) Mixture (B/BV + LJ). Corresponding total gut health score 
per sampled group (n = 5) at each sampling timepoint is shown above each column. 
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Figure 3.23:  The relationship between the abundance of ileal Lactobacillus spp. at Day 4 
and the total gut score at Day 28.  
The abundance of Lactobacillus spp. identified in the ileal digesta of 4 day-old birds and the total 
gut score for 28 day-old birds is shown for A) Line X and B) Line Y birds. Black circles: water 
control, Blue circles: Lactobacillus johnsonii challenge, Red circles: Bacteroides/Barnesiella 
viscericola challenge and Orange circles: Mix challenge. Each data point represents 5 sampled 
birds (n = 5). * P < 0.05; One-tailed Spearman rank correlation. 
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3.2.8 Microbial activities of jejunal mucosal scrapes  
Although the microbiome of the small intestine is mainly populated by Lactobacillus spp. 
(Gong et al., 2007), it has been revealed that intestinal overgrowth of bacterial species 
that are normally resident in the gut has been implicated in enteric diseases in poultry 
such as necrotic enteritis (Long et al., 1974) and dysbacteriosis (Bailey, 2010). To 
investigate the ability of the host intestinal mucosa to facilitate the growth of potentially 
opportunistic pathogens, in this case E. coli, total protein extracts from jejunal gut scrapes 
were prepared from the same birds that were assessed for microbiota and gut health.   
 
Microbial growth assays for sampled jejunal scrapes from Line X and Line Y birds are 
shown in Figures 3.24 and 3.27 - 3.29, respectively. Data from Line X and Y water control 
groups in Hatches 1 and 2 are shown in Figure 3.24. For Hatch 1 no significant effect of 
bird line on E. coli growth was identified. When the Line X birds were analysed in 
isolation the gut scrapes from birds at day 21 post-hatch facilitated significantly less % 
E. coli growth than the Day 4 birds (P < 0.01, Students T-test). For Hatch 2 a significant 
effect of line was observed with mean % E. coli growth for the Line Y gut scrapes 
supporting higher mean % E. coli growth for all three sampling time-points, and this was 
found to be highly significant at Day 7 (P < 0.001, Bonferonni post-tests).  
 
Figure 3.25A shows that Day 4 jejunal scrapes from control birds with abnormal gut 
health supported significantly higher % E. coli growth than scrapes from birds with 
healthy guts. When all bird data, irrespective of challenge, were pooled the same result 
was observed with higher % mean E. coli growth found in the abnormal group, however 
there was complete overlap between the normal and abnormal groups (Figure 3.25B). 
The E. coli growth (%) induced by gut scrapes from birds aged 21 days is presented in 
Figures 3.26A and B. No significant relationship was found between gut score and E. coli 
growth (%) for the either the water control birds (3.26A) or all challenged birds (3.26B). 
 
A comparison of jejunal scrapes from Line X and Y birds from control and Lactobacillus 
johnsonii pens is shown in Figure 3.27. For Hatch 1: Line X (Figure 3.27A), there was a 
significant interaction between challenge and sampling time-point indicating that the 
challenge did not have the same effect at each time-point (Two-way ANOVA, P < 0.01). 
At Day 4 the gut scrapes from the LJ challenged birds induced significantly lower mean 
% E. coli growth than the water group (P < 0.05, Bonferonni post-tests). Similarly, the 
scrapes from the LJ challenged Hatch 1 Line Y birds also suppressed E. coli growth 
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relative to the water control (Figure 3.27B)(Two-way ANOVA, P < 0.05). However, in 
Hatch 2 the gut scrapes from Line X LJ challenged birds supported higher mean % E. 
coli growth than the water control groups at all sampling time-points (Figure 3.27C) 
(Two-way ANOVA, P < 0.05). Higher mean % E. coli growth was also observed in Line 
Y birds, but only for the gut scrapes taken from birds at 7 days post-hatch (P < 0.05, 
Bonferonni post-tests), which suggested that the response was age-dependent (interaction 
between sampling timepoint and effect of challenge; P < 0.01, Two-way ANOVA). At 
Day 4 and 21 there was a suggestion of reduced E. coli growth in Line Y: LJ challenged 
birds, but this was not statistically significant.  
 
Figures 3.28A-D illustrate the differences in % E. coli growth induced by jejunal gut 
scrapes between B/BV and water challenged pens. The data from Hatch 1 shows that gut 
scrapes sampled from Line X: B/BV challenged birds supported significantly higher % 
E. coli growth than samples from the water challenged pen (Figure 3.28A)(P < 0.05, Two-
way ANOVA). Furthermore, the gut scrapes from Line X birds sampled at 21 days post-
hatch were associated with lower  E. coli growth than the Day 4 gut scrapes (P < 0.05, 
Two-way ANOVA) (Figure 3.28A). In Hatch 2, significantly higher E. coli growth was 
supported by gut scrapes from the Line X (P < 0.05) and Line Y B/BV challenged birds 
(P < 0.01) sampled at 7 days post-hatch (Figures 3.28C and D).  
 
Figures 3.29A-D show the differences in % E. coli growth associated with jejunal gut 
scrapes from water and mix challenged Line X and Line Y birds.  For Hatch 1 no 
significant differences in E. coli growth between birds from mix challenged and control 
pens were observed for either Line X (Figure 3.29A) or Line Y (Figure 3.29B). However, 
for Hatch 2, gut scrapes from Line X birds facilitated higher mean % E. coli growth than 
the water control birds across all three sampling time-points (P < 0.01, two-way 
ANOVA). Moreover, a significant effect of bird age was found. Gut scrapes from birds 
sampled at Day 4 supported higher mean % E. coli growth than jejunal scrapes taken at 
7 and 21 days post-hatch (P < 0.05). There was no effect of challenge in Line Y birds for 
this hatch although % E. coli growth did vary significantly with age (P < 0.01, Two-way 
ANOVA).  
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Figure 3.24: The effect of jejunal protein extracts from Line X and Y birds on % E. coli 
survival. 
 Microbial growth assay (colony counting) data shows the mean and individual % E. coli survival 
facilitated by jejunal gut extracts from Line X and Y birds aged 4, 7 and 21 days for Hatch 1 (A) 
and Hatch 2 (B)  (n=4/5 for all groups). Line X – solid circles, Line Y – open circles, Solid line 
– Line X mean. Dotted line – Line Y mean. 
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Figure 3.25: Jejunal protein extracts from abnormal birds aged 4 days-old support higher 
% E. coli growth.  
E. coli growth (%) was calculated in a colony counting assay following incubation with jejunal 
mucosal proteins extracted from Line X and Y birds aged 4 days-old with normal and abnormal 
gut scores.  Birds were sampled from (A) water control pens (B) all pens irrespective of challenge. 
Gut score 0 = normal gut health; Gut score 1-2 = abnormal gut health.  Line X – solid circles, 
Line Y – open circles, Solid Line – Line X mean, Dotted Line – Line Y mean.  
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Figure 3.26: Jejunal protein extracts from normal and abnormal birds aged 21 days-old 
support similar levels of % E. coli growth.  
E. coli growth (%) was calculated in a colony counting assay following incubation with jejunal 
mucosal proteins extracted from Line X and Y birds aged 21 days-old with normal and abnormal 
gut scores.  Birds were sampled from (A) water control pens (B) all pens irrespective of challenge. 
Gut score 0 = normal gut health; Gut score 1-6 = abnormal gut health.  Line X – solid circles, 
Line Y – open circles, Solid Line – Line X mean, Dotted line – Line Y mean.  
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Figure 3.27: The effect of Lactobacillus johnsonii challenge on the ability of jejunal protein extracts to support E. coli growth. 
Mean and individual % E. coli survival facilitated by jejunal protein extracts was assessed using the microbial growth assay (colony counting).   Data is shown for 
Line X birds from Hatch 1 (A) and 2 (C) (solid circles) and Line Y birds from Hatch 1(B) and 2 (D) (open circles). Samples were analysed from birds aged 4, 7 and 
21 days-old (n=3 - 5 for all groups). Water challenged – black circles, Lactobacillus johnsonii challenged – blue circles.  Black line – water challenged mean, Blue 
line - Lactobacillus johnsonii challenged. (* = P < 0.05, Two-way ANOVA followed by Bonferonii post-tests specific to sampling timepoint). 
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Figure 3.28: The effect of Bacteroides dorei/Barnesiella viscerocola challenge on the ability of jejunal protein extracts to support E. coli growth. 
Mean and individual % E. coli survival facilitated by jejunal protein extracts was assessed using the microbial growth assay (colony counting).   Data is shown for 
Line X birds from Hatch 1 (A) and 2 (C) (solid circles) and Line Y birds from Hatch 1(B) and 2 (D) (open circles). Samples were analysed from birds aged 4, 7 and 
21 days-old (n=3 - 5 for all groups). Water challenged – black circles, Bacteroides dorei/Barnesiella viscerocola   challenged – red circles.  Black line – water 
challenged mean, Red line - Bacteroides dorei/Barnesiella viscerocola challenged. (* = P <0.05, ** = P < 0.01 Two-way ANOVA followed by Bonferonni post-tests) 
(P values indicated are for the effect of B/BV challenge on % E. coli growth only; age-related effects and age-challenge interactions are discussed in the text).  
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Figure 3.29: The effect of mix challenge (B/BV + LJ) on the ability of jejunal protein extracts to support E. coli growth. 
Mean and individual % E. coli survival facilitated by jejunal protein extracts was assessed using the microbial growth assay (colony counting).   Data is shown for 
Line X birds from Hatch 1 (A) and 2 (C) (solid circles) and Line Y birds from Hatch 1(B) and 2 (D) (open circles). Samples were analysed from birds aged 4, 7 and 
21 days-old (n= 3 - 5 for all groups). Water challenged – black circles, Mix challenged – orange circles.  Black line – water challenged mean, Orange line – Mix 
challenged. (* = P <0.05, two-way ANOVA followed by Bonferonni post-tests) (P values indicated are for the effect of mix challenge on % E. coli growth only; age-
related effects and age-challenge interactions are discussed in the text).  
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3.2.9 Identification of sugars in gut samples 
To investigate whether differences in E. coli growth were influenced by sugar content in 
the gut scrapes, thin layer chromatography was performed. Initially, a series of sugar 
standards were spotted in conjunction with a single gut scrape (Figure 3.30) and these 
data suggested that the most prominent sugar band corresponded to galactose. To 
confirm, a series of sugar standards were analysed in conjunction with the gut scrape 
sample by HPLC. The result, shown in Figure 3.31, demonstrated that the sugar 
associated with this TLC band was galactose.  
 
To explore potential differences between the bird lines, ages and treatments, gut scrapes 
sampled at Days 4 and 7 from Line X and Y birds challenged with either LJ or B/BV 
were analysed by TLC (Figure 3.32). The pattern of sugar bands revealed a switch from 
a strong galactose signal in Line X day 4 birds to a strong galactose signal in Line Y, Day 
7 birds. That this occurred in the control birds, as well as in the LJ and B/BV challenged 
groups indicated that it was intrinsic to these two bird lines rather than an effect of the 
bacterial challenge. Moreover, these results taken with the microbial growth data reveal 
that the presence of sugar is linked to bird line and age, but not to E. coli survival. For 
example, in Line X the mean E. coli growth (%) at Day 4 and Day 7 were similar (314% 
vs. 285%) even though clear sugar differences were observed.  
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Figure 3.30: Thin Layer Chromatography showing 6 sugar standards.  
(F – Fucose, G – galactose,  GA - glucaronic acid, M – mannose, A – arabinose, X – Xylose) and 
one gut scrape extract from hatch 2 Line Y bird at 7 days-post hatch. The sugar standard for 
galactose migrates the same distance as the sample. 
 
 
Figure 3.31: High Pressure Liquid Chromatography chromatogram reveals that galactose 
is the predominant sugar in the sample.   
3 sugar standards (A - Arabinose , M - Mannose  and G - Galactose ), sample H2 D7 (S) , and 
Galactose standard + sample H2 D7 (Gal + S).  
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Figure 3.32: Age and line-dependent shifts in jejunal galactose content.  
TLC of extracted gut scrapes showing sugar differences between Line X and Line Y birds challenged with water, Lactobacillus johnsonii and Bacteroides 
dorei/Barnesiella viscericola. LX – Line X, LY – Line Y. The band corresponding to galactose is indicated.  
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3.3 Discussion 
Analysing the causes of enteric disease and implementing strategies to improve bird gut 
health has grown in importance over recent years, particularly since the E.U ban on anti-
microbial growth promoters (Van Immerseel et al., 2004). The aim of this trial was to 
investigate the gut health differences between two genetically different commercial breeding 
lines, namely X and Y, and to assess their response to further bacterial challenge with the 
long-term objectives of genetically selecting for improvements in disease susceptibility. 
Indeed, genetic loci have already been identified as a mechanism to help reduce the incidence 
of gut associated conditions including ascites (fluid accumulation in abdominal cavity) 
(Krishnamoorthy et al., 2014), coccidiosis (Pinard-van der Laan et al., 2009) and Salmonella 
susceptibility (Calenge et al., 2009; Thanh-Son et al., 2012).  
 
3.3.1 Gut health 
This trial was unique in that comparisons were made not only between two genetic lines of 
birds but also between the birds in two different hatches. Assessments from both hatches 
indicated gut health deterioration from the Day 4 sampling time-point up to Day 28 followed 
by marginal improvement at Day 35. However, comparison of Day 28 control bird gut data 
produced unexpected findings in that the overall gut health was worse in Hatch 2 than Hatch 
1 birds. The reasons for this hatch difference remain unknown as the rearing conditions were 
comparable. It is recognised that stress-related hormones such as adrenaline and cortisol can 
lower immune function, which may in turn increase the risk of intestinal problems (Mayer, 
2000). Thus unique environmental stresses experienced by Hatch 2 birds including those of 
temperature, humidity and bedding may have induced hormonal responses that adversely 
affected their gut immune defences. It has however been established that enteric disease is 
more closely linked to lower hygiene conditions, particularly caused by poor litter 
management (Dawkins et al., 2004).  In fact, the litter on which the birds are reared not only 
helps form the intestinal microbiota, but is a major source of potentially pathogenic microbes 
including parasites (Fries et al., 2005; Hermans et al., 2006). A comparison of bacterial loads 
and diversity in the bedding and the drinking water from the two hatches was not undertaken 
in this study, but these data may have helped unravel the exact cause of the inferior enteric 
health observed in Hatch 2 birds.  
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In this study, birds were challenged with either LJ or B/BV, and a combination of the two 
(B/BV + LJ). The rationale for using a LJ challenge was that Lactobacillus spp. function as 
probiotics (Torres-Rodriguez et al., 2007a; Brisbin et al., 2011; Mappley et al., 2011), and so 
the aim was to assess if any gut health improvements linked to LJ challenge were consistent 
between the bird lines. Probiotics function through a combination of factors including 
competitive exclusion, production of beneficial metabolites particularly butyric acid, 
production of bacteriocins and a lowering of environmental pH all of which prevent gut 
colonization by exogenous pathogenic bacteria or overgrowth of the normal commensal 
microbiota (Ng et al., 2009; Sherman et al., 2009). At 28 days post-hatch, when poor gut 
health was readily observed, the total gut health score per sampled group was lower in all LJ 
challenged groups than the water control groups (i.e. indicative of better gut health). This 
observation indicated that an immediate probiotic intervention following hatch does improve 
the gut health of birds in a commercial rearing environment, even those birds that are more 
susceptible to enteric problems such as Line X. However, it is also worth noting the number 
of birds per group that were healthy and those that had abnormalities. In Hatch 2, the guts of 
all five sampled Line Y birds from the water control pen were abnormal (>1 gut score), but 
only one abnormal bird was observed in the LJ challenged group (Figure 3.8). In contrast, 
four Line X birds from Hatch 2 suffered gut abnormalities in the LJ challenged group 
compared to five in the water challenged group (Figure 3.6). These data indicated that the 
Line Y birds responded more favourably to LJ as a probiotic than Line X birds. Interestingly, 
examination of two probiotic preparations, previously successful in piglets, revealed that 
Ross 308 broilers fed a diet supplemented with Lactobacillus casei had significantly 
improved feed conversion efficiency relative to control groups whilst Sasso X40 broilers did 
not (Fajardo et al., 2012).  This variation in response between breeds therefore indicates that 
bird performance following probiotic intervention is, at least, partially-dependent on host 
genetics.  
 
A study which analysed the broiler gut microbiome using denaturing gradient gel 
electrophoresis (DGGE) identified the presence of bands in birds with dysbacteriosis, which 
were not found in healthy birds (Bailey, 2010). Sequencing analysis revealed that two of 
these bands corresponded to Bacteroides dorei and Barnesiella visericola. Although resident 
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in the digesta of healthy birds, the organisms are present at low levels in comparison to the 
diseased birds (Bailey, 2010). This observation led to the hypothesis that overgrowth of these 
two species is linked to the dysbacteriosis phenotype. In the present study, Bacteroides dorei 
and Barnesiella visericola, referred to as B/BV, were used to challenge the Line X and Y 
birds. A key finding was that the gut health of the Line Y birds did not deteriorate upon B/BV 
challenge whereas the gut health of the Line X birds was visibly worse, again supporting that 
bird genetics has a strong influence on host-bacterial interactions that shape the microbiome. 
However, the addition of LJ to B/BV as part of the mix challenge (LJ + B/BV) did result in 
lower overall gut scores relative to the B/BV groups alone (Figure 3.2), suggesting that LJ 
can alleviate some of the effects of the B/BV challenge, at least when administered 
concurrently. It was noted that in many of the challenged pens, including those challenged 
with “probiotic-like” LJ, had birds with lower mean weight than birds from the control pens. 
The reason for this is unknown but it did not appear to relate to actual gut health. However 
if reproducible then there is a potential commercial impact that warrants further investigation.  
 
3.3.2 Ileal microbiota 
In this trial the ileal and caecal microbiota of control and challenged birds were sampled at 
various timepoints up to 28 days post-hatch and the composition, and development, of the 
microbiota assessed by 454 sequencing. Analyses of the caecal and ileal microbiomes were 
performed on groups of five birds that represented the microbiome of the entire pen. Due to 
differences in gut health within sampled groups, particularly in the first week of life, there is, 
with hindsight, a strong argument for performing such analyses on individual birds and 
comparing data from normal (gut score 0) and abnormal birds (gut score >1). Indeed, the 
individual sequencing approach may be more likely to indicate whether, and if so, which 
bacterial species are useful markers of gut health. It would be interesting, for example, to 
know whether the high Escherichia/Shigella spp. found in Hatch 2 Line X, ‘mix’ challenge 
birds aged 14 days (Figure 3.21) were specific to the digesta of the two birds with abnormal 
guts or whether they also inhabited the ileal microbiota of the three healthy birds. Individual 
birds within a sampled group have a unique microbiota (van der Wielen et al., 2002), thus 
correlating individual microbiomes with observable phenotypes such gut health status and 
nutrient absorption may actually be necessary to link microbial composition to desirable or 
non-desirable breeding characteristics. However, pooling of samples to reduce variation and 
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sequencing costs is common practice and allowed initial comparisons between treatment 
groups to be performed. 
 
Factors in addition to rearing environment that influence the chicken microbiota are diet 
(Apajalahti et al., 2001; Knarreborg et al., 2002) and age (Lu et al., 2003). In this trial the 
diet was the same for both hatches allowing the effects of age on the microbiome to be 
assessed. The microbiome data from this trial mirrored the reported patterns of ileal 
microbiota formation in broilers. It has been shown previously that over 70% of 16s rRNA 
sequences are related to Lactobacillus spp. with 6.5% of sequences corresponding to 
Streptococcus spp. and Enterococcus spp. (Lu et al., 2003). These values correlated with the 
bacterial profiles found in this farm trial as the ileal microbiomes, with one exception that 
had a high E. coli profile, contained over 75% of sequences corresponding to Lactobacillus 
spp. Interestingly, fluctuations in the composition of the ileal microbiota could not be linked 
to gut health outcomes. For example, Bacteroides spp. associated with dysbacteriosis 
(Bailey, 2010), were only found in the ileal contents of a single group (<2% abundance) 
which had the healthiest gut health score. Moreover, E. coli levels were extremely high in 
the Day 14 Line X birds (69%) and yet no adverse effect on gut health was observed. There 
was, however, a strong suggestion in Line X birds (Figure 3.23), that a high abundance of 
Lactobacillus spp. at day 4 was protective allowing the gut to mature without suffering 
inflammation, increased watery contents or weakening of the gut tone. Intestinal overgrowth 
of endogenous bacterial commensals has been reported in human irritable bowel syndrome 
(IBS) (Madden and Hunter, 2002). If the poor gut health displayed by birds in this trial is 
analogous to human IBS, then it is possible that an overall higher count of bacteria were 
present in the ilea of such birds. However, only relative abundances were determined and 
culture-based methods would be required to determine actual bacterial densities.  
 
However the gut scrape assay data (Figure 3.28), suggested that the B/BV challenge affected 
the jejunal mucosa of birds so that it was able to support excess bacterial growth relative to 
unchallenged birds. This was in contrast to the mucosa of the LJ challenged birds that, on the 
whole, inhibited bacterial proliferation relative to the control birds (Figure 3.27). 
Furthermore, jejunal scrapes from four day-old birds with abnormal gut health also supported 
higher E. coli growth (Figure 3.25), suggesting that small intestinal bacterial overgrowth may 
112 
 
be linked to adverse gut health outcomes. However, it was also noted that higher E. coli 
growth was supported by gut scrapes from seven day-old Line Y birds compared to Line X 
birds and, as previously shown, the Line Y birds have fewer gut abnormalities. Furthermore, 
correlations between absolute % E. coli growth values and gut health scores did not reveal 
any clear links to gut health (data not shown). In practice, such assays would have little 
commercial use for determining the susceptibility of a pen to gut health problems, but do hint 
at physiological changes to the jejunal gut mucosa resulting from the LJ and B/BV 
challenges. 
 
3.3.3 Caecal microbiota 
The caecal microbiome is of huge interest because it not only provides nutrients via bacterial 
fermentation of polysaccharides but also functions as a reservoir for zoonotic food borne 
pathogens such as Salmonella spp. and Campylobacter spp., and pathogens adversely 
affecting bird gut health such as E. coli and C. perfringens (Clench and Mathias, 1995, 
Stanley et al., 2014). Previous pair-wise comparisons of the broiler ileal and caecal 
microbiomes have shown that the caecal microbiota at 3 days of age is not significantly 
different to the ileum being dominated by genera such as Clostridia spp. and Lactobacilli 
spp.  However, from 21 days onwards the caecal microbiota differs significantly showing 
increased complexity, and comprising of Fusobacterium spp., Bacteroides spp., and various 
species from the family Clostridiaceae (Lu et al., 2003). 
 
Caecal microbiota profiling using DGGE revealed an increase in species diversity in birds 
with dysbacteriosis compared to healthy birds, although it was the presence of two bands that 
corresponded to Bacteroides dorei and Barnesiella viscericola, respectively, that appeared 
to mark the enteric health status of the birds (Bailey, 2010). In the present study the 
microbiota were analysed at the genus level only so it was possible that excess growth of 
these two species occurred.  Exposing newly hatched chicks with Bacteroides dorei and 
Barnesiella viscericola was predicted to induce intestinal overgrowth of bacterial species and 
enteritis. However, while it was clear that these species induced gut health deterioration, the 
microbiota data indicated no consistent ileal or caecal microbial shifts. It should be noted that 
unclassified bacteria were often the most abundant group found and thus it cannot be 
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excluded that species, of as yet unclassified, bacteria are influential in causing gut health 
changes.  
 
The microbiota of the birds sampled for this trial showed that Bacteroides spp. dominated 
prior to formation of a stable caecal microbiome, then decreased in relative abundance. 
Moreover, closer analyses hinted that a high level of Bacteroides spp. in very young birds 
was detrimental to gut health. For example, in the pen with the worst gut health (Hatch 2: 
Line X, B/BV challenged) Bacteroides spp. were the dominant caecal species at Day 4. This 
was not observed in Line Y (Figure 3.12). Analyses of the caecal microbiota from the 
healthiest group of birds (LJ challenged Line Y: Hatch 2) revealed no Bacteroides spp. at 
Day 4 and a relatively low abundance at 14 days post-hatch (5%) (Figure 3.8), and this may 
have been crucial in the continued good gut health that followed (only 1 abnormal bird gut 
recorded at Day 28). In contrast, in the Hatch 2 Line X birds the relative abundance of 
Bacteroides spp. at Day 14 was 29% in both the LJ and the water control groups, and the 
number of birds suffering gut abnormalities by Day 28 was 4 and 5, respectively (Figure 3.6). 
In swine Bacteroides spp. are linked to the production of ammonia and amines (Gaskins, 
2001). It is therefore feasible that the presence of high levels of Bacteroides spp., and such 
metabolites, in the first two weeks post-hatch when the bird gut is still developing, may 
contribute to adverse gut health outcomes. It is also possible that the presence of Bacteroides 
spp. is indicative of protein malabsorption in the small intestine leading to an excess of 
protein in the caeca, conditions that actually favour Bacteroides spp. growth. Paradoxically 
however, data from the current trial (Figure 3.18) also showed that a high abundance of 
Bacteroides spp. in birds, aged 21 and 28 days, was associated with better gut health. 
Bacteroides spp. have been shown to confer many benefits to the host and have even been 
described as mutualistic (Backhed et al., 2005). For example, they have been shown to be 
involved in the activation of host T-cell mediated responses (Mazmanian, 2008), and the 
exclusion of potentially pathogenic bacteria (Mazmanian et al., 2008). Crucially, they are 
known to contribute to dietary energy via uptake of short-chain fatty acids, such as butyrate, 
derived from bacterial fermentation of complex polysaccharides (Flint et al., 2008; Martens 
et al., 2011). Therefore, the relationship between bird gut health and the presence of 
Bacteroides spp. is not simplistic but it is possible that the age at which Bacteroides spp. 
colonises the bird gut is critical in determining the effects of the colonisation on gut health.  
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3.3.4 Carbohydrate utilisation 
In this trial, TLC analysis revealed an interesting age and line-dependent pattern of galactose 
in jejunal gut scrapes. Poultry feed contains cereal grains of which the hemicellulose 
component contains galactan and galactomannan (Hsiao et al., 2006). Birds, like mammals, 
do not possess the enzymes able to break down complex polysaccharides and instead these 
dietary fibres are degraded in the caeca by species such as Bacteroides to produce short chain 
fatty acids (Mead 1989; Bolam and Sonnenburg 2011; Martens et al., 2011). However, many 
species of Lactobacilli, which are found at high levels in the bird crop, proventriculus and 
gizzard, have the ability to break down more complex sugars using a variety of glycosyl 
hydrolases (O'Donnell et al., 2013), which may in turn explain the intestinal galactose.  
 
Comparisons revealed that gut scrapes from Line X birds contained galactose at four days 
post-hatch, but not at seven days, whereas, in Line Y galactose was only found in birds aged 
seven days. Therefore, it is reasonable to speculate that the absence of galactose in Line X 
birds is linked to their less robust gut health. Birds lack lactase and are thus unable to break 
down lactose;  the sugar has, however, been utilized as a prebiotic because it can be 
metabolized by caecal anaerobes resulting in a reduction in the hindgut pH and decreased 
proliferation of potentially pathogenic bacteria (Hume et al., 1992). Low levels of galactose 
(2 -4 %) have also been shown to increase broiler body weight (Douglas et al., 2003), while 
lactose supplementation is associated with an increase in the weight of normal healthy turkey 
hen poults (Torres-Rodriguez et al., 2007b), and those given a Salmonella challenge (Vicente 
et al., 2007). Specific benefits relating to enteric disease have also been noted with a 2.5% 
lactose supplementation reducing necrotic enteritis lesions following C. perfringens 
challenge (McReynolds et al., 2007). Therefore, the presence of jejunal galactose in older 
Line Y birds, and from whatever source, may inadvertently function to maintain good gut 
health.  
 
3.3.5 Immune response to host microbiota 
Part of the rationale for using Lactobacillus spp. as a probiotic is that these species may help 
prevent excessive immune responses in young birds, such as those associated with gut 
inflammation, whereas Bacteroides spp. do not. Indeed, in murine models, various 
Lactobacillus species have been shown to produce cytokines that help modulate immune 
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responses (Christensen et al., 2002), and such modulation has also been reported for in vitro 
and in vivo chicken models (Brisbin et al., 2010; Brisbin et al., 2011). A study by Tsuda et 
al., (2007) comparing the cytokine stimulating properties of Lactobacillus johnsonii and 
Bacteroides acidofaciens on  antigen presenting cells showed that the former induced lower 
levels of pro-inflammatory cytokines IFN-γ and IL-6 and higher levels of anti-imflammatory 
cytokines IL-10 and IL12p40 than Bacteroides acidofaciens (Tsuda et al., 2007). Although 
Bacteroides spp. are regarded as normal bacteria in the gut flora, some species such as 
Bacteroides vulgatus have been associated with inflammatory gut conditions in transgenic 
rats (Rath et al., 1996), and guinea pigs (Onderdonk et al., 1981). Within the GI tract the 
precise role(s) of Bacteroides spp. in the induction and/or maintenance of an inappropriate 
immune response have not been fully described but various strains have been implicated in 
enteric diseases. For example high antibody titres against B. vulgatus surface antigens in 
ulcerative colitis have been described (Bamba et al., 1995) and it has been suggested that 
enterotoxigenic B. fragilis may cause inflammation and damage to epithelial cells in 
inflammatory bowel disease (Wu et al., 1998; Wu et al., 2004).  
 
Lines X and Y are commercial broiler breeds genetically selected for optimal broiler 
performance i.e. efficiency in converting feed to muscle mass. However, the selective 
breeding processes employed to produce Line X birds has resulted in a bird with a 
compromised gut health. This facet is not uncommon because the selective breeding process 
per se has not been tailored towards robust gut immunity (van der Most et al., 2011). For this 
trial no markers of immune response were measured, but it is possible that the increased 
inflammation in Line X birds was driven by an unregulated gut epithelial response to the host 
microbiota. Indeed, further analysis investigating the expression of immune effectors 
including host defense peptides and cytokines may help explain the susceptibility of such 
birds to enteric disease.   
 
3.3.6 Summary 
In summary, Line X birds had sub-optimal gut health relative to Line Y birds, were less 
robust to bacterial challenge and responded less favourably to the probiotic intervention 
although there were suggestions from the microbiome data that a high abundance of 
Lactobacillus spp. in the ileum of young birds did help protect the gut. Of interest was the 
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observation that colonization of the young bird gut with Bacteroides spp was linked with 
reduced gut health whereas high abundances in older birds was associated with improved gut 
health. Clear differences in jejunal galactose content between Lines X and Y warrants deeper 
investigation as sugar utilization may be linked to microbiome stability. Finally, bacterial 
overgrowth in the small intestinal is thought to cause dysbiosis, which can lead to enteric 
problems. B/BV treated birds were characterized by reduced gut health and interestingly 
microbial growth assays revealed that the gut scrapes from B/BV challenged birds supported 
increased E. coli growth, which reinforced the bacterial overgrowth and dysbiosis theory.  
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Chapter 4: Farm Trial 2 
4.1 Overview 
Line X is an important part of the breeding programme at Aviagen Ltd. and the data resulting 
from Trial 1, Chapter 3, indicated that Line X bird gut health is less robust than that of Line 
Y.  The data, however, indicated that bird gut health differences were particularly marked 
following a B/BV bacterial challenge at Day 0, i.e. the day of hatch. To further examine this 
observation, a second farm trial was performed to characterise, specifically, the gut innate 
defences of Line X birds following a B/BV challenge. The gut pathology of Line X birds 
makes it a good model to investigate bird gut immunity with the aim of improving gut health 
and therefore, maximising the potential of the Line X birds for commercial breeding 
purposes.  
 
An overview of this trial is shown in Figure 4.1. The aims were first to identify individual 
and/or groups of birds whose gut health was robust to bacterial exposures representative of 
commercial rearing environments, secondly to investigate potential relationships between 
gut health and AvBD gene expression, and thirdly to identify potential biomarkers of gut 
health. On arrival from the hatchery (Day 0), five male and female Line X birds were 
sacrificed, and tissue samples taken for AvBD gene expression (AvBD1 and 10) and 
immunohistochemical analyses. In addition, a jejunal gut scrape was taken from each bird 
for microbial growth assay analysis. The remaining birds were assigned to one of six pens so 
each pen contained 100 birds. Birds were provided with either acute (high B/BV seeding 109 
CFU/bird), prolonged (low B/BV seeding 109 CFU/water container) or water control 
challenges. At 7, 14, 21, and 28 days post-hatch a random sample of three birds per pen were 
individually weighed, sacrificed and visually assessed for gut health as in Trial 1. As 
described for the newly hatched chicks, tissue samples, jejunal scrapes and digesta were 
collected.  
 
All birds were fed the same diet as in Trial 1 and underwent the normal vaccination protocols 
(section 2.2.2). In contrast to Trial 1, birds were put into pens containing re-conditioned ‘old 
litter’ with fresh bedding layered on top to represent conditions found on commercial farms 
outside of the U.K.   
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Figure 4.1:  Farm trial 2 overview.  
Line X birds were separated into males and females and reared in six pens that were given one of three treatments: water (control), high seeding of B/BV 
(~109 C.F.U per individual) or low seeding B/BV (109 C.F.U per drinking water container). The trial was repeated for three hatches. Bacterial challenges 
and gut health assessments were performed by Aviagen Ltd. 
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4.2 Gut Health Assessments  
Gut health assessments were performed by Dr Richard Bailey and Mr Johnny Begley 
(Aviagen Ltd.). 
 
Figure 4.2A-C shows the gut health scores per sampled group (n = 3) at 7, 14, 21 and 28 
days, respectively, for three separate hatches following the B/BV challenges. The mean data 
for all three hatches, Figure 4.2D, shows that the bird gut health scores increased up to 21 
days post-hatch, supporting deterioration in gut health, but decreased at 28 days post-hatch, 
suggesting some improvement. For male birds the challenged groups had significantly higher 
gut scores at all sampling time-points whereas in females the adverse effect of challenge was 
delayed until 21 days post-hatch (P < 0.001, Two-way ANOVA, Bonferroni post-tests).  A 
comparison of low with high seeding challenge groups revealed no significant differences in 
gut health score between the groups (P > 0.05).  
 
4.3 Effects of B/BV challenge on bird weight 
Figure 4.3A-C illustrates the effect of low and high B/BV seeding on mean bird weight per 
sampled group (n = 3) for hatches 1, 2, 3 and all three hatches combined at 7, 14, 21 and 28 
days (Figure 4.3D). No significant differences in bird weight were observed between control 
and challenged groups at days 7, 14 and 21. However, by day 28, both male and female birds 
that underwent prolonged challenge (low seeding) were significantly lighter (Males: P< 0.01, 
Females P < 0.05), than the birds from the control pens. When all the hatch data was 
combined no significant effects of the acute challenge (high seeding) on bird weight were 
identified although if Hatch 1 and Hatch 3 birds were considered separately the high seeding 
female birds were significantly lighter than the three sampled birds from the water control 
pen  (P < 0.05). 
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Figure 4.2: The effect of low and high Bacteroides spp/Barnesiella spp. (B/BV) seeding on the gut health of male and female Line X birds.  
Birds were sampled at 7, 14, 21 and 28 days post-hatch and the data are displayed for Hatch 1 (A), Hatch 2 (B), Hatch 3 (C), and Hatches 1-3 combined 
(D). Bars not sharing letters are significantly different according to Bonferronii post-tests (P < 0.05). Only the significant effects of challenge are shown. 
Significant differences relating to sampling age and gender are not shown and instead are discussed in the text. Gut health analyses were performed by Dr 
Richard Bailey (Aviagen Ltd.). 
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Figure 4.3: The effect of low and high Bacteroides spp/Barnesiella spp. (B/BV) seeding on the mean bird weight of male and female Line X birds.  
Birds were sampled at 7, 14, 21 and 28 days post-hatch and the mean weights (± SEM) are displayed for Hatch 1 (A), Hatch 2 (B), Hatch 3 (C), and Hatches 
1-3 combined (D). A – C: n = 3 birds per pen; D: n = 9. Bars not sharing letters are significantly different according to Bonferronii post-tests (P < 0.05). 
Only the significant effects of challenge are shown. Significant differences relating to sampling age and gender are not shown and instead are discussed in 
the text.  
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4.4 AvBD1 gene expression 
Avian beta-defensins (AvBD) are hypothesised to be important effectors of the innate 
immune system, particularly during the first week of life when birds are vulnerable to 
bacterial infections (Bar-Shira et al., 2003; Bar-Shira and Friedman, 2006). In this study the 
effects of the B/BV challenges on AvBD 1 and 10 gene expression and the links, if any, to 
gut health were examined. AvBD1 was studied as the gene carried by Line X birds contains 
SNPs within the mature peptide coding sequence that may impact on its microbial killing 
capacity (Butler, 2010). AvBD10 contains a SNP in the 5’UTR region (Rs14411785), which 
may affect expression and, in addition, previous work had hinted at an unusual expression 
profile with expression detected not only in tissues of the GI tract but also at high levels in 
the kidney and liver (Butler, 2010).   
 
4.4.1 RT-endpoint PCR tissue panels (AvBD1) 
Initially, endpoint RT-PCR was performed on RNA extracted from the ten sampled tissues 
to determine tissue expression profiles prior to performing extensive real-time quantitative 
PCR analysis. AvBD1 was expressed in numerous tissues of newborn chicks (Day 0) and 
older birds (Figure 4.4) but real-time quantitative PCR analyses was limited to the gut tissues 
including duodenum, jejunum, ileum, caecum and caecal tonsil as well as  kidney and liver. 
As this study was primarily an investigation of gut immunity and gut health analysis of the 
spleen, bursa of Fabricus and thymus were not performed. 
 
Endpoint RT-PCR tissue panels for AvBD1 and 10 were performed by Dr Catherine 
Mowbray, Newcastle University. 
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Figure 4.4: Endpoint PCR tissue panels showing AvBD1 gene expression at Day 0 and Day 21 for control and challenged birds. 
A)  AvBD1 tissue panel utilising a single newly hatched bird for each tissue and for B) three birds aged 21 days, each one sampled from either the water 
control pen (W), the low seeding B/BV challenge pen (L) or the high seeding B/BV challenge pen (H). RNA was extracted from Kidney (K), Spleen (S), 
Liver (L), Bursa (B), Thymus (T), Duodenum (D), Jejunum (J), Ileum (I), Caecum (C) and Caecal Tonsil (CT). –ve = negative control.  Data supplied by 
Dr Catherine Mowbray, Newcastle University. 
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4.4.2 Housekeeping genes 
Quantitative PCR requires the use of housekeeping genes for data normalisation i.e. to enable 
variations in yields of RNA extraction and subsequent reverse transcription to be controlled 
between samples. Guidelines released as the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) suggest that the use of a single 
housekeeping gene is not normally acceptable and all chosen genes must be experimentally 
validated (Bustin et al., 2009). 
 
The chicken GEnorm kit (PrimerDesign, UK) was used to select suitable housekeeping genes 
for sample normalisation. Genes assessed for suitability were GAPDH, YWHAZ, ACTB, 
UBC, SDHA and SF3A1. Figure 4.5 shows the output from the GEnorm software, which 
indicates the average expression stability value (M) of the six potential reference genes. The 
lower the M value the more stable the gene expression. The software indicated that SDHA 
and SF3A1 were the most suitable housekeeping genes for avian tissue.  
 
 
Figure 4.5: GeNorm analysis to determine the most appropriate genes for real-time qPCR in 
avian tissues.  
The average expression stability value (M) of six chicken reference genes in the GeNorm kit 
(PrimerDesign); GAPDH, YWHAZ, ACTB, UBC, SDHA and SF3A1. The expression stability 
increases from left to right.  
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4.4.3 AvBD1 standard curve and melt curve 
Using a 1:10 dilution series of AvBD1 plasmid, real-time qPCR reactions were performed to 
provide a large range of crossing point (CP) values that could be used for relative 
quantification of individual samples. This procedure was repeated at least three times to 
ensure reproducibility, an amplification efficiency of ~2 and a low error value for sample 
replicates (P < 0.05).  The standard curve used for relative quantification of AvBD1 is shown 
in Figure 4.6A. For each sample, melt curves were checked for a single peak at 83°C which 
ensured AvBD1 primer specificity. A series of melt curves for AvBD1 PCR products from 
gut tissue cDNAs is shown in Figure 4.6B.  
 
 
Figure 4.6: Real-time qPCR standard and melt curve for AvBD1.  
A) Standard curve for serial dilutions of AvBD1 plasmid against calculated CP values. B) Melt curve 
for AvBD1 PCR products of gut tissue samples (n = ~ 40 samples).  A single peak for each product 
was observed at the melting temperature of ~83.3°C.  
A) Standard curve
B) Melt curves
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4.4.4 Summary of AvBD1 gene expression in tissues of birds aged 0, 7 and 21 days  
A total of 236 birds from three hatches were sampled for this study, but unfortunately no 
samples were available for Hatch 1, Day 0 birds. As this was considered to be an important 
time-point, subsequent analyses focussed on data resulting from Hatch 2 and 3 birds only. 
Real-time qPCR analyses for Farm Trial 2 were performed in collaboration with Dr Catherine 
Mowbray, Newcastle University.  
 
Figure 4.7 shows the AvBD1 gene expression profiles of tissues from Hatch 2 (A, C and E) 
and Hatch 3 (B, D and F) birds aged 0, 7 and 21 days. It is clear from these data that newly 
hatched chicks exhibit intrinsically large variation in AvBD1 expression, and for all tissue 
groups a small number of birds have extremely high expression levels (hence necessitating 
the use of split Y-axis graphs). To ascertain if the expression values were sampled from a 
Normal (Gaussian) distribution, the D'Agostino & Pearson omnibus normality test was 
performed. Many of the tissue groups tested suggested that the data was not normally 
distributed. However, with this taken into consideration and the use of non-parametric 
statistical tests, comparison of median AvBD1 expression levels revealed significant 
differences between tissue types at all sampling time-points in both Hatch 2 and 3, indicating 
that expression is tissue dependent. In summary, on the day of hatch there was a pattern of 
increased AvBD1 expression in the distal gut (ileum/caecum/caecal tonsil) compared to the 
proximal gut tissues (duodenum/jejunum). In both hatches, AvBD1 expression had decreased 
markedly by the Day 7 sampling time-point (Panels C and D) with only caecal tonsil 
expression being maintained. Interestingly, by Day 21 although AvBD1 expression was low 
throughout, a single bird in each hatch expressed a relatively high level of the AvBD1 gene 
in the caecal tonsils (Panels E and F). 
 
At Day 0 a comparison of the median AvBD1 values between Hatch 2 and Hatch 3 revealed 
statistically significant differences in AvBD1 expression (P < 0.001, Two-way ANOVA). 
For this reason, all subsequent data were presented according to the individual hatches.  
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Figure 4.7: AvBD1 gene expression in tissues of newly hatched chicks (Day 0) and birds aged 7 
and 21 days  
Gene expression is shown in arbitary units for newly hatched chicks in Hatch 2 (A) and Hatch 3 (B), 
birds aged 7 days in Hatch 2 (C) and Hatch 3 (D), and birds aged 21 days in Hatch 2 (E) and Hatch 
3 (F).  K – kidney, L – liver, D – duodenum, J – jejunum, I – ileum, C – caecum, CT – caecal tonsil. 
Solid line indicates the median expression level. (n = 6 - 10 birds). (* P < 0.05, *** P < 0.001; 
Kruskal-Wallis test compares the median values of all tissue types).  
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4.4.5 AvBD1 expression in the kidney and liver 
Figures 4.8 and 4.9 show the kidney and liver AvBD1 expression data for Hatch 2 (A) and 3 
(B) in control birds aged 0, 7 and 21 days  and, specifically, 7-day old control and B/BV 
challenged birds from Hatches 2 (C) and 3 (D), respectively. 
 
Examination of bird age on kidney and liver AvBD1 expression indicated that newly hatched 
birds exhibited higher median expression values than older birds aged 7 or 21 days, with the 
exception of Hatch 3 birds that exhibited relatively high kidney expression at 7 days of age. 
For Hatch 2 this difference in expression was statistically significant (P < 0.01) in the kidney 
between birds aged 0 days and 21 days (Figure 4.8), but it did not reach statistical significance 
in the liver. However in Hatch 3 the Day 0 birds i.e. newly-hatched had significantly higher 
liver AVBD1 expression than birds aged 7 days (Figure 4.9). 
 
A comparison of water control groups with the B/BV challenged groups revealed no 
consistent patterns, but it was noted that in Hatch 3 birds the kidney AvBD1 expression in 
the control group was significantly higher (P< 0.05) than in the high seeding group.  
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Figure 4.8: The effects of age of sampling and bacterial challenge on kidney AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  * P < 0.05, ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.9: The effects of age of sampling and bacterial challenge on liver AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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4.4.6 AvBD1 expression in the GI tract 
AvBD1 gene expression is illustrated in the duodenum (Figure 4.10), jejunum (Figure 4.11), 
ileum (Figure 4.12), caecum (Figure 4.13) and caecal tonsil (Figure 4.14) of control birds 
aged 0, 7 and 21 days in Hatches 2 (A) and 3 (B), respectively. Also shown in each Figure is 
AvBD1 gene expression of  the 7 day old birds sampled from the control and B/BV seeded 
pens of Hatch 2 (C) and 3 (D), respectively. 
 
Duodenal expression for both Hatch 1 and 2 showed a significant effect of bird age on 
AvBD1 expression. Compared to Day 0, the trend was for the median AvBD1 expression to 
be lower at the 7 day time-point and to remain low in the 21 day-old birds. This trend was 
consistent between hatches and was statistically significant between birds aged 0 and 21 days 
(P < 0.05). This pattern of age-dependent AvBD1 expression was repeated for the jejunum 
(Figure 4.11), ileum (Figure 4.12), caecum (Figure 4.13) and caecal tonsil (Figure 4.14). 
 
The expression data relating to the B/BV challenged birds was less clear. The duodenal data 
showed that seeding newly-hatched chicks with B/BV (low and high) resulted in significantly 
lower AvBD1 expression in the 7 day-old challenged birds compared to the water control 
birds (Figure 4.10 C and D). This bacterial challenge effect was not, however, observed in 
Hatch 3 although the expression values recorded for the challenged Hatch 3 birds were 
reduced by over 150-fold compared to Hatch 2. Similarly, in the jejunum, B/BV seeded 
groups had lower AvBD1 expression in Hatch 2 than control birds and this reached statistical 
significance between control and high-seeding birds (P < 0.05). As described for duodenal 
tissues, no effect of challenge was seen in Hatch 3 although the expression values were 
extremely low (<0.02 A.U) for all birds. No significant differences between control and 
B/BV challenged groups were observed in the ileum (Figure 4.12), caecum (Figure 4.13) and 
caecal tonsil (Figure 4.14). Generally these data suggest that the B/BV challenge was 
associated with a further down-regulation of AvBD1 expression, particularly in the proximal 
gut tissues. 
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Figure 4.10: The effects of age of sampling and bacterial challenge on duodenal AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints. * P < 0.05, ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.11: The effects of age of sampling and bacterial challenge on jejunal AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  * P < 0.05, *** P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
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Figure 4.12: The effects of age of sampling and bacterial challenge on ileal AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  * P < 0.05, *** P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
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Figure 4.13: The effects of age of sampling and bacterial challenge on caecal AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  * P < 0.05, ** P < 0.01, *** P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
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Figure 4.14: The effects of age of sampling and bacterial challenge on caecal tonsil AvBD1 gene expression in Line X birds.  
AvBD1 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD1 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella visericola 
(B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at other 
sampling timepoints.  * P < 0.05, Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
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4.4.7 Summary of AvBD1 expression data 
Tables 4.1 and 4.2 summarise the statistically significant differences in AvBD1 expression 
that were found when considering the effect of age and bacterial seeding, respectively. Table 
4.1 shows that, compared to birds at Day 0, AvBD1 gene expression was  significantly lower 
at Day 7 in tissues sampled from birds in Hatch 2 (liver, ileum) and Hatch 3 (kidney, jejunum, 
ileum, caecum). This age-dependent decrease in expression relative to Day 0 was also 
observed at the Day 21 sampling time-point in which significantly lower AvBD1 expression 
was found in all tissues accept the liver (Hatch 2 and 3) and the caecal tonsil (Hatch 3). 
 
 
Table 4.1: The effect of age on AvBD1 expression (compared to Day 0) 
 Day 7 Day 21 
 Hatch 2 Hatch 3 Hatch 2 Hatch 3 
Kidney NS ↓ P < 0.01 ↓ P < 0.01 ↓ P < 0.01 
Liver ↓ P < 0.01 NS NS NS 
Duodenum NS NS ↓P < 0.05 ↓P < 0.05 
Jejunum NS ↓ P < 0.01 ↓ P < 0.001 ↓ P < 0.001 
Ileum ↓ P < 0.05 ↓ P < 0.05 ↓ P < 0.001 ↓ P < 0.001 
Caecum NS ↓ P < 0.05 ↓ P < 0.01 ↓ P < 0.001 
Caecal tonsil NS NS NS ↓ P < 0.05 
P value represents significant differences between birds at hatch and birds aged 7 and 21 days. 
NS – no significance, ↓ - lower gene expression than Day 0 
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Table 4.2 shows that, compared to control birds, those that were seeded with B/BV at low 
levels had significantly lower AvBD1 expression in the duodenum (Hatch 2). When 
comparing to birds exposed to high B/BV seeding, significantly lower AvBD1 expression 
was found in the kidney, duodenum and jejunum (Hatch 3). No consistent effect was 
observed across both hatches for either low or high seeding. 
 
Table 4.2: The effect of seeding type on AvBD1 expression in birds aged 7 days 
 Low seeding High seeding 
 Hatch 2 Hatch 3 Hatch 2 Hatch 3 
Kidney NS NS NS ↓ P < 0.05 
Liver NS NS NS NS 
Duodenum ↓ P < 0.05 NS ↓ P < 0.01 NS 
Jejunum NS NS ↓ P < 0.05 NS 
Ileum NS NS NS NS 
Caecum NS NS NS NS 
Caecal tonsil NS NS NS NS 
P value represents significant differences between control and seeded birds 
NS – no significance. ↓ - lower gene expression than control birds. 
 
 
 
4.5  Immunolocalisation of AvBD1 
IHC staining was performed by Dr Catherine Mowbray, Newcastle University. 
 
To explore the gut localisation of AvBD1 a custom polyclonal AvBD1 antibody was 
commercially produced and gut tissue sections (duodenum and caecum) from Hatch 2 birds 
aged 0 and 7 Days were stained for AvBD1 (Figure 4.16). These data revealed that the 
AvBD1 peptide was present in birds at both sampling ages and, at the protein level, no clear 
differences were discernible. Moreover, Figure 4.15 C and D showing the AvBD1 stain at a 
higher magnification (x400), indicates that AvBD1 is present throughout the tissue and not 
localised to a specific region.  
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Figure 4.15: Antibody staining for AvBD1 peptide in caecum.  
Tissue was provided from a  single bird (Bird 79). A) Negative control – No primary antibody, x 40. B) 1/250 dilution of AvBD1 antibody in EDTA, x 40 
C) and D) 1/250 dilution of AvBD1 antibody in EDTA, x400. Data supplied by Dr Catherine Mowbray, Newcastle University. 
  
A B
C D
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Figure 4.16: AvBD1 peptide is present in the GI tract of birds aged 0 and 7 days.  
Sections of gastrointestinal tract from Line X birds at Day 0 (A and B) and Day 7 (C and D) immunostained for AvBD1; A) and C) duodenum, B) and D) 
caecum. Data supplied by Dr Catherine Mowbray, Newcastle University. Brown staining indicates AvBD1 presence.
A B
C D
Day 0
Day 7
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4.6 AvBD10 gene expression 
4.6.1 RT-endpoint PCR tissue panels (AvBD10) 
Figure 4.17 shows endpoint RT-PCR AvBD10 expression for the kidney, liver and the GI 
tract (duodenum, jejunum, ileum, caecum and caecal tonsil) for A) day 0 i.e. newly-hatched 
chicks and B) 21 day-old control and B/BV challenged birds.  The data, although not 
quantitative, shows AvBD10 expression throughout all tissues in newly hatched chicks, but 
also suggests marked liver and kidney expression in control and challenged 21 day-old birds. 
 
4.6.2 AvBD10 standard curve and melt curve for real-time qPCR 
A real time qPCR assay was developed to quantitate expression.  Figure 4.18A shows the 
standard curve produced from qPCR reactions using AvBD10 primers and a 1:10 dilution 
series of cloned plasmid containing the AvBD10 partial gene sequence.  As performed for 
AvBD1, this procedure was repeated at least three times and a curve with an amplification 
efficiency of 2.02, and an error value of 0.045 for sample replicates was chosen to enable 
relative quantification of cDNA samples.  In addition, for each sample, melt curves were 
checked for a single peak at 83°C which ensured specificity of the AvBD10 primers. An 
example of a series of melt curves for AvBD10 PCR products from a range of GI tissue 
cDNA is shown in Figure 4.18B.  
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Figure 4.17: Endpoint PCR tissue panels showing AvBD10 gene expression at Day 0 and Day 21 for control and challenged birds. 
A)  AvBD10 tissue panel for a newly hatched bird and for B) three birds aged 21 days, each one sampled from either the water control pen (W), the low 
seeding B/BV challenge pen (L) or the high seeding B/BV challenge pen (H). RNA was extracted from Kidney (K), Spleen (S), Liver (L), Bursa (B), 
Thymus (T), Duodenum (D), Jejunum (J), Ileum (I), Caecum (C) and Caecal Tonsil (CT). –ve = negative control. Data supplied by Dr Catherine Mowbray, 
Newcastle University. 
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Figure 4.18: Real-time qPCR standard and melt curve for AvBD10.  
A) Standard curve for serial dilutions of AvBD10 plasmid against calculated CP values. B) Melt 
curve for AvBD10 PCR products of gut tissue samples (n = ~ 40 samples).  A single peak for each 
product was observed at the melting temperature of 83°C.  
  
A) Standard curve
B) Melt curves
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4.6.3 Summary of AvBD10 gene expression in tissues of birds aged 0, 7 and 21 days 
Figure 4.19 shows the AvBD10 gene expression profiles of tissues from Hatch 2 (A, C and 
E) and Hatch 3 (B, D and F) birds aged 0, 7 and 21 days. 
 
As for AvBD1, significant within-group variability was observed and the data at the Day 0 
sampling time-point was skewed indicating a non-Gaussian distribution for the kidney, 
duodenum, ileum and caecum in Hatch 2 and all GI tissues in Hatch 3 (Panel A and B) (P < 
0.001, D'Agostino & Pearson omnibus normality test).  A comparison of the median AvBD10 
expression between sampled tissue groups revealed that expression patterns were tissue-
dependent in both Hatch 2 and 3 (P < 0.001). In particular, AvBD10 expression was elevated 
in the liver and kidney tissues compared to those of the GI tract. Interestingly, these relatively 
high levels of kidney/liver expression remained at the Day 7 and Day 21 sampling time-
points, in contrast to the gut tissues which displayed a pattern of decreasing AvBD10 
expression with time. 
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Figure 4.19: AvBD10 gene expression in tissues of newly hatched chicks (Day 0) and birds aged 
7 and 21 days  
Gene expression is shown in arbitary units for newly hatched chicks in Hatch 2 (A) and Hatch 3 (B), 
birds aged 7 days in Hatch 2 (C) and Hatch 3 (D), and birds aged 21 days in Hatch 2 (E) and Hatch 
3 (F).  K – kidney, L – liver, D – duodenum, J – jejunum, I – ileum, C – caecum, CT – caecal tonsil. 
Solid line indicates the median expression level. (n = 6 - 10 birds). (* P < 0.05, *** P < 0.001; 
Kruskal-Wallis test compares the median values of all tissue types).  
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4.6.4 AvBD10 expression in the kidney and liver 
Figures 4.20 and 4.21 show the kidney and liver AvBD10 expression data for control birds 
aged 0, 7 and 21 days, respectively for Hatch 2 (A) and 3 (B), and for 7 day-old birds sampled 
from the control and B/BV seeded pens in Hatch 2 (C) and 3 (D). 
 
Analyses of the data shows that, although individual variation in AvBD10 expression was 
observed, the general pattern was for both liver and kidney expression levels to be maintained 
at relatively high values throughout the sampling period.  
 
For Hatch 2, no effect of B/BV seeding on AvBD10 expression was found in either the 
kidney or liver. In Hatch 3, no differences between control and challenged groups were found 
in the kidney, but in the liver, the expression in the ‘high’ seeding group was significantly 
lower than in the control group (P < 0.01, Dunn’s multiple comparison test).  
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Figure 4.20: The effects of age of sampling and bacterial challenge on kidney AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints.  * P < 0.05, ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.21: The effects of age of sampling and bacterial challenge on liver AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints.  ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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4.6.5 AvBD10 expression in the GI tract 
Figures 4.22 to 4.26 illustrate AvBD10 gene expression in the duodenum, jejunum, ileum, 
caecum and caecal tonsil of Hatch 2 (A) and 3 (B) birds aged 0, 7 and 21 days, respectively, 
and specifically birds aged 7 days sampled from the water control pens or pens with low and 
high B/BV seeding in Hatch 2 (C) and 3 (D). 
 
Age was found to impact significantly on AvBD10 expression.   Higher median AvBD10 
expression was found in the newly-hatched chicks compared to 7 and 21 day-old birds and 
this reached statistical significance for many of the groups sampled (Duodenum H3, P < 
0.001; jejunum H2/H3, P < 0.001; ileum H2/H3, P < 0.001; caecum H2, P < 0.01; caecum  
H3, P < 0.001; caecal tonsil H2/H3, P < 0.001). 
 
Interestingly the data indicated that birds from Hatch 2 and Hatch 3 responded differently to 
B/BV seeding. Hatch 3 data, with the exception of ileal expression, indicated higher 
duodenal, jejunal, caecal and caecal tonsil expression in challenged than control birds and 
this reached statistical significance in the caecal tonsil (low seeding, P < 0.05; high seeding, 
P < 0.001) (Figure 4.26). In contrast, data from Hatch 2 illustrated that birds from B/BV 
seeded pens had lower median AvBD10 expression than the control birds, and this was 
statistically significant for duodenum (high seed, P < 0.05) and caecum (low seed, P < 0.05; 
high seed, P < 0.01), although there were no differences in AvBD10 expression between 
control and challenged groups for jejunal, ileal and caecal tonsil tissues. 
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Figure 4.22: The effects of age of sampling and bacterial challenge on duodenal AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints.  * P < 0.05, ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.23: The effects of age of sampling and bacterial challenge on jejunal AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints. * P < 0.05, *** P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.24: The effects of age of sampling and bacterial challenge on ileal AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints. * P < 0.05, ** P < 0.01; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
W
at
er
Lo
w
 se
ed
in
g
H
ig
h 
se
ed
in
g
0
2000
4000
6000
8000
10000
100000
200000
Challenge
A
v
B
D
1
0
 e
x
p
r
es
si
o
n
 (
A
.U
)
W
at
er
Lo
w
 se
ed
in
g
H
ig
h 
se
ed
in
g
0
500
1000
1500
2000
2500
Challenge
A
v
B
D
1
0
 e
x
p
r
es
si
o
n
 (
A
.U
)
0 7 21
0
25000
50000
75000
100000
125000
150000
Sampling timepoint (days)
A
v
B
D
1
0
 e
x
p
re
ss
io
n
 (
A
.U
)
0 7 21
0
20000
40000
60000
80000
100000
250000
500000
1000000
2000000
Sampling timepoint (days)
A
v
B
D
1
0
 e
x
p
re
ss
io
n
 (
A
.U
)
**
Hatch 2
Hatch 3
A
B
C
D
**
*
**
153 
 
 
Figure 4.25: The effects of age of sampling and bacterial challenge on caecal AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints. * P < 0.05, **P < 0.01, *** P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Figure 4.26: The effects of age of sampling and bacterial challenge on caecal tonsil AvBD10 gene expression in Line X birds.  
AvBD10 gene expression in arbitrary units (A.U) is shown for birds aged 0, 7 and 21 days sampled from water control pens for Hatch 2 (A) and Hatch 3 
(B). AvBD10 gene expression is shown for birds aged 7 days sampled from water control pens and pens with low and high Bacteroides/Barnesiella 
visericola (B/BV) seeding in Hatch 2 (C) and Hatch 3 (D). Sampled groups comprised of 5 males/5 females for 0-day old birds and 3 males/3 females at 
other sampling timepoints.  *P < 0.05, ** P < 0.01, ***P < 0.001; Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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4.6.6 Summary of AvBD10 expression data  
Tables 4.3 and 4.4 summarise the statistically significant differences in AvBD10 expression 
that were found when considering the effect of age and bacterial seeding, respectively. Table 
4.3 shows AvBD10 gene expression in the kidney and liver was not age-dependent. In 
contrast, distal gut tissues sampled from birds in Hatch 2 (ileum, caecum, caecal tonsil) and 
Hatch 3 (ileum) were significantly lower at Day 7 than at Day 0. In addition, by Day 21 
significantly lower expression was maintained in the ileum, caecum and caecal tonsil for 
both hatches, a finding which was also observed in the proximal gut tissues in Hatch 2 
(jejunum) and Hatch 3 (duodenum and jejunum). 
 
Table 4.3: The effect of age on AvBD10 expression (compared to Day 0) 
 Day 7 Day 21 
 Hatch 2 Hatch 3 Hatch 2 Hatch 3 
Kidney NS NS NS NS 
Liver NS NS NS NS 
Duodenum NS NS NS     ↓ P < 0.01 
Jejunum NS NS ↓ P < 0.001 ↓ P < 0.001 
Ileum ↓ P < 0.01 ↓ P < 0.05 ↓ P < 0.01     ↓ P < 0.01 
Caecum ↓ P < 0.05 NS ↓ P < 0.01 ↓ P < 0.001 
Caecal tonsil ↓ P < 0.05 NS ↓ P < 0.001 ↓ P < 0.001 
P value represents significance differences between birds at hatch and birds aged 7 and 21 days.   
NS – no significance. ↓ - lower gene expression than Day 0 
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Table 4.4 shows that, compared to control birds, those that were seeded with B/BV at low 
levels had significantly lower AvBD10 expression in the caecum (Hatch 2) but significantly 
higher AvBD10 expression in the caecal tonsil (Hatch 3).  The high B/BV seeding resulted 
in significantly lower AvBD10 expression in the liver (Hatch 3), duodenum (Hatch 2) and 
caecum (Hatch 2) and, as observed for low seeding, higher AvBD10 expression was found 
in the caecal tonsil tissues from birds sampled from Hatch 3.  No consistent effect was 
observed across both hatches in any tissue for either low or high seeding. 
 
 
 
Table 4.4: The effect of seeding type on AvBD10 expression in birds aged 7 days 
 Low seeding High seeding 
 Hatch 2 Hatch 3 Hatch 2 Hatch 3 
Kidney NS NS NS NS 
Liver NS NS NS ↓ P < 0.05 
Duodenum NS NS ↓ P < 0.01 NS 
Jejunum NS NS NS NS 
Ileum NS NS NS NS 
Caecum ↓ P < 0.05 NS ↓ P < 0.01 NS 
Caecal tonsil NS ↑P < 0.05 NS ↑P < 0.01 
P value represents significance differences between control and seeded birds 
NS – no significance. ↓ - lower gene expression than control birds; ↑ - higher gene expression than 
control birds. 
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4.7 The relationship between GI tract AvBD expression and gut health. 
Bird tissue data for both AvBD1 and 10 consistently demonstrated that expression reduced 
during the first week and by 21 days host-hatch the expression levels were often negligible. 
For this reason no investigation of the relationship between AvBD expression and gut health 
was undertaken in 21 day-old birds.  However, data from 7 day-old birds will be reported as 
gut health abnormalities were observed at this time-point. Bird guts were scored for redness 
(measure of inflammation), water content and tone. Figures 4.10 – 4.14 (AvBD1) and 4.22 – 
4.26 (AvBD10) suggested that a B/BV challenge was associated with the down-regulation 
of AvBD expression. To further explore whether down-regulation was linked to poor gut 
health. The AvBD1 and 10 expression data for birds with healthy (gut score 0) and inflamed 
guts (gut score 1) were analysed (Figures 4.27 and 4.28).  
 
Overlaps in expression values existed between birds with healthy or inflamed guts, but 
comparison of AVBD expression values did uncover some consistent patterns. For AvBD1, 
median expression values for all tissues in the birds with inflamed guts were lower than for 
healthy birds and this reached statistical significance (P,<0.05)  in the caecum. Similarly, 
significantly lower AvBD10 levels were observed in the ileum (P < 0.05) for inflamed birds 
and lower median values were also observed in the duodenal and jejunal tissues of the 
inflamed birds without reaching statistical significance. 
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Figure 4.27: AvBD1 and 10 gene expression in birds with healthy and inflamed guts (duodenum, jejunum and ileum).  
AvBD1 (A, B & C) and AvBD10 (D, E & F) expression in 7 day-old birds challenged with B/BV (low and high seeding) is shown in birds that have normal 
gut health (gut score 0) and birds that have inflamed guts (gut score 1). Solid line is the median value for all sampled birds and includes both control and 
challenged birds from Hatches 2 and 3. Expression was analysed in duodenal (A & D), jejunal (B and E) and ileal (C & F) tissues. * P < 0.05, Mann-
Whitney U test.  
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Figure 4.28: AvBD1 and 10 gene expression in birds with healthy and inflamed guts (caecum and caecal tonsil).  
AvBD1 (A and B) and AvBD10 (C and D) expression in 7 day-old birds challenged with B/BV (low and high seeding) is shown in birds that have normal 
gut health (gut score 0) and birds that have inflamed guts (gut score 1). Expression was analysed in caecal (A & C) and caecal tonsil tissues (B and D). 
Solid line is the median value for all sampled birds and includes both control and challenged birds from Hatches 2 and 3.  * P < 0.05, Mann-Whitney U 
test.  
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4.8 Identification of individual birds with low and high AvBD10 expression in the GI 
tract 
Gene expression data has revealed marked variability within sampled groups and it was noted 
that some birds had expression values many fold higher than the median. A facet of this trial 
was to identify individual birds within the challenged pens that had relatively high AvBD 
gene expression values and to ascertain if these birds had improved gut health outcomes. To 
address this, individual birds were ranked against each other according to their tissue 
(duodenum, jejunum, ileum, caecum and caecal tonsil) AvBD expression. Figure 4.29 shows 
the ranked AvBD1 expression for each individual bird within the challenged pens in Hatch 
2 (A) and 3 (B), and ranked AvBD10 expression in the challenged pens for Hatch 2 (C) and 
3 (D).  
 
Examination of the gut health scores in conjunction with the ranked AvBD1 expression 
indicated that birds with relatively low AvBD1 expression were characterised by high gut 
scores, indicating gut abnormalities, whereas birds with relatively high AvBD1 expression 
such as 158 and 152 (Hatch 3) had completely normal gut health despite the B/BV challenge.  
Indeed,  dividing the birds  into two groups of six based on the ranked AvBD expression 
values showed the higher expressing birds returned combined gut scores of 4 and 5 (Hatch 2 
and 3, respectively) compared to 8 and 11 for the group of lower expressing birds. 
 
For AvBD10, there was no clear evidence that high expression protected against gut 
problems and birds that were revealed to have relatively high expression throughout the GI 
tract such as 66 and 75 (Hatch 2) and 147 and 156 (Hatch 3) had abnormal gut health.  
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Figure 4.29: Individual birds ranked for GI AvBD1 and 10 expression and their corresponding gut health scores.  
The data is displayed as the relative AvBD1 (A & B) and AvBD10 (C & D) expression in each tissue for B/BV challenged birds ranked within the group 
for Hatch 2 (A & C) and Hatch 3 (B & D). The highest expression value for a given tissue is ranked 1 and the lowest expression is ranked 12. Solid lines 
indicate the mean of the ranked expression and provide an indication of the overall AvBD expression throughout the GI tract relative to each bird.  Orange 
– duodenum, Red – jejunum, Green – ileum, Blue – caecum and Purple – caecal tonsil. Overall gut scores for each bird are shown above each column 
(black), alongside scores for redness (red). Total gut scores and redness scores for two groups of six birds are shown above. 
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4.9 Microbial growth assays using jejunal gut scrapes. 
Assay data reported in Chapter 3 suggested that the B/BV challenge resulted in a gut mucosa 
that supported increased E. coli growth. Moreover, gut scrapes from 4 day-old birds that had 
abnormal gut health also supported higher E. coli growth than healthy birds. To explore this 
further and determine if any relationship exists between gut health and bacterial growth, 
jejunal gut scrapes from birds in this trial were analysed to assess their ability to support the 
growth of Salmonella typhimurium, a human pathogen found in the bird caecum, and 
Lactobacillus johnsonii, a potential probiotic. 
 
Figure 4.30 shows S. typhimurium and L. johnsonii growth supported by jejunal scrapes from 
birds aged 7 and 21 days, respectively. The data for S. typhimurium was very variable with 
no distinct patterns observed due to some gut scrapes proving to be anti-microbial, and thus 
inhibiting S. typhimurium growth, while others were extremely pro-microbial supporting S. 
typhimurium growth. In addition, scrapes sampled from 7 day-old birds supported higher 
microbial growth than those from birds aged 21 days. Comparison of gut scrapes from 
healthy birds aged 7 days with those from birds with inflamed guts revealed that there were 
no significant differences in S. typhimurium growth. However, by Day 21, the mean growth 
supported by the gut mucosa of birds with inflamed guts appeared elevated, although this did 
not reach statistical significance (P > 0.05).  Unlike S. typhimurium, the data for L. johnsonii 
showed no age-dependent effects although a similar pattern of higher mean growth was 
observed when reviewing the scrape data from Day 21 birds with inflamed guts.  
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Figure 4.30: The effect of jejunal gut scrape protein extracts on Lactobacillus johnsonii  and Salmonella typhimurium growth. 
Data is presented as the percentage growth of Lactobacillus johnsonii  (A & B) and Salmonella typhimurium facilitated by total protein extracts from jejunal 
gut scrapes in Line X birds (all treatment groups combined). Data are shown for gut scrapes from birds aged seven days (A and C) and 21 days (B & D).  
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4.10 Discussion 
To further characterise the gut health deterioration observed in birds following early B/BV 
exposure, a second trial was performed utilising an acute (high seeding) and prolonged (low 
seeding) challenge of Line X birds, characterised by their increased susceptibility to gut 
issues. Gut health assessment data revealed no differences in bird gut health between the two 
types of bacterial challenge, but each challenge did result in birds that displayed significantly 
higher gut scores at the later sampling time-points than control birds indicating poorer gut 
health (Figure 4.1). The second trial was performed at the same location and under the same 
environmental parameters as Trial 1 (Chapter 3), but crucially in Trial 2 the birds were reared 
on re-used and not fresh litter. The use of recycled litter, despite a top layer of fresh litter, 
may have exposed the newly hatched chicks to numerous microbial species at high densities 
(1010/g) and such bacterial exposures through bedding have been reported to contribute up to 
90% of the host microbiota (Bolan et al., 2010). For Trial 2, neither the bacterial loads in the 
bedding or the host microbiome were determined, but it is probable that the ‘old litter’ used 
in Trial 2 introduced an earlier and more varied bacterial challenge than in Trial 1. 
Interestingly, a comparison of the gut health assessment data between the two trials (Figures 
3.1 and 4.1) indicated that the birds in Trial 2 exhibited a more rapid deterioration in gut 
health (gut health worse at Day 21) than birds from Trial 1 (gut health worse at Day 28), 
suggesting that re-used litter may be detrimental, supporting excess bacterial growth in the 
small intestine and leading to a ‘dysbacteriosis’-type phenotype (Bailey, 2010). To determine 
if the jejunal mucosa of ‘unhealthy’ birds with gut inflammation supported excess microbial 
growth, colony counting assays were performed to assess the growth of Lactobacillus 
johnsonii, a potential probiotic and Salmonella typhimurium, a potential human pathogen.  
No assays were performed using E. coli as this had been explored in Chapter 3. Analyses of 
the gut scrape data, despite some overlap, revealed a trend for birds aged 21 days with 
inflamed guts to support increased microbial growth (relative to ‘healthy’ mucosal scrapes) 
of both L. johnsonii and S. typhimurium (Figure 4.30). Despite the large variability within 
groups, data from Chapter 3 also revealed that gut scrapes from unhealthy birds facilitated 
increased microbial growth (E. coli) and overall this assay, irrespective of bacterial species 
utilised, appears to offer some support to the theory that excess growth of proximal gut 
bacteria is linked to a poor gut health phenotype.   
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In Trial 2, individual birds were weighed prior to tissue sampling and their gut health assessed 
to enable the relationship between bacterial challenge, gut health and weight to be 
determined. Birds aged 28 days given a prolonged bacterial challenge with B/BV were 
significantly lighter (Figure 4.3). Interestingly, Chapter 3 showed that a bacterial challenge, 
irrespective of the gut health outcome, has the potential to decrease the mean bird weight per 
pen.  Thus, it is possible that microbe challenged birds divert energy away from muscle mass 
gain and towards immune functions (Korver, 2006). 
 
An aim of the tissue sampling in Trial 2 was to quantitatively assess AvBD gene expression 
in three hatches of Line X birds over a number of time-points and to investigate AvBD gene 
expression following B/BV challenge. AvBD expression was examined in relation to gut 
health to evaluate if AvBDs are potential biomarkers of gut health at the group or individual 
bird level. Quantitative expression was determined for the AvBD1 and 10 genes, chosen 
specifically due to the presence of SNPs with potential to affect gene expression and/or the 
anti-microbial activity of the encoded products (Chapter 6). In this study, ten tissues were 
sampled for each individual bird and the endpoint PCR data (Figures 4.4 and 4.17) revealed 
that in newly hatched chicks, AvBD1 and 10 transcripts were present in all tissues analysed 
(kidney, spleen, liver, bursa, thymus, duodenum, jejunum, ileum, caecum and caecal tonsil) 
supporting the importance of these two genes in the innate defences of the young birds. 
Although not quantitative, and only performed on a single bird, the PCR data suggested a 
different expression pattern in the older (21 day-old) birds. In fact AvBD1 and 10 exhibited 
differences in tissue expression, with AvBD1 linked to relatively strong caecal tonsil 
expression and AvBD10 showing high kidney and liver expression (Figure 4.7 and 4.17).  
The first reported studies of AvBD expression, using an endpoint PCR approach, also 
revealed that AvBD10 was prominently expressed in the kidney and liver, but interestingly 
did not report any GI tissue expression (Lynn et al., 2004; Xiao et al., 2004). However, the 
tissues analysed in these early studies were from two month-old chickens (Xiao et al., 2004) 
and a single three week-old chicken (Lynn et al., 2004), which is consistent with the loss of 
gut AvBD expression in older birds. A later study did indicate that AvBD10 is prominently 
expressed in the small intestine, in addition to the liver (Ma et al., 2008); this is consistent 
with the PCR panels reported in this chapter and supports a role for AvBD10 in protecting 
the chicken gut against pathogenic invasion.  
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Due to time constraints, and because the focus of this study was gut health, only seven tissues 
were analysed using quantitative real-time PCR (qPCR). These were the five gut tissues and 
the kidney and liver, chosen due to the apparently high constitutive AvBD10 expression as 
evident in the endpoint PCR panels.  For newly-hatched birds (Day 0), the qPCR analysis 
revealed firstly, that AvBD expression was highly variable within groups of sampled birds 
and, secondly, expression was significantly different between tissue types. As suggested by 
the endpoint PCR data, AvBD10 expression was particularly interesting in that, relative to 
the GI tissues, high kidney and liver expression were identified. In Hatch 2, for example, in 
newly-hatched chicks AvBD10 expression was over 20 and 400-fold higher in the kidneys 
and livers, respectively, than in the highest expressing gut tissue (ileum). Within the gut 
tissues there was a general trend for higher expression in the distal tissues (ileum, caecum 
and caecal tonsil) relative to the proximal tissues (duodenum and jejunum), which is perhaps 
reflective of the higher bacterial load and increased species diversity found in the hind gut 
(Gong et al., 2002b), necessitating the increased protection of the epithelium from bacterial 
attachment and invasion.  
 
For both genes analysed, differences in expression were observed between hatches, most 
notably, the lower AvBD1 tissue expression of Hatch 3 birds. This was surprising and the 
reasons unknown. It was not a technical issue as the Hatch 3 samples were processed blind 
alongside those from Hatch 2. It may have resulted from the bird genetics, but this was 
unlikely as the birds used throughout all the trials originated from the same parent stocks. 
The most likely factor was that it was linked to an as yet unidentified environmental and/or 
microbial parameter influential on the day of arrival from the hatchery and responsible for 
gene up/down-regulation. 
 
Comparison of the three sampling time-points 0, 7 and 21 days, revealed that across all GI 
tissues AvBD1 and 10 gene expression were higher in the newly-hatched chicks than at either 
of the later sampling time-points. This pattern of decreasing expression with bird age has also 
been shown in a study on AvBD4, but using semi-quantitative RT-PCR. The authors noted 
high expression in birds aged 4-days but no PCR product was observed at 17 and 38 days-
post hatch indicative of gene down-regulation (Milona et al., 2007). These data support the 
167 
 
idea that AvBDs are defence molecules, functioning as vital effectors of innate immunity in 
the first week post-hatch, but are of less importance in older birds with a functioning adaptive 
immune system. In support, researchers have shown that broilers aged less than seven days 
cannot mount an effective adaptive antibody response due to functionally immature B and T 
lymphocytes (Bar-Shira et al., 2003)  and instead utilise maternal anti-bodies, pro-
inflammatory cytokines (IL-1β and IL-8) and defensins throughout the first week in response 
to bacterial and environmental antigens (Bar-Shira and Friedman, 2006). This 2006 study 
also revealed that expression of AvBD1 and 2 in duodenal, ileal and caecal tissues decreased 
significantly during the first week of life although the fold differences were in the region of 
3 – 10, compared to the ≥100 fold differences reported in the present sudy. Differences could 
be due to sensitivity of assays used in the 2006 study, employing less sensitive semi-
quantitative methods. The study by Bar-Shira and Friedman (2006) also showed that in the 
second week of life, AvBD1 and 2 expression increased reaching a peak at 14 days post-
hatch, arguing that the response was linked to the increase in pro-inflammatory cytokine 
expression at the end of the first week of life (Bar-Shira and Friedman, 2006). In Trial 2 no 
samples were analysed for AvBD gene expression at the Day 14 time-point, but it is worth 
stating that the expression values were already falling at Day 7.  In retrospect, the addition 
of additional early sampling time-points would have provided more information on when 
AvBD expression starts to fall.    
 
Many in vivo studies have investigated the effects of bacterial challenge, usually human 
pathogens, especially Salmonella spp., on AvBD gene expression although no consistent 
patterns of regulation have been identified and the data are likely to be influenced by bird 
age, genetic line, and the tissues examined (Sadeyen et al., 2004; Sadeyen et al., 2006; Milona 
et al., 2007; Cheeseman et al., 2008; Derache et al., 2009a; Ramasamy et al., 2012). 
Interestingly, challenge of 5-day old chicks with Salmonella spp. did not induce a significant 
up-regulation of AvBD4, 5 or 6 in the small intestine (Milona et al., 2007), and similarly, 
another study showed no changes in AvBD2 expression at 1 week post-inoculation 
(Cheeseman et al., 2008). In contrast, increased caecal tonsil expression of AvBD1, 2, 4 and 
6 has been shown in S. typhimurium challenged birds at 3 and 5 days post-infection (Akbari 
et al., 2008), and S. pullorum was shown to both up-regulate (AvBD3, 4, 5, 6 and 12) and 
down-regulate (AvBD10, 11 and 13) expression (Ramasamy et al., 2012). In comparison 
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with other challenge studies, the trial reported here was novel, in that the bacteria utilised 
(B/BV) are classed as gut commensals, and the challenge was performed on newly-hatched 
chicks.   
 
Comparison of B/BV challenged and control birds at 7 days revealed that the challenged 
birds had significantly lower AvBD expression in the duodenum (AvBD1/10) (Figures 4.10 
and 4.22), jejunum (AvBD1) (Figure 4.11) and caecum (AvBD10) (Figure 4.25). This 
suggested interactions between the exogenous B/BV bacteria and the small, and large, 
intestinal epithelia. For example down-regulation of anti-microbial peptide expression could 
be a bacterial strategy adopted to evade the immune response, which provides time for 
exogenous bacterial species to colonise and establish a microbial niche within the host. 
Indeed, it has been reported that 4-day-old broilers challenged with Camplylobacter jejuni 
had 2-fold lower cathelicidin-(CATH-2) expression in the small intestine than control birds 
(van Dijk et al., 2012). These data suggest the functioning of microbial specific factors that 
interact with the bird innate defences to facilitate gut colonisation.  C. jejuni is a potential 
zoonotic pathogen, but its presence is less detrimental to bird than human health (van Gerwe, 
2012) and it is often viewed, albeit controversially (Humphrey et al., 2014), as a bird 
commensal. Commensal bacteria have evolved mechanisms to reduce or prevent host 
recognition involving concealing themselves from the impact of innate immune effectors. 
For example, Bifidobacterium spp, a normal part of the human gut microbiome, suppresses 
the pro-inflammatory cytokine IL-8 in an intestinal epithelial cell line (Jijon et al., 2004). 
Studies have also revealed the down-regulation of anti-microbial peptides by pathogenic 
species. In patients infected with Shigella spp. infections, human cathelicidin LL-37 and 
hBD1 transcription were down-regulated and loss of epithelial LL-37 peptide was confirmed 
using IHC (Islam et al., 2001). In mice challenged with live Salmonella typhimurium the 
expression of cryptdin, an alpha defensin, and lysozyme were down-regulated three-fold in 
comparison to controls, as measured by Northern blot analysis (Salzman et al., 2003).  
 
As previously mentioned, Hatch 3 birds were characterised by lower AvBD1 tissue 
expression than Hatch 2 birds.  For AvBD10, a hatch dependent pattern of regulation was 
also observed. Higher median expression was found in Hatch 3 challenged birds compared 
to controls, in contrast to Hatch 2, in which AvBD10 down-regulation was found in the 
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duodenal and caecal tissues. The reason why AvBD10 remained high following challenge in 
one hatch but decreased in another hatch is open to conjecture, as no differences between the 
hatches were noted. As mentioned earlier it was possible that the environmental challenges 
in Hatch 2 and 3 were different resulting in hatch specific microbiotas that impacted uniquely 
on AvBD tissue expression patterns. 
 
To explore a potential link between gut health and AvBD gene expression, 7 day-old 
challenged birds were pooled into groups of 12 and ranked for AvBD1 and 10 expression for 
all five GI tissues (Figure 4.29). This type of analysis enabled birds with high/low AvBD 
gene expression to be identified. For AvBD1, the general trend in both hatches was for the 
birds with low GI tract expression to present with worse gut health supporting a potential 
protective effect of AvBD1. This pattern was repeated for AvBD10 in Hatch 2 but not Hatch 
3, perhaps suggesting that AvBD1 is more important than AvBD10 in maintaining healthy 
gut tissue. Further support for the hypothesis that birds with high levels of AvBD expression 
are more protected against bacterial challenge was shown by data in Figures 4.27 and 4.28, 
in which birds challenged with B/BV yet were inflammation free at Day 7 had higher AvBD1 
and 10 expression than those with inflamed guts. A number of studies have shown that birds 
with higher AvBD expression are less prone to Salmonella spp. colonisation, which supports 
the theory that birds, which are able to maintain relatively high levels of AvBDs are, on the 
whole, less likely to suffer  from enteric upset. For example, a 2009 study showed that 
primary intestinal cells isolated from a Salmonella-resistant bird line constitutively expressed 
higher AvBD1 and 2 than cells expanded from a Salmonella-susceptible chicken line, 
suggesting high AvBD expression contributes towards the prevention of Salmonella  spp. 
colonisation (Derache et al., 2009a). Furthermore, Sunkara et al. (2011) showed that butyrate 
supplementation, resulted in a significant up-regulation of AvBD9 leading to significantly 
decreased caecal S. enteriditis titres (Sunkara et al., 2011). Higher constitutive AvBD 
expression has also been revealed in a certain strain of commercial Ross broilers compared 
to Cobb strain and, interestingly, these lines differed in their susceptibility to necrotic enteritis 
(NE) (Hong et al., 2012) with the former more resistant. Thus genetically divergent bird lines 
exhibit different patterns of constitutive and induced AvBD expression and such differences 
appear linked to disease susceptibility.  
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In humans, defensin regulation has been shown to be an important factor in inflammatory 
conditions such as Crohn’s disease and Ulcerative Colitis (Ramasundara et al., 2009). For 
example, the ileal mucosa of patients with Crohn’s disease showed significantly lower gene 
expression of the alpha defensins, HD5 and HD6, compared with healthy mucosa although 
this down-regulation was found irrespective of the level of inflammation (Wehkamp et al., 
2005).   Moreover, the authors state that it is difficult to determine if defensin down-
regulation either predisposes the gut to inflammation or is a consequence of the diseased 
state.  Similarly, in birds further studies are required to determine if decreased AvBD 
expression contributes towards a ‘poor gut health’ phenotype or is a marker of enteric disease. 
Regarding the B/BV challenge model, future work could compare AvBD expression between 
Line X (‘B/BV susceptible-phenotype’) and Line Y (‘B/BV resistant-phenotype’) under 
control and challenged conditions.    
 
To date, the majority of studies have used a PCR-based molecular approach to examine 
AvBD gene expression. The lack of commercially available antibodies, has meant that 
studies evaluating AvBD expression at the protein level have been limited to AvBD3, 11 and 
12 in the reproductive tract and reported by a single research group (Mageed et al., 2009; 
Mageed et al., 2011; Abdelsalam et al., 2012). Examination of AvBD localisation in the 
oviduct of 400-day old laying hens using custom antibodies to AvBD3, 11 and 12, chosen 
due to their up-regulation following LPS challenge (Mageed et al., 2008), showed that these 
defensins were found throughout the oviduct in epithelial cells and in the eggshell and 
eggshell membrane (Mageed et al., 2009). As part of the tissue analysis in the current 
experiment, a customised polyclonal antibody to AvBD1 was produced. The real-time qPCR 
data for AvBD1 revealed that at the later sampling time-points, particularly 21 days-post 
hatch, gene expression had decreased markedly in the gastro-intestinal tissues compared to 
tissues sampled from newly-hatched chicks. However, IHC analyses of the tissues indicated 
that the AvBD1 peptide was present at all sampling time-points and an age-dependent 
decrease in protein levels could not be confirmed.  A possible hypothesis could be that high 
levels of gene expression observed in the young birds reflect high transcript turnover due to 
continuous peptide secretion, while in the older birds the low expression reflects peptide 
storage in epithelial cells.  
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To summarise, Chapter 4 has demonstrated that AvBD expression is tissue, age and hatch-
dependent but can be down and up-regulated by bacterial challenge. Importantly, there was 
a trend for birds with relatively high GI tract AvBD1 expression to exhibit lower 
inflammation and better gut health, indicating the potential importance of the AvBD family 
in the innate gut defenses. The gut health assessment data from both farm trials have 
established that the B/BV challenge does adversely affect the gut health of Line X birds, and, 
as shown by the additional gut scrape mucosal analysis, this could be partially through 
supporting intestinal bacterial over-growth. 
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Chapter 5: In vitro bacterial challenge model 
 
5.1  Overview 
The in vivo data from Trial 2 (Chapter 4) indicated that the challenge of Day 0 i.e. newly 
hatched chicks with B/BV was associated with the down-regulation of AvBD expression in 
the bird GI tract. Moreover, these data also suggested that the down-regulation of expression 
was linked to an increased susceptibility to gut inflammation. Although persuasive, the bird 
data was variable and the intent of this chapter was to use an in vitro cell model to further 
explore and compare the effects of bacterial challenges, namely Bacteroides dorei (BD), 
Lactobacillus johnsonii (LJ) and Salmonella typhimurium (ST) on AVBD expression 
profiles. B. dorei (BD) and L. johnsonii (LJ) were chosen to reflect the in vivo challenges of 
Farm Trials 1 and 2 while S. typhimurium was used to expand the study and investigate the 
effects of a human pathogenic strain. 
 
The in vivo data from Chapter 3 showed that birds challenged with LJ exhibited lower gut 
scores, indicative of healthy guts, and therefore lower redness (inflammation), than birds 
challenged with B/BV. Therefore to investigate this in vitro, the expression patterns of pro-
inflammatory cytokines, namely IL6 and IL1β were also analysed following the bacterial 
challenges.  
 
To date, no commercially available immortalised avian gut epithelial cell lines are available 
so the in vitro experiments were performed using chicken embryo cells designated CHCC-
OU2 (Ogura and Fujiwara, 1987).  These cells have been used in a number of chicken 
immunological studies, defending their use as a suitable model to study the regulation of 
innate immune gene expression. For example, CHCC-OU2 cells pre-treated with IFN-ɣ have 
been shown to inhibit the development of one of the intra-cellular parasites, Eimella tenella, 
associated with coccidiossis (Lillehoj and Choi, 1998, Heriveau et al., 2000). Other studies 
have investigated the latency of Marek’s disease virus (Abujoub and Coussens, 1997) and 
cytokine expression (IL6/8) following challenge with chicken interleukin-17D (Hong et al., 
2008). 
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5.2 AvBD1 gene and CHCC-OU2 cells  
As indicated earlier, the AvBD1 gene carried by Aviagen bird lines is characterised by SNPs, 
which impact on the primary structure of the encoded peptide. To identify which allelic 
version was expressed in the OU2 cell line, the genomic DNA was isolated,  subjected to 
PCR using AvBD1 genomic primers and the PCR product sequenced (Figure 5.1 A & B). 
The sequencing data showed that the AvBD1 gene codes for a SNP variant that is common 
to the Line X birds and designated ‘NYH’. 
 
 
 
 
 
CCCTTTCTTCTGGACAGGGTGCTGCAGGTGAGGTGTGAGTTCTGTGGGGTTCTCCATATCCCAGGAGGTGGCTTGTCAG
GGATGGGTAACGACTAGGAGGGCTCTGATCAGTTGGTTCAGGAGGGAGGGAAGATTTAGGTTGGATATCAGGGGGAAGT
TCTTTACAGAGAGAGAGGTGAGGTGCTGGAACAGCTGCCCAGAGAGGCTGTGGATGCCCCGTCCATCCCTGGAGGTGTTC
AAGGCCAGGTTGGATGGGGCCCTGGGCAGCCTGGGCTGGTGTTAGATGTGGAGGTTGGTGGCCCTGCCTGTGGTGGGTGG
GTTGGAGCTTCATGATCCTTGAGGTCCCTTCCAACCCAACCATTCTGTGATTCTGTGGTTTGGATGAGTGGCTGGGCTTTTG
GGTTTGGTGCTTTGTGCACGTGTTAGACTGAGATCCATGGGACAGCCACTCTAGAACCACACACAGCTTGTACAGGTATCC
CACACTCATTTTCTTTTGGTCTGTGCAGGATCCTCCCAGGCTCTAGGAAGGAAGTCAGATTGTTTTCGAAAGAATGGC
TTCTGTGCATTTCTGAAGTGCCCTTACCTCACTCTCATCAGTGGGAAATGCTCAAGATTTCACCTCTGCTGCAAAAG
GTAAGCTTTGGAATTAGGGATGAAATTGGATCTGCTACCACGATGGCAGAAATAGCTGTTGTTGTGTTTGATCCCCAAACC
TAGCTACTGGCTTTGGGCTATATATGATCCAGGGCAGGGGCTTGGGGAGGAAAGGAGAAGGTGCTAGGACCGGTCCTTTA
AAGGAACTGGAGGAACCCCAGATCAGACACTGGCCTCCCCATTGCCCTCAGTTACACGGGGCTGCCTGGCTTTGGGGTTTT 
 
Figure 5.1: Genomic endpoint PCR and sequencing of the AvBD1 gene in CHCC-OU2 cells 
A) Endpoint PCR (55 – 64°C temperature gradient) for AvBD1 primers against genomic DNA 
extracted from chicken OU2 cells. AvBD1 product size is 911 b.p. M – hyperladder 1, Lane 1 – 6: 
55.5°C - 64°C, 7 – negative control (no DNA).  
B) Sequence of extracted cDNA from PCR (Panel A) showing 98% sequence identity with the ‘NYH’ 
variant of the mature peptide that is most prevalent in Line X birds. Codons that confer the ‘NYH’ 
SNP are shown in yellow and the SNP is underlined; AAT – N, TAC – Y and CAC – H. Partial 
sequence for Exon 1 and full sequence for Exon 2 are indicated in bold. 
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5.3 Housekeeping genes for real-time qPCR in CHCC-OU2 cells 
The reliability of housekeeping genes has been shown to vary according to the samples used 
and thus, the recommended practice is that housekeeping genes are experimentally validated 
prior to selection (Bustin et al., 2009; Bustin, 2010). 
 
As performed for the in vivo tissue expression studies, the chicken geNorm kit 
(PrimerDesign, U.K.) was used to select suitable housekeeping genes (GAPDH, YWHAZ, 
ACTB, UBC, SDHA and SF3A1) for sample normalization in the CHCC-OU2 in vitro 
model. Figure 5.2 shows the output from the geNorm software (Vandesompele et al., 2002), 
which indicates the average expression stability value (M) of the six potential reference 
genes. The lower the M value the more stable the gene expression. The software indicated 
that, in contrast to the tissue samples, YWHAZ (Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide) and GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) were the most suitable housekeeping genes for CHCC-OU2 gene 
expression analysis.  
 
 
 
Figure 5.2: GeNorm analysis to determine the most appropriate genes for real-time qPCR in 
chicken CHCC-OU2 cells.  
The average expression stability value (M) of six chicken reference genes in the GeNorm kit 
(PrimerDesign) is shown; GAPDH, YWHAZ, ACTB, UBC, SDHA and SF3A1. The expression 
stability increases from left to right indicating that YWHAZ is the most stable reference gene. 
ACTB UBC SF3A1 SDHA GAPDH YWHAZ
Average expression stability of reference targets
0.650
0.600
0.550
0.500
0.450
0.400
0.350
0.300
0.250
0.200
G
eN
o
rm
M
175 
 
5.4 AvBD1 and 10 expression in CHCC-OU2 cells 
In vitro experiments were performed to explore whether AvBD1 and 10 were expressed in 
CHCC-OU2 cells and if expression was linked to cell growth and, hence, cell density.  
 
Figure 5.3 shows the AvBD1 and 10 mean gene expression data at 24, 72, 96 and 120 h 
respectively, following CHCC-OU2 seeding at 2 x 105 cells per 12-well plate. These data 
indicated that for both AvBDs, gene expression was significantly altered as a function of time 
(One-way ANOVA, P < 0.05). For AvBD1, expression peaked at 72 h post-seeding (P < 
0.01) and decreased at the later time-points, whereas, mean AvBD10 expression increased 
over time and was significantly higher at 96 h (P < 0.01) and 120 h (P < 0.001) post-seeding. 
Therefore, to address any potential changes in expression due to cell growth, all challenge 
data was presented as fold or percentage change relative to an appropriate time-point control. 
 
  
Figure 5.3: Mean AvBD expression (A.U) ± S.E.M in unchallenged CHCC-OU2 cells.  
AvBD1 (A) and 10 (B) were assessed at 24, 72, 96 and 120 h post-seeding at 2 x 105 cells in 12 –
well plates. Bars with different letters have means that are significantly different from each other. N 
= 2 experiments, n = 6 replicate wells.  
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5.5 AvBD1 expression in CHCC-OU2 cells challenged with bacteria 
Challenge experiments were performed using heat killed bacteria at 2 x 106 colony forming 
units (C.F.U) per well of a 12 well plate, and  OU2 cells seeded at 2 x 105 at 80%-100% 
confluence. Figure 5.4 shows AvBD1 expression following 4, 8 and 24 h challenge of the 
CHCC-OU2 cells with two clinical strains of BD, ST and LJ.  These data show that at 4 h, 
aside from ST, which caused significant gene up-regulation (P < 0.05), the mean AvBD1 
expression was lower in the challenged wells reaching statistical significance for BD 1 (P < 
0.05). At the 8h time-point all bacterial species caused a significant down-regulation of 
AvBD1 expression relative to control cells (P < 0.001). Similarly, at 24 h sampling the two 
BD and ST challenges, but not the LJ challenge, caused significantly lower AvBD1 
expression (P < 0.001). To confirm that down-regulation was not the result of decreased cell 
viability, a MTS assay was performed (see section 2.5.4) that compared the viability of 
control and challenged cells (Figure 5.5). No significant relationship between the number of 
C.F.U utilized and cell viability was found, with > 95% viability observed even when a high 
2 x 106 bacterial inoculum was employed. 
 
To explore if the down-regulation, observed using 2 x 106 C.F.U, was responsive to bacterial 
numbers the challenges were repeated using a range of bacterial C.F.U. (102 - 105) at the 8 h 
time-point (Figure 5.6). For BD strain 1, AvBD1 was significantly down-regulated relative 
to the control wells at all C.F.Us tested (P < 0.001). A similar pattern was found for ST treated 
cells, although statistical significance was only reached at 102 C.F.U (P < 0.05). At 102 C.F.U. 
no effects of LJ on AvBD1 expression were noted, but at higher inocula gene down-
regulation was hinted although this was not statistically significant (P > 0.05, One-way 
ANOVA followed by Dunnett’s test).  
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Figure 5.4: The effect of high C.F.U bacterial challenge for 4, 8 and 24 h on AvBD1 expression  
The mean expression values (± SEM) are shown as percentage change relative to mean control 
expression at each sampling time-point. CHCC-OU2 cells were challenged with 2 x 106 heat-killed 
colony-forming units (C.F.Us) per well and sampled at 3 timepoints: A) 4h, B) 8h and C) 24h (N = 1 
- 3 experiments, n = 3 - 9 wells). Unchallenged control – blue bars, Bacteroides dorei strain 1 – red 
bars, Bacteroides dorei strain 2 – dark red bars, Salmonella typhimurium – orange bars, Lactobacillus 
johnsonii – green bars. Significance values are for comparisons of means between control and 
challenged groups (One-way ANOVA followed by Dunnett's Multiple Comparison Test * P < 0.05, 
** P < 0.01, and *** P < 0.001). For control cells, N = 3 experiments, n = 8 replicates. For BD and 
LJ challenged cells, N = 2 experiments, n = 6 replicates. For ST, N = 1 experiment, n = 3 replicates. 
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Figure 5.5: Cell viability (%) of CHCC-OU2 cells following 24 h incubation with Bacteroides 
dorei.  
The MTS assay data shows the percentage viability of CHCC-OU2 cells relative to PBS control 
(Mean ± SEM) following 24 h incubation with Bacteroides dorei at 102, 103, 104, 105 and 2 x 106 
C.F.U per well. N = 1 experiment, n = 5 replicate wells. 
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Figure 5.6: The effect of C.F.U. number on mean AvBD1 expression in CHCC- OU2 cells 
challenged for 8 h.  
The mean expression values (± SEM) are shown as percentage change relative to mean control 
expression. Wells were challenged with heat-killed colony-forming units (CFUs) at 102- 2 x 106 per 
well of A) Bacteroides dorei strain 1 (red columns) B) Salmonella typhimurium (orange columns), 
and C) Lactobacillus johnsonii (green columns). Significance values are for comparisons of means 
between control and challenged groups (One way ANOVA followed by Dunnett's Multiple 
Comparison Test * P < 0.05, *** P < 0.001). N = 2 experiments, n = 3 - 6 replicates.  
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5.6 AvBD10 expression in CHCC-OU2 cells challenged with bacteria 
AvBD10 expression in CHCC-OU2 cells following 4, 8 and 24 h of challenge with the two 
BD strains and LJ (2 x 106 C.F.U.) is shown in Figure 5.7. Although these data were 
characterized by large SEMs, all the 8h challenges were typified by a significant decrease in 
gene expression (P < 0.001). At 24h post-challenge, no statistically significant differences 
between challenged and control groups were detected although the LJ challenge did suggest 
the up-regulation of AvBD10 gene expression.  
 
The effect of the bacterial inoculum count on AvBD10 expression is shown in Figure 5.8. 
These data  suggested that bacterial challenges over a range lower than 2 x 106 C.F.U (102 – 
105 C.F.U.) were associated with  AvBD10 up-regulation as the mean AvBD10 expression 
was higher than the controls for all bacterial species at all C.F.U used. However, due to the 
large variability in expression a statistically significant effect was only observed for ST (P < 
0.05, one-way ANOVA) and at 104 C.F.U the mean AvBD10 expression was significantly 
higher than control (P < 0.05).    
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Figure 5.7: The effect of high C.F.U bacterial challenge for 4, 8 and 24 h on mean AvBD10 
expression. 
The mean expression values (± SEM) are shown as percentage change relative to mean control 
expression at each sampling time-point. Cells were challenged with 2 x 106 heat-killed colony-
forming units (C.F.Us) per well and sampled at 3 timepoints: A) 4h, B) 8h and C) 24h (N = 1 - 3 
experiments, n = 3 - 9 wells). Unchallenged control – blue bars, Bacteroides dorei strain 1 – red bars, 
Bacteroides dorei strain 2 – dark red bars, Lactobacillus johnsonii – green bars. Significance values 
are for comparisons of means between control and challenged groups (One-way ANOVA followed 
by Dunnett's Multiple Comparison Test *** P < 0.001). For control cells N = 3 experiments, n = 8 
replicates. For BD and LJ challenged cells, N = 2 experiments, n = 6 replicates.  
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Figure 5.8: The effect of C.F.U. number on mean AvBD10 expression in CHCC- OU2 cells 
challenged for 8 h.  
The mean expression values (± SEM) are shown as percentage change relative to mean control 
expression. Cells were challenge with heat-killed colony-forming units (CFUs) at 102 – 2 x 106 per 
well of A) Bacteroides dorei strain 1 (red columns) B) Salmonella typhimurium (orange columns), 
and C) Lactobacillus johnsonii (green columns). Significance values are for comparisons of means 
between control and challenged groups (One-way ANOVA followed by Dunnett's Multiple 
Comparison Test * P < 0.05). N = 2 experiments, n = 3 - 6 replicates.  
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5.7  Cytokine standard curves and melt curves for real-time qPCR 
Figures 5.9 and 5.10 show the standard curves used for relative quantification of cDNA 
samples (Panel A) and melt curves (Panel B) produced from qPCR reactions using IL-1β and 
IL-6 primers, respectively. As described for the AvBDs, the standard curve was checked for 
amplification efficiency of ~2 and for each sample melt curves were performed to ensure 
primer specificity. 
  
 
 
Figure 5.9: Real-time qPCR standard and melt curve for IL-1β.  
A) Standard curve for serial dilutions of IL-1β plasmid against calculated CP values. B) Melt curve 
for IL-1β PCR products of gut tissue samples (n = ~ 20 samples).  A single peak for each product was 
observed at the melting temperature of 89°C.  
  
A) Standard curve
B) Melt curves
7870 74 84 9280 8866 7268 86 9476 82 90
-0.298
1.502
3.302
5.102
6.902
8.702
1 2 3 4 5 6 7 8
12
14
16
18
20
22
24
26
32
C
ro
ss
in
g
 p
o
in
t (
C
P
) 28
30
F
lu
o
re
sc
en
ce
184 
 
 
 
 
 Figure 5.10: Real-time qPCR standard and melt curve for IL-6.  
A) Standard curve for serial dilutions of IL-6 plasmid against calculated CP values. B) Melt curve for 
IL-6 PCR products of gut tissue samples (n = ~ 20 samples).  A single peak for each product was 
observed at the melting temperature of 83°C.  
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5.8 Cytokine expression in CHCC-OU2 cells challenged with bacteria 
The in vivo data (Chapter 3 and 4) revealed that the B/BV challenge resulted in a progressive 
deterioration in gut health, including gut inflammation, whereas the LJ challenge appeared 
to be linked to anti-inflammatory effects. Therefore, pro-inflammatory cytokine expression 
was compared in vitro in response to BD, LJ and ST challenges (2 x 106 C.F.U).  
 
IL-6 and IL-1β expression were significantly up-regulated (up to >300 fold) following the 
challenge (Figure 5.11), with expression maximal at the 4 h sampling time-point. At 24 h 
sampling, gene expression was reduced although still above control values with fold-changes 
for IL-6 and IL-1β, of greater than 5-fold (P < 0.05) and 15-fold (P < 0.001), respectively.  
 
Figure 5.12 illustrates the effects of increasing the inoculum count on cytokine expression. 
Although compromised by large SEMs, these data clearly show that as the number of BD 
and ST C.F.Us. increased so did the expression of IL-6 and IL-1β. In contrast, this dose-
response type relationship was not as pronounced in the LJ challenged cells. Moreover, IL-6 
and IL-1β expression were reduced in the LJ compared to the BD and ST challenged cells, 
and this was statistically significant at the higher C.F.U. inocula (104, P < 0.05; 105, P < 
0.001).  
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Figure 5.11: The effect of bacterial challenge for 4, 8 and 24 h on IL-1β and IL-6 gene 
expression. 
Gene expression is shown as mean fold-change ± SEM relative to control cells, for IL-1β (A, B and 
C) and IL-6 (D, E and F).  Cells were challenged with 2 x 106 heat-killed colony-forming units (CFUs) 
per well and sampled at 3 timepoints: 4h (A and D), 8h (B and E) and 24h (C and F) (N = 1 - 2 
experiments, n = 2 - 6 replicate wells). Unchallenged control – blue bars, Bacteroides dorei strain 1 
– red bars, Bacteroides dorei strain 2 – dark red bars, Lactobacillus johnsonii – green bars. 
Significance values are for comparisons of means between control and challenged groups (One-way 
ANOVA followed by Dunnett's Multiple Comparison Test * P < 0.05, ** P < 0.01, *** P < 0.001). 
N = 1 – 2 experiments, n = 2 – 6 total replicates.  
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Figure 5.12: IL-1β and IL-6 gene expression induced by 8 h challenge with three species of 
bacteria over a range of C.F.U.  
Gene expression is shown as mean fold-change ± SEM relative to control cells, for IL-1β (A) and IL-
6 (B).  Chicken OU2 cells were challenged for 8h with heat-killed colony-forming units (CFUs) at 
102- 105 per well of Bacteroides dorei strain 1 (BD1) (red columns), Salmonella typhimurium (ST) 
(orange columns), and Lactobacillus johnsonii (LJ) (green columns). Bars with different letters have 
means that are significantly different from each other (P < 0.05, Two-way ANOVA). N = 2 
experiments, n = 3 - 6 replicate wells.  
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5.9 Discussion 
The in vivo data from Chapter 4 revealed that the B/BV challenge was linked to a significant 
reduction in the expression of AvBD1 and 10 in a number of bird gut tissues.  However, as 
no tissues were taken for gene expression analysis in Farm Trial 1, data on the effect of the 
LJ challenge were lacking. The aim of this chapter was to further explore the effects of gut 
associated bacteria on AvBD and inflammatory cytokine gene expression, but using an in 
vitro model. Bacterial challenges were performed using the commensal species utilised in 
Farm Trials 1 and 2: Bacteroides dorei (BD) and Lactobacillus johnsonii (LJ), in addition to, 
Salmonella enterica serovar Typhimurium 1344 (ST). The latter was chosen due to its 
potentially pathogenic nature (Christenson, 2013).  
 
The preferred in vitro model to investigate such challenges was a chicken gut epithelial line 
but, to date, none are commercially available. A number of groups have utilised primary cells 
from tissues such as the caecal tonsil (Brisbin et al., 2008), and intestine (Derache et al., 
2009a). These primary cell systems are, however, technically difficult to prepare, requiring 
a constant supply of birds, as well as strict quality control criteria to address reproducibility 
issues.  As an alternative to primary cell culture, this study utilised the CHCC-OU2 cell line, 
which has been used by a number of groups to investigate avian immune responses (Heriveau 
et al., 2000; Hong et al., 2008). Moreover, genomic sequencing revealed that the DNA of the 
CHCC-OU2 cells used in this study encoded the ‘NYH’ version of the AvBD1 peptide that 
is predominantly expressed by Line X birds. This strongly supported the use of the CHCC-
OU2 cells as an appropriate in vitro model and moreover enabled any results obtained using 
the in vitro work to be compared to the in vivo study data.  
 
Real-time PCR analysis, utilising a new set of house-keeping genes (GAPDH/YWHAZ), 
showed that AvBD1 and 10 genes were constitutively expressed by the cells under the growth 
conditions employed. Challenging the cells with bacteria did affect AvBD1 and 10 gene 
expression, although the data were often characterized by large SEMs that masked 
statistically significant changes. Nevertheless, the overall trend in relation to  AvBD1 
expression was that all the bacterial challenges down-regulated AvBD1 expression relative 
to the control even when low (102) bacterial doses were employed (Figure 5.6). These data 
indicated that the mechanism of AvBD1 down-regulation in the CHCC-OU2 cells was highly 
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sensitive and did not require high bacterial loads with MOI of less than one producing an 
effect. Interestingly, the CHCC-OU2 cells appeared more tolerant to LJ as down-regulation 
was only observed following a challenge of ≥1000 C.F.U. This contrasted to the AvBD10 
expression data where significant down-regulation was only observed at the 8 h time-point 
and when a bacterial challenge of 2 x 106 C.F.U., which did not affect CHCC-OU2 cell 
viability, was used. There was however a strong suggestion of AvBD10 up-regulation in the 
ST challenged cells, which reached statistical significance at 8h.  
 
The in vivo data shown in Chapter 4 indicated that AvBD1 was down-regulated in the gut 
tissues of 7 day-old birds and was not up-regulated following bacterial challenge. Therefore, 
both the in vitro and in vivo data suggest that AvBD1 expression is prone to down regulation, 
which perhaps reflects an immune evasion strategy by the bacterial strains associated with 
the gut epithelia. A similar observation was reported by investigators using primary intestinal 
cells expanded from a Salmonella susceptible bird line who reported that challenge with S. 
enteritidis (SE), did not significantly affect AvBD1 expression (Derache et al., 2009a).  This 
pattern was also observed in an in vivo challenge model utilising commercial broilers in 
which C. jejuni and S. typhimurium challenges had no effect on AvBD1 regulation; yet C. 
jejuni down-regulated AvBD3, 4, 8, 13 and 14 and S. typhimurium infection significantly up-
regulated AvBD3, 10 and 12 (Meade et al., 2009b). In vitro experiments have also revealed 
that the fatty acid butyrate, a major hind gut metabolite arising from bacterial fermentation, 
has no effect on AvBD1 expression but does up-regulate the expression of AvBD3, AvBD4, 
AvBD8, AvBD9, AvBD10, and AvBD14 in a time and dose-dependent manner (Sunkara et 
al., 2011). It is clear therefore, that differences exist in the regulation of AvBD expression 
with AvBD1 being more recalcitrant to up-regulation and prone to down-regulation although 
the reasons for this are not known. Although the mechanisms of HDP down-regulation have 
not been explored in avian species, the down-regulation of human HDPs has been 
demonstrated in an in vitro cell line model. RT-PCR and western-blot analyses revealed that 
the expression of LL-37 at the mRNA transcript and protein level is completely abrogated in 
epithelial cells (HT-29) by infection with the dysentery causing bacterium, Shigella 
dysenteriae (Islam et al., 2001). To ascertain the PAMP from S. dysenteriae that was 
responsible for the down-regulation, the authors challenged a monocyte cell line with two 
forms of LPS (E. coli and Shigella spp.), and two sonicated S. dysenteriae lysates, one 
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containing bacterial DNA and the other treated with DNase. The data confirmed that LL-37 
suppression was facilitated by bacterial DNA only (Islam et al., 2001). Therefore, it may be 
possible that in the BD, ST and LJ challenges, outlined in Chapter 5, the bacteria also utilised 
bacterial CpG DNA to suppress AvBD1 expression, putatively through chicken TLR21 
signalling but further work is required to explore this hypothesis. Other studies have 
suggested that the ability of Helicobacter pylori to persist in the human stomach is associated 
with its ability to down-regulate the human defensins, hβD1, which is constitutively 
expressed in non-infected individuals (Patel et al., 2013), and hBD3 (Bauer et al., 2014). For 
both genes the bacterial protein CagA is delivered into the host cell via a type IV secretion 
system which activates cell signalling cascades. For hBD1, it was shown that blocking NFκB 
expression using small interference RNA resulted in significant increases in hBD1 peptide 
relative to the H. pylori WT strain (Patel et al., 2013), whilst in another in vitro study hBD3 
expression was down-regulated via blocking epidermal growth factor (EGFR) activation 
(Bauer et al., 2014). The ability of bacterial toxins to down-regulate hBD1 expression in 
intestinal epithelial cells was shown by Vibrio cholerae and enterotoxigenic E. coli (ETEC) 
and the signalling mechanisms were through ERK MAPKinase, protein kinase A (PKA), and 
Cox-2 pathways (Chakraborty et al., 2008). In summary, the data from these in vitro human 
cell line models highlight that no single pathway exists for the suppression of human HDPs. 
This is also likely to be the case in regards to AvBD signalling and could explain why 
following a specific microbial challenge some AvBDs are up-regulated whilst some are 
down-regulated, presumably through multiple signalling pathways.   
   
It is recognised that cytokines and chemokines are important effectors of chicken innate, as 
well as, adaptive immunity (Kaiser et al., 2005). Chapter 4 identified potential links between 
inflammation and AvBD expression thus the expression of the pro-inflammatory cytokines 
IL-6 and IL-1β were also examined following the in vitro bacterial challenges. The data 
presented in this chapter indicated that the three bacterial challenges all induced IL-6 and IL-
1β expression. In addition, a dose-dependent response was observed in relation to the BD 
and ST challenges, but interestingly not for the LJ challenge. Further, and, most strikingly, 
the LJ challenge was associated with significantly lower IL-6 and IL-1β expression than the 
BD and ST challenges at the intermediate inoculums used (104 and 105 C.F.U.). The reasons 
for this are not known but as discussed in Chapter 3, LJ is regarded as a probiotic organism 
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and studies have shown that probiotic strains have a decreased ability to up-regulate pro-
inflammatory cytokines. For instance, in contrast to the E.coli strain Nissle 1917, 
Lactobacillus and Bifidobacterium have been shown not to induce the pro-inflammatory 
cytokine IL-8, as measured by ELISA, in gut associated HT29 cells that were incubated with 
bacterial cell debris for 32 h (Lammers et al., 2002). Microarray data has also shown that 
chicken caecal tonsil mononuclear cells, challenged with the isolated cell envelope from 
Lactobacillus acidophilus did not result in up-regulation of any innate genes but was 
characterized by the repression of the pro-inflammatory cytokine IL-17 gene, which the 
authors suggest may represent the adaptive response of the gut to normal host microbiota 
(Brisbin et al., 2008).  These studies, alongside the in vitro data presented in this chapter, 
indicate that Lactobacillus spp., such as LJ can modulate the immune response in part by not 
activating the release of pro-inflammatory cytokines such as IL-6/IL-1β and hence reducing 
inflammation.  
 
Bacteroides are commonly classed as gut commensals (Wexler, 2007). However, heat in-
activated strains of Bacteroides spp. such as Bacteroides fragilis have been shown to 
stimulate the release of pro-inflammatory cytokines IL-6 and TNF from human mononuclear 
cells and whole blood (Nagy et al., 1998). This could indicate that outside of its normal 
microbial niche in the caeca, Bacteroides spp. functions as an opportunistic pathogen 
resulting in an epithelial response and the up-regulation of pro-inflammatory cytokine genes. 
Accordingly, it is possible to hypothesise that the B/BV species ingested by the birds as part 
of the challenges outlined in Chapters 3 and 4, induced an excessive inflammatory response 
upon contact with the proximal gut epithelia whereas the LJ challenge did not. If BD also 
induces high levels of inflammation in vivo this could be potentially damaging to the 
immature gut structures of a bird that is newly hatched.  
 
The in vivo data in Chapter 4 suggested that individual birds maintaining relatively high 
AvBD1 expression despite the B/BV challenge suffered less GI inflammation and were less 
prone to poor gut health. This suggested the importance of the defensins in protecting the 
bird gut.  The in vitro data presented in this chapter provides further evidence that even at 
low numbers, BD can down-regulate AvBD1 expression at the cellular level, which is 
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indicative of an immune evasion strategy employed by opportunistic pathogens such as 
Bacteroides spp.  
 
The in vitro data also supported AvBD10 down regulation in response to 106 CFU of 
supposedly commensal bacteria (Figure 5.7), which again suggests the potentially pathogenic 
characteristics of such bacteria.   The in vitro data did however suggest that Lactobacillus 
species such as LJ, induce lower levels of pro-inflammatory cytokines and may be less able 
to down-regulate important innate associated genes such as the AvBDs. These findings 
provide a possible cellular mechanism that explains why the in vivo LJ challenge, as shown 
in Chapter 3, helped to maintain good enteric health, in contrast to the deterioration in gut 
health induced by B/BV. Overall, the CHCC-OU2 bacterial challenge model, as outlined by 
the data presented in this chapter, is a useful tool for evaluating innate immune gene 
regulation, at least until commercially available epithelial gut lines become available. 
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 Chapter 6: Properties of three AvBD1 variants and AvBD10 
6.1  Overview 
Chapter 4 demonstrated the expression of AvBD1 and 10 in chicken GI tissues, particularly 
newly-hatched chicks, which supports their importance in protecting young birds from 
exogenous pathogens, and shaping, potentially, the composition of the early gut microbiota. 
To date fourteen AvBDs have been identified and studies have reported the anti-microbial 
properties of a number of the peptides against numerous bacterial species (van Dijk et al., 
2008; Cuperus et al., 2013). While genes encoding the defensins tend to be conserved, natural 
allelic variation has been reported and linked to an altered potency. For example, single 
nucleotide polymorphisms (SNPs) in the great tit AvBD7 (Hellgren et al., 2010) as well as 
the chicken NK-lysin gene (Lee et al., 2012) have been shown to confer differences in anti-
microbial activity (AMA). In this chapter the production of AvBD1 and 10 peptides is 
described, in addition to, their anti-microbial potency against microbes associated with the 
chicken GI tract.   
 
Although originally investigated for anti-microbial activities, it is has been established  that 
host-defense peptides expressed in avian and mammalian species modulate immune 
functions by inducing cytokine production as well as stimulating wound healing (Otte et al., 
2008; Steinstraesser et al., 2011; Choi et al., 2012)  Therefore, in addition, to investigating 
anti-microbial activity, AvBD1 and 10 were assessed for cell proliferative properties and 
AvBD10 for wound healing capacity. 
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6.2  SNPs within AvBD1 locus 
The SNP study commissioned by Aviagen Ltd. to identify allelic variation within the 
commercial breeding lines has been previously reported (Butler, 2010). In summary, three 
non-synonymous SNPs were identified in the AvBD1 mature peptide coding region and 
shown in Figure 6.1. The three AvBD1 variants designated 'NYH', 'SSY' and 'NYY', 
according to the differences in their primary amino acid sequences were targeted for 
synthesis. ‘NYH’ represented the major AvBD1 form synthesized in Line X birds, ‘SSY’  
typified AvBD1 in Line Y birds, while ‘NYY’ represented Line Z, which has the most robust 
gut health,  but was not investigated in this PhD.  
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Figure 6.1: Three single nucleotide polymorphisms (SNPs) are present within the coding region of AvBD1. 
Nucleotide sequences are shown in black and the corresponding translated amino acids are shown underneath. The three non-synonymous coding SNPs are 
identified in green, red and blue. The AvBD1 peptides were designated A) ‘NYH’, B) SSY’ and C) ‘NYY’ according to the polymorphisms which are 
present. The prevalence of each SNP form in each genetic line is shown in D).  Percentage values are for homozygous alleles (TT or GG) and were 
calculated using data from the Aviagen Ltd. SNP study performed by Illumina (San Diego, U.S.A) in combination with sequencing of pooled bird DNA (n 
= 120) (Butler 2010). 
Genetic 
Line
SNP 1
(N or S)
SNP 2
(Y or S)
SNP 3
(Y or H)
X N (100%) Y (76%) H (86%)
Y S (89%) S (96%) Y (90%)
Z N (49%) Y (30%) Y (61%)
C
K S D C F R KG R N G F
C A F L K C P Y L T L I
GGA AGG AAG TCA GAT TGT TTT CGA AAG AAT GGC TTC 
TGT GCA TTT GTG AAG TGC CCT TAC CTC ACT CTC ATC   
AGT GGG AAA TGC TCA AGA TTT CAC CTC TGC TGC AAA  
S G K C S R F H L C C K
AGA ATA TGG GGC TGA
R I W STOPG
K S D C F R KG R S G F
C A F L K C P S L T L I
GGA AGG AAG TCA GAT TGT TTT CGA AAG AGT GGC TTC 
TGT GCA TTT GTG AAG TGC CCT TCC CTC ACT CTC ATC   
AGT GGG AAA TGC TCA AGA TTT TAC CTC TGC TGC AAA  
S G K C S R F Y L C C K
AGA ATA TGG GGC TGA
R I W STOPG
K S D C F R KG R N G F
C A F L K C P Y L T L I
GGA AGG AAG TCA GAT TGT TTT CGA AAG AAT GGC TTC 
TGT GCA TTT GTG AAG TGC CCT TAC CTC ACT CTC ATC   
AGT GGG AAA TGC TCA AGA TTT TAC CTC TGC TGC AAA  
S G K C S R F Y L C C K
AGA ATA TGG GGC TGA
R I W STOPG
A
B D
‘NYH’ Line X ‘NYY’ Line Z
‘SSY’ Line Y
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6.3  Production of recombinant AvBDs 
6.3.1 Overview 
The system chosen for AvBD peptide production was the Glutathione S-transferase (GST) 
fusion system (GE Healthcare) and is described fully in Chapter 2. Briefly, cDNA sequences 
corresponding to the mature peptide of AvBD1 ‘NYH’, ‘SSY’ and ‘NYY’ and AvBD10 were 
cloned into the pGEX-6P1 vector followed by transformation into competent JM101 cells. 
After sequence confirmation, pGEX-6P1-AvBD plasmids were transformed into E. coli 
BL21(DE3)pLysS cells for hyperexpression and the GST-AvBD fusion proteins purified. 
6.3.2 Engineering of AvBD1 and 10 hyperexpression vectors 
Cloning was performed in collaboration with Dr Vanessa Armstrong, now School of 
Biomedical Sciences, Newcastle University. Briefly, primers incorporating the restriction 
enzyme sites BamHI and EcoR1 were designed to the mature peptide DNA sequences for 
AvBD1 and 10, and PCR was used to amplify cDNA from Line X and Y birds (Gel 
electrophoreses not shown). The cDNA sequences were cloned into the expression vector 
PGEX6p-1, transformed into JM101, plasmids prepared and sequenced (GeneVision, UK). 
To illustrate, the sequencing results for AvBD10 is shown in Figure 6.2.  
 
GTGAGCTTGATGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGG
GGCCCCTGGGATCCGACCCACTTTTCCCTGACACCGTGGCATGCAGGACTC
AGGGGAATTTCTGCCGTGCTGGGGCATGCCCCCCCACCTTCACCATCTCT
GGGCAGTGCCATGGGGGGCTGTTAAACTGCTGTGCCAAGATTCCGGCGCA
GTAAGAATTCCCGGGTCGACTCGAGCGGCCGCATCGTGACTGACTGACGATCT
GCCTCGCGCGTTT 
 
Figure 6.2: The nucleotide sequence for the AvBD10-GST construct plasmid. 
The DNA sequence encoding the mature peptide is shown in bold underlined, the location of the 
restriction enzyme sites BamH1 are in yellow and EcoR1 in blue, the DNA encoding the GPLGS 
amino acid sequence following GST-tag removal is in pink and stop codon is in red.   
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6.3.3 Hyperexpression and Purification of AvBD1 and 10 
Aliquots at each stage of the hyper-expression and purification procedures were sampled and 
analysed by NuPAGE gel electrophoresis. Figure 6.3 shows gel electrophoresis of aliquots 
from each stage of the AvBD1 protein purification procedure. Lane 1 showed that that the 
majority of protein appeared as inclusion bodies in the bacterial pellet indicating that the 
GST-AvBD1 fusion protein had poor solubility in the cell free extract.  The lack of GST-
AvBD1 in the soluble fraction (Lane 2) resulted in less GST-fusion available for enzyme 
cleavage and thus only a small amount of peptide was produced (red box in Lane 7). 
Crucially, no separation using a 10kDa MW cut-off column was observed (Lane 8), and the 
cleaved AvBD1 peptide appeared in the >10kDa fraction alongside the GST tag, cleavage 
protease and other contaminants (Lane 9). An additional attempt to separate cleaved AvBD1 
from higher M.W proteins using size exclusion chromatography failed to yield AvBD1 
peptide. However at this time a PhD top-up grant from the Knowledge Transfer Network 
(KTN) for £5,000 was awarded, and this funded the commercial synthesis of the three 
versions of AvBD1 as linear peptides. 
 
In contrast, comparison of Lanes 1 and 2 in Figure 6.4 illustrated that the AvBD10 fusion 
protein (~30kDa), was at a higher concentration in the soluble cell free extract (CFE) 
compared to the insoluble pellet. In addition, following GST-AvBD10 cleavage, relatively 
high levels of peptide were found corresponding to the correct M.W ~ 5kDa (lanes 5 – 9). 
The single band at ~5kDa observed in Lane 11 in the <10kDA fraction following size 
separation demonstrated that this strategy enabled high levels of purification.  
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Figure 6.3: AvBD1: InstantBlue™ NuPAGE® 4-12% Bis-Tris Gel  
Aliquots of each step of hyperexpression and purification for AvBD1 were as follows: M – Novex® 
Sharp molecular marker. 1 – re-suspended pellet; 2 - cell free extract; 3 – PBS wash No. 1; 4 – PBS 
wash No. 10; 5 – elution of GST-AvBD1; 6 – buffer exchange into PBS; 7 - enzyme cleaved GST-
AvBD1 peptide; 8 - Collection of <10kDa proteins; 9 - Collection of >10kDa proteins. The cleaved 
AvBD1 peptide is highlighted by the red box. 
 
Figure 6.4: AvBD10: InstantBlue™ NuPAGE® 4-12% Bis-Tris Gel  
Aliquots of each step of hyperexpression and purification for AvBD10 were as follows: M – Novex® 
Sharp molecular marker. 1 – re-suspended pellet; 2 - cell free extract; 3 – PBS wash No. 1; 4 – PBS 
wash No. 10; 5 – 9: 1ml elutions of cleaved peptide + GST + enzyme; 10 – Collection of >10kDa 
proteins; 11 - Presumed recAvBD10 peptide. The cleaved AvBD10 peptide is highlighted by the red 
box.  
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6.3.4  Predicted properties of AvBD1 and AvBD10 
The predicted properties for the three AvBD1 mature peptides and recombinant AvBD10 
with additional cleavage tag (GPLGS) at the N-terminus were determined using online 
software (Innovagen, http://www.innovagen.se/custom-peptide-synthesis/peptide-property-
calculator/peptide-property-calculator.asp), and are shown in Table 6.1. The predicted 
properties revealed that unlike many cationic anti-microbial peptides, AvBD10 has a low net 
charge at pH7 and an iso-electric point close to neutral pH (7.64). 
 
Table 6.1: Predicted properties of three AvBD1 variants (‘NYH’, ‘SSY’ and ‘NYY’) and 
recombinant AvBD10 + GPLGS tag.  
 
AvBD10 
 
AvBD1 
(NYH) 
 
AvBD1 
(SSY) 
 
AvBD1 
(NYY) 
 
Molecular weight (g/mol) 
5193 
 
4644.6 
 
4567.6 
 
4670.7 
 
Extinction coefficient (M-1cm-1) 0 6970 6970 8250 
Iso-electric point (pH) 7.64 9.92 9.92 9.81 
Net charge at pH 7 0.8 7.8 7.7 7.7 
Est. water solubility Poor Good Good Good 
 
6.3.5  Peptide sequencing of AvBD10 using Mass Spectrometry 
To authenticate the purified AvBD10 peptide an aliquot was sent to the Proteomics 
Laboratory, York University; peptide sequencing was performed using MALDI-MS/MS and 
In-Source Decay (ISD). A combination of MS/MS fragmentation (Figure 6.5A) and ISD 
fragmentation (Figure 6.5B) revealed the first 26 amino acids of AvBD10 (in bold) attached 
to GPLGS from the GST-tag used for purification (Figure 6.5C). Although the remaining 25 
amino acids in the sequence could not be identified, a signal of mass (5189.5 m/z.), similar 
to predicted expected full length mass of 5193g/mol (Table 6.1), was observed in the full 
MALDI-ISD spectra suggesting the full length peptide was present. 
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Figure 6.5: Identification of AvBD10 sequence using MALDI-MS/MS and In-Source Decay 
(ISD).   
A) MALDI-MS/MS spectrum of precursor at 1385.6 m/z with DHB matrix, annotated with the de 
novo derived sequence PLFPDTVA. B) MALDI-ISD spectrum of AvBD10 with overlaid sequence 
ACRTQGNFCRAGA.  ISD was used to fragment the entire component of the sample and read back 
to the N-terminus. C) Total sequence of AvBD10 identified using both using MALDI-MS/MS and 
In-Source Decay (ISD) is shown in bold.  
 
A
B
C
GPLGSDPLFPDTVACRTQGNFCRAGACPPTFTISGQCHGGLLNCCAKIPAQ
P L F P D T V A
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6.4  Anti-microbial activities of AvBD1 and 10 
The AvBD1 and 10 peptides were used in anti-microbial assays and their activities tested 
against bacteria linked to the chicken GI tract. The assays employed both gram negative 
(Escherichia. coli, Salmonella typhimurium, Barnesiella viscericoli, Bacteroides dorei) and 
gram positive (Enterococcus faecalis, Lactobacillus johnsonii) isolates. The assays included 
a colony counting time-kill assay (Townes et al., 2004; Milona et al., 2007), a radial diffusion 
assay (Lehrer et al., 1991; Schroeder et al., 2011) and microbroth dilution assay (van Dijk et 
al., 2007). The colony counting assay, developed in the Hall Laboratory (Townes et al., 
2004), provides a quantitative method to assess the activity of peptide against a diluted 
bacterial broth over a 2 – 3 h incubation period. Similarly, the microbroth dilution assay 
performed in a microtitre plate utilises a 1 in 2 dilution series of peptide (125 – 0.1μg/ml) 
against a set dilution of bacteria with the aim of determining the minimum inhibitory 
concentration (MIC), which is the lowest concentration at which there is no visible growth. 
Typically, the assays are performed overnight and checked for growth the following day; for 
the assays reported herein the plates were incubated overnight in a plate reader and OD600nm 
was plotted every 20 min to produce a growth curve at all concentrations. Finally, the radial 
diffusion assay was set up, which enabled a straightforward visual comparison of the AMA 
of different peptides, visualized as a zone of inhibition, against a bacterial lawn. This assay 
can be used semi-quantitatively by measuring the diameter of inhibition or, as reported in the 
results, a percentage area was calculated using imaging software. The colony counting and 
microbroth dilution assays were unsuccessful for assessing peptide AMA against Bacteroides 
spp., and so a modified version of the radial diffusion assay for anaerobic bacteria was 
adopted as previously outlined (Schroeder and Wehkamp, 2011).  
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6.4.1 Anti-microbial activities of sAvBD1 ‘NYH’, ‘SSY’ and ‘NYY’  
Figure 6.6 shows the anti-microbial activity of the AvBD1 ‘NYH’, ‘SSY’ and ‘NYY’ 
peptides against E. coli (clinical isolate) using the colony counting (A), microbroth dilution 
(B) and the radial diffusion (C) assays. The data from the colony counting assays revealed 
that at 10μg/ml the ‘NYH’ form of the peptide exhibited E. coli killing activity whereas at 
the same concentration, the SSY and NYY peptides were associated with E. coli survival, 
18% and 22%, respectively. To determine the MIC for each peptide the microbroth dilution 
assay was employed. These data, shown in Panel B, supported the colony counting data in 
that ‘NYH’ peptide was revealed to be the most active peptide form with complete E. coli 
killing demonstrated up to 15.6μg/ml (MIC 15.6μg/ml); ‘SSY’ killed at 125μg/ml (MIC 
125μg/ml) but ‘NYY’ did not kill E. coli at any of the concentrations tested (MIC > 
125μg/ml). These data confirmed that ‘NYH’ is the most active of the three AvBD1 variants 
against E. coli and suggested that the ‘SSY’ form is more active than ‘NYY’ (Panel B). To 
examine the effects of these peptides at a high concentration against a bacterial lawn, the 
radial diffusion assay was employed. At 1μg concentration the relative size of the inhibition 
zone was 51% for the ‘NYH’ variant compared to 35% and 31% for ‘SSY’ and ‘NYY’, 
respectively; again demonstrating that ‘NYH’ is the most potent peptide of the three different 
forms (panel C). 
 
Figure 6.7 shows the anti-microbial activity of AvBD1 ‘NYH’, ‘SSY’ and ‘NYY’ against 
Enterococcus faecalis using the colony counting (A), microbroth dilution (B) and radial 
diffusion (C) assays.  Colony counting assays showed a lower mean E. faecalis growth (%) 
at 5, 10 and 25μg/ml for the ‘NYH’ variant, although this did not reach statistical significance 
(panel A). The microbroth dilution assay produced MIC values of 1.98, 3.9 and 3.9μg/ml for 
‘NYH’, ‘SSY’ and ‘NYY’ respectively, establishing that the ‘NYH’ variant was more active 
against E. faecalis than the ‘SSY’ and ‘NYY’ forms. Further evidence for the enhanced 
potency of ‘NYH’ was shown by the radial diffusion assay that illustrated larger zones of 
inhibition at 1 and 2µg for the ‘NYH’ form compared to either the ‘SSY’ or ‘NYY’ variants. 
In summary for E. faecalis, all three assays supported that ‘NYH’ was the most potent peptide 
although no difference in activities between ‘SSY’ and ‘NYY’ could be established.  
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Figure 6.8 shows that all forms of AvBD1 completely inhibited Salmonella typhiumurium 
growth, at concentrations of >7.5µg/ml, but at 2.5 and 5µg/ml the ‘NYH’ peptide resulted in 
significantly lower S. typhiumurium growth than the SSY and NYY peptide forms (P < 
0.001). These data were corroborated by the radial assay results that showed larger inhibition 
zones for ‘NYH’ than ‘SSY’ and ‘NYY’ at all concentrations tested (Panel B). Furthermore, 
a comparison between ‘SSY’ and ‘NYY’ at 2μg illustrated a larger inhibition zone area for 
‘SSY’ (74%) than ‘NYY’ (48%), suggesting increased ‘SSY’ potency. However, no MIC 
values were determined for any of the variants to support the radial diffusion assay data. An 
initial attempt at the microbroth assay failed, due to contamination between wells, and was 
not re-attempted due to time constraints.  
 
The anaerobic bacteria, both facultative (LJ, BV) and obligate (BD) were difficult to culture 
and experiments utilising the colony counting and microbroth methodologies were only 
partially successful in that colonies were counted for BV and LJ. Radial assays performed 
under anaerobic conditions were however, successful for all three anaerobes. The colony 
counting assay data showed that ‘NYH’ was the most anti-microbial of the three variants 
against LJ (Panel A). At the highest concentration of 50µg/ml the ‘NYH’ form completely 
inhibited growth while the ‘SSY’ and ‘NYY’ variants did not. This result was confirmed by 
the radial diffusion assay, as well as illustrating larger areas of inhibition for the ‘SSY’ (2μg 
64%, 1μg 51%), than the ‘NYY’ (2μg 47%, 1μg 27%), peptide (Figure 6.9C).  
 
As shown for the other bacterial strains tested, the ‘NYH’ variant was more potent than the 
‘NYY’ form against BV (Figure 6.10) and BD (Figure 6.11). In addition, for BV, at 2μg/ml 
the ‘SSY’ variant appeared to be less potent than ‘NYH’, with clearing areas of 48% and 
72% determined, respectively. However, no clear differences between the ‘NYH’ and ‘SSY’ 
forms could be demonstrated for BD (Figure 6.11).  
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Figure 6.6: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) against avian Escherichia coli.  
A) Colony-counting assay showing percentage bacterial growth (E. coli) following 2 h incubation of mid-log bacteria (1/1000 dilution) with three 
AvBD1 peptides (NYH, SSY and NYY) at a final concentration of 1 - 25μg/ml. All percentage growth is shown relative to PBS + bacteria control 
(dotted line). Percentage values < 0% indicate fewer colonies after 2 h than at 0 h and hence, indicate bacterial killing. Each point shows the mean 
± SEM from three experiments (N = 3).  
B) Growth curves for the microbroth dilution assay showing growth of E. coli (mid-log diluted 1/20000) in LB media as a measure of OD600nm over 
time (min) following the addition of AvBD1 NYH, SSY and NYY at a final concentration of 125 – 3.9µg/ml. The Minimum Inhibitory 
Concentration (MIC) is indicated for each peptide next to the relevant growth curve (N = 1 experiment). 
C) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and ‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition 
is assigned a value of 100% and relative size of each inhibition zone (%) was determined using ImageJ software (N = 1 experiment). 
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Figure 6.7: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) against avian Enterococcus faecalis. 
A) Colony-counting assay showing percentage bacterial growth (E. faecalis) following 2 h incubation of mid-log bacteria (1/1000 dilution) with three 
AvBD1 peptides (NYH, SSY and NYY) at a final concentration of 1 - 25μg/ml. All percentage growth is shown relative to PBS + bacteria control 
(dotted line). Percentage values < 0% indicate fewer colonies after 2 h than at 0 h and hence, indicate bacterial killing. Each point shows the mean 
± SEM from three experiments (n = 3).  
B) Growth curves for the microbroth dilution assay showing growth of E. faecalis (mid-log diluted 1/20000) in LB media as a measure of OD600nm 
over time (min) following the addition of AvBD1 NYH, SSY and NYY at a final concentration of 7.8 – 0.98µg/ml. The Minimum Inhibitory 
Concentration (MIC) is indicated for each peptide next to the relevant growth curve (N = 1 experiment). 
C) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and ‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition 
is assigned a value of 100% and the relative size of each inhibition zone (%) was determined using ImageJ software.  
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Figure 6.8: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) against avian Salmonella typhimurium. 
A) Colony-counting assay showing percentage bacterial growth (S. typhimurium) following 2 h incubation of mid-log bacteria (1/1000 dilution) with 
three AvBD1 peptides (NYH, SSY and NYY) at a final concentration of 1 - 25μg/ml. All percentage growth is shown relative to PBS + bacteria 
control (dotted line). Each point shows the mean ± SEM from three replicates (n = 3). *** P < 0.001; Bonferroni post-tests.  
B) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and ‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition 
is assigned a value of 100% and the relative size of each inhibition zone (%) was determined using ImageJ software.  
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Figure 6.9: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) against avian Lactobacillus johnsonii.  
A) Colony-counting assay showing percentage bacterial growth (L. johnsonii) following 3.5 h incubation of mid-log bacteria (1/1000 dilution) with 
three AvBD1 peptides (NYH, SSY and NYY) at a final concentration of 1 - 50μg/ml. All percentage growth is shown relative to MRS media (5%) 
+ bacteria control (dotted line). Each point shows the mean ± SEM from three experiments (n = 3). *** P < 0.001; Bonferroni post-tests comparing 
‘NYH’ to ‘SSY’ and ‘NYY’. 
B) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and ‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition 
is assigned a value of 100% and the relative size of each inhibition zone (%) was determined using ImageJ software.  
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Figure 6.10: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) 
against avian Barnesiella viscericola. 
 A) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and 
‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition is assigned a value of 100% and the relative 
size of each inhibition zone (%) was determined using ImageJ software.  
 
 
Figure 6.11: The anti-microbial activities of three AvBD1 variants (NYH, SSY and NYY) 
against avian Bacteroides dorei. 
 A) Radial diffusion assay showing the inhibitory effect of AvBD1 variants ‘NYH’, ‘SSY’ and 
‘NYY’ at 4, 2 and 1μg. The largest zone of inhibition is assigned a value of 100% and the relative 
size of each inhibition zone (%) was determined using ImageJ software. 
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6.4.2 Effects of lipid-AvBD1 interactions on secondary structure 
The three SNP peptide variants were synthesised commercially as linear peptides. It has 
been shown by using circular dichroism (CD) that AMPs can change confirmation, for 
example, from a random to a helical structure in the presence of anionic phospholipids 
(Lee et al., 2012; Yeaman and Yount, 2003). To determine if such a change in peptide 
secondary structure was observed in the three AvBD SNP variants, CD experiments were 
performed in the presence and absence of SDS, the latter mimicking a bacterial 
phospholipid membrane. The data shown in Figure 6.12A indicated that all three peptides 
formed disorganised structures in aqueous solution, although the NYY variant also 
formed a partial beta-sheet-like structure (negative band at 217nm and a positive band 
below 200nm). However, the data in Figure 6.12B demonstrated that following the 
addition of SDS, all three peptides change to an alpha-helical conformation, which was 
probably linked to their anti-microbial activities. 
 
 
Figure 6.12: CD spectra of three AvBD1 variants (NYH, SSY, NYY)  
A) In 50mM sodium phosphate buffer the AvBD1 variant NYY shows beta-sheet-like 
structures in contrast to random coil structures for NYH and SSY. 
B) Addition of SDS induces a conformational change in all three AvBD1 variants from a 
random to an alpha-helical structure.  
Experiment performed by Sherko Subhan, PhD student, Newcastle University. 
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6.4.3 Anti-microbial activity of recombinant AvBD10  
Figures 6.13 – 6.17 show the anti-microbial activities of recombinant AvBD10 against E. 
coli, E. faecalis, B. viscericola, L. johnsonii and B. dorei, respectively. 
 
The colony counting assay data for E. coli showed that as peptide concentration increased 
from 0.5 to 10μg/ml, E. coli growth was inhibited to approximately 70% of the PBS 
control (Figure 6.13). No further growth inhibition was observed when the AvBD10 
concentration was increased from 10 to 25μg/ml. The radial diffusion however, showed 
a clear zone of inhibition at 1μg that increased in size at 2μg, indicating E. coli killing 
(Figure 6.13B). Colony counting assay data for E. faecalis (Figure 6.13A), showed that 
recAvBD10 (0.5 – 5μg/ml) inhibited the bacterial growth to 30 - 40% of the PBS control 
and to less than 20% at 10μg/ml.  No further decrease in bacterial growth was observed 
at the highest concentration of 25μg/ml, suggesting that AvBD10 is not able to completely 
kill the bacteria (Figure 6.14A). The lack of E. faecalis killing capacity by AvBD10 was 
confirmed by the microbroth dilution assays (Figure 6.14B). These data did, however, 
support a concentration-dependent inhibition of growth. For example, at 7.8μg/ml 
measurable growth was delayed for approximately 400min, while at 125μg/ml the 
bacterial growth was inhibited until >900min.   
 
Similar to that observed with E. coli and E. faecalis, the colony counting assay data for 
B. viscericola (Figure 6.15), showed a decrease in bacterial growth as the peptide 
concentration was increased up to 25μg/ml. A further increase in AvBD10 concentration 
up to 50μg/ml did not result in further inhibition, a pattern also observed with E. faecalis 
and E. coli. 
 
Figures 6.16 and 6.17 show the results of the radial diffusion assays for AvBD against L. 
johnsonii and B. dorei, respectively. A thinning of the bacterial lawn was observed for L. 
johnsonii suggesting inhibition, although a complete zone of clearing, as seen for 
lysozyme, was not observed (Figure 6.16). For B. dorei no zones of inhibition were 
observed although lysozyme/cecropin (positive controls) also did not inhibit at 2μg. 
Zones of inhibition were only observed for lysozyme at 20μg (Figure 6.17).  
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Figure 6.13: The anti-microbial activity of recombinant AvBD10 (recAvBD10) against avian 
Escherichia coli. 
 
 A) Colony-counting assay showing percentage bacterial growth (E. coli) following 2.5 h 
incubation of mid-log bacteria (1/1000 dilution) with recAvBD10 (1 - 25μg/ml). All percentage 
growth is shown relative to PBS + bacteria control (dotted line). Each point shows the mean ± 
SEM from three experiments using different protein purification batches (n = 3). 
B) Radial diffusion assay showing the inhibitory effect of recAvBD10 at 1μg and 2μg, PBS (0μg) 
and positive controls (cecropin/hen-egg lysozyme at 2μg) on E. coli.  
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Figure 6.14: The anti-microbial activity of recombinant AvBD10 (recAvBD10) against avian 
Enterococcus faecalis. 
   
A) Colony-counting assay showing percentage bacterial growth (Enterococcus faecalis) 
following 2.5 h incubation of mid-log bacteria (1/1000 dilution) with recAvBD10 (1 - 25μg/ml). 
All percentage growth is shown relative to PBS + bacteria control (dotted line). Each point shows 
the mean ± SEM from four experiments using different protein purification batches (n = 4).  
B) Microbroth dilution assay showing Enterococcus faecalis growth as a measure of OD600nm with 
the addition of recAvBD10 at 8.5, 17, 34, 67.5 and 125µg/ml. 
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Figure 6.15: The anti-microbial activity of recombinant AvBD10 (recAvBD10) against avian 
Barnesiella viscericola.  
 
A) Colony-counting assay showing percentage bacterial growth (Barnesiella viscericola) 
following 2.5 h incubation of mid-log bacteria (1/1000 dilution) with recAvBD10 (1 - 50μg/ml). 
All percentage growth is shown relative to PBS + bacteria control (dotted line). Each point shows 
the mean ± SEM from three replicates within a single assay (n = 1).  
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Figure 6.16: The anti-microbial activity of recombinant AvBD10 (recAvBD10) against avian 
Lactobacillus johnsonii.  
A) Radial diffusion assay showing the effect of PBS (0μg), recAvBD10 (1 and 2μg/μl) and hen-
egg lysozyme (+ve control) on Lactobacillus johnsonii.  
 
 
 
Figure 6.17: The anti-microbial activity of recombinant AvBD10 (recAvBD10) against avian 
Bacteroides dorei.  
A) Radial diffusion assay showing the effect of recAvBD10 (1 and 2μg/μl), cecropin (+ve control) 
and hen-egg lysozyme (+ve control) on Bacteroides dorei  
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6.5 Comparison of the anti-microbial activity of AvBD1 and AvBD10  
The data presented in Figures 6.17 and 6.18 show data from the colony counting assays 
that compare the anti-microbial activity of synthetic variants of AvBD1 and recombinant 
AvBD10 (0.5 - 10μM) against E. coli in high nutrient conditions of 10% LB media 
(Figure 6.18) and low nutrient conditions of PBS (Figure 6.19).  
 
In the high nutrient assay (Figure 6.18), at the lowest concentration tested (0.5μM) the 
recombinant AvBD10 reduced  E. coli growth to 75%, which was significantly different 
to the ‘NYH’ (P < 0.05), but not the other two AvBD1 forms. As the peptide concentration 
increased, E. coli growth decreased and differences in the antimicrobial activities of the 
peptides became apparent. At 2.5μM and 5μM respectively, incubation with both AvBD1 
‘NYH’ and AvBD10 resulted in significantly lower E. coli (%) growth than either AvBD1 
‘SSY’ or ‘NYY’ (P < 0.01). No significant differences between the ‘SSY’ and ‘NYY’ 
forms were found using this assay. At 10μM all AvBD1 variants completely inhibited E. 
coli growth, whereas, interestingly, AvBD10 only reduced growth to ~20% of the control 
(10% LB media). 
  
Figure 6.19 shows a comparison of the activity of AvBD1 ‘NYH’ and AvBD10 against 
E. coli grown in the low nutrient conditions of PBS. At 0.5 and 1μM no significant 
differences were observed, but the data indicated that at concentrations greater than 
2.5μM, AvBD1 ‘NYH’ treatment, in contrast to AvBD10, resulted in complete inhibition 
of E. coli growth, (2.5μM: P < 0.05, 5μM: P < 0.001, 10μM: P < 0.01).  
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Figure 6.18: A comparison of the anti-microbial activity of three AvBD1 variants with 
recombinant AvBD10 under high nutrient conditions (10% LB media). 
The data is illustrated as a line graph (A) and histogram (B).  
A)  Colony-counting assay showing percentage bacterial growth (E. coli) following 2 h incubation 
of diluted mid-log bacteria (1/1000) with three AvBD1 peptides (NYH, SSY and NYY) and 
recombinant AvBD10 at a final concentration of 0.5 - 10μM. All percentage growth is shown 
relative to the control of 10% LB media + bacteria (dotted line). Each point shows the mean ± 
SEM from three replicates in a single experiment (n = 1).  
B)  Significant differences between peptides at each concentration are presented as a histogram. 
Bars not sharing the same letters are significantly different according to Two-way ANOVA 
followed by Bonferroni's Multiple Comparison Test (P < 0.05).  
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Figure 6.19: Colony-counting assay showing percentage bacterial growth (E. coli) in low 
nutrient conditions (PBS buffer).  
AvBD1 peptide ‘NYH’ and recombinant AvBD10 were incubated for 2 h with diluted mid-log E. 
coli (1/1000) at a final concentration of 0.5 - 10μM. All percentage growth is shown relative to 
PBS + bacteria control (dotted line). Each point shows the mean ± SEM from three replicates in 
a single experiment (n = 1). * P < 0.05, ** P < 0.01, *** P < 0.001; Bonferroni post-tests.  
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6.6 Novel properties of AvBD1 and AvBD10 
Data from Chapter 4 indicated that relative to AvBD1, AvBD10 showed different patterns 
of tissue expression (high kidney/liver expression relative to gut tissues). The data from 
this chapter indicated that AvBD10 had an inhibitory rather than bactericidal function. 
Therefore, due its high constitutive tissue expression but low AMA, AvBD10 appeared 
to be a good candidate to investigate for further functions including those of cell 
proliferation wound healing. CHCC-OU2 cells were used for such experiments.  
 
Cell proliferation, relative to a PBS control was examined for CHCC-OU2 cells incubated 
with one of the four AvBDs (AvBD1 NYH/SSY/NYY and AvBD10), or Fibroblast 
growth factor (FGF) – a positive control, or Bovine Serum Albumin (BSA)- a generic 
protein source or Mitomycin C - a anti-proliferative control (Figure 6.20). Due to lack of 
chicken peptide, human basic FGF was used as the positive control; however, at the 
concentrations used it did not significantly affect cell proliferation, although at 1nM FGF 
it did produce a higher mean cell proliferation, 117%, compared to control. The results 
using the AvBD peptides were also negative in that 48 h incubation of the CHCC-OU2 
cells with either AvBD10 or the two AvBD1 variants (‘NYH’ and ‘SSY’) at 1, 5 and 
10nM did not significantly affect cell proliferation, as measured by Cell Titre-Blue assay, 
relative to the PBS control. Mitomycin C was used as an anti-proliferative control and 
was shown to significantly inhibit cell proliferation at 5 (P < 0.05) and 10nM (P < 0.01) 
 
The effects of AvBD10 on CHCC-OU2 cell wound healing were examined by performing 
scratch assays. Following ‘wounding’ the confluent cell layer with a pipette tip and 
incubating the wells at peptide concentrations of 0.1, 0.5 and 1nM,  the closure of the 
wound was imaged over a 72 h time period (Figure 6.21). At 0.1nM and 0.5nM AvBD10 
induced higher mean wound healing at each sampling time-point relative to control but 
this did not reach statistical significance. For example, at 0.1nM of AvBD10, percentage 
wound closure was 19% (24h), 45% (48h) and 43% (72h) compared to the PBS control 
that had wound closure measured at 9% (24h), 27% (48h) and 31% (72h). 
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Figure 6.20: No significant effect of AvBD incubation on cell viability. 
Viability is shown relative to PBS control (Mean ± SEM) following 48 h incubation with Bovine 
Serum Albumin (BSA), Mitomycin C, fibroblast growth factor (FGF), AvBD10, AvBD1 ‘NYH’, 
and AvBD1 ‘SSY’ at A) 1nM, B) 5nM and C) 10nM. After 48 h incubation, wells were incubated 
with CellTiter-Blue® Reagent for 2 -3 h. P values show comparisons of PBS control with treated 
wells. * P < 0.05, *** P < 0.001; Dunnett’s Multiple Comparison Test. N = 3 experiments. 
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Figure 6.21:  Effect of AvBD10 on wound healing.  
For each concentration (0, 0.1, 0.5 and 1nM) three wells containing confluent cells were scratched 
and incubated with AvBD10 for 0, 24, 48 and 72 h.  Photographs were taken at each time-point 
and percentage wound healing was calculated as the total wound area (black pixels) minus the 
number of cells (represented by white pixels) that had migrated into the wound area (example 
shown in panel B). The mean ± SEM for three wells were taken for each experiment. N = 3 
experiments.  
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6.7 Discussion 
Avian, unlike many human defensins, are not commercially available, and had to be 
produced ‘in house’. To obtain biologically active peptide for anti-microbial testing, 
many methods have been employed e.g. AvBDs have been either directly extracted from 
leukocytes (Harwig et al., 1994) or produced using bacterial (Ma et al., 2012a), human 
cell (van Dijk et al., 2007), and yeast (Cao et al., 2012) expression systems or chemically 
synthesised (Higgs et al., 2007; Hellgren et al., 2010). Many of the assays using 
recombinant peptides have been performed using tagged peptides that have molecular 
weights much larger than those found in vivo and although the peptides have been shown 
to have anti-microbial activity, such properties may not be biologically representative.  
 
To enable the production of peptides that are comparable to those found in vivo, this study 
utilized the GST fusion system (GE Healthcare Lifesciences), and following purification, 
removed the GST fusion tag by protease cleavage. The results shown in Figures 6.3 and 
6.4 indicate that hyperexpression was successful for both AvBD1 and 10.  However, in 
contrast to AvBD10 in which the majority of the GST fusion was in the cell free extract, 
the majority of GST- AvBD1 was found in insoluble fusion bodies. For AvBD10, this 
enabled a simple purification strategy of GST tag removal followed by size separation 
using spin columns with a 10kDa molecular weight cut-off, but solubility and/or charge 
issues meant it did not work for AvBD1. The likelihood of hyperexpressed proteins, 
including AvBD1, accumulating in inclusion bodies is high and protocols, including 
commercially available kits, are available to solubilize inclusion bodies in denaturing 
buffers such as guanidine hydrochloride or urea, followed by a re-folding step (Burgess, 
2009; Yang et al., 2011). However, this is a technically demanding and time-consuming 
process which does not guarantee biologically active protein that is correctly folded 
(Panda, 2003). The successful production of a number of recombinant duck AvBD 
peptide GST-fusions in E. coli followed by purification using a refolding kit from 
Novagen has been described (Ma et al., 2009; Ma et al., 2012a), and this strategy was 
considered. Following a KTN PhD top-up award, the decision was taken to synthesise, 
chemically, the three AvBD1 variants. All three peptides were produced to >95% purity, 
which enabled a controlled assessment of how single amino acid changes altered their 
anti-microbial activities. Circular dichroism (CD) experiments have revealed that two 
synthetic SNP variants of NK-lysin are in an unorganised form in aqueous solution but, 
when in contact with dipalmitoylphosphatidyglycerol (DPPG) liposomes, used to mimic 
bacterial membranes, change to a helical structure (Lee et al., 2012). Figure 6.12 
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confirmed that a similar conformational change in secondary structure also occurred in 
the AvBD1 SNP variants in the presence of SDS, an amphiphilic detergent, mimicking 
bacterial membranes.  
 
Data from the three anti-microbial assays employed (radial diffusion, colony counting 
and microbroth dilution), revealed that all three AvBD1 variants displayed anti-microbial 
activity against all the chicken gut bacterial isolates tested: E. coli, E. faecalis, L. 
johnsonii, B. viscericola and B. dorei. Moreover, the majority of data indicated that 
‘NYH’ was the most potent AvBD1 variant. In addition, a number of the experiments 
revealed that the ‘SSY’ form was more potent than the ‘NYY’ form. In summary the 
overall trend for AMA was ‘NYH’ > ‘SSY’ > ‘NYY’. It can be assumed that the potency 
is linked to interaction of peptide with bacterial membrane, but future CD analyses are 
required to verify this. 
 
The linear AvBD1 SNP variants were synthesized to compare the properties of the 
AvBD1 peptides produced by the three Aviagen commercial breeding lines, that differ in 
their susceptibility to enteric problems: X (‘NYH’), Y (‘SSY’) and Z (‘NYY’). The gut 
health assessments detailed in Chapter 3 and 4 revealed that Line Y has more optimal gut 
health compared to Line X, with Line Z showing the most robust gut health of the three 
lines (Aviagen Ltd., personal communication). The AMA data presented in this chapter 
therefore indicated a trend for the less potent AvBD1 peptides to be associated with better 
gut health.  The genetic and physiological determinants of bird gut performance are likely 
to be complex and are, therefore, unlikely to be driven by the activity of a single gut 
peptide. Nevertheless, Chapter 4 indicated that AvBD1 gene expression is at its highest 
immediately post hatch and it is possible that the increased potency of the NYH peptide 
may actually be disruptive in the early formation of the gut microbiota. Indeed, the NYH 
peptide was the most potent against LJ (Figure 6.9), a known gut probiotic organism. 
Thereby, it could be speculated that Line X birds may actually inhibit early Lactobacillus 
spp. colonisation, and, in doing so, expose the gut to other species that cause gut damage. 
Some support for this theory was shown by the Farm Trial 1 data which showed that the 
relative abundance of Lactobacillus spp. in the microbiome of Line X birds was only 10% 
compared to 40% in Line Y (Chapter 3; Figure 3.3).  
 
The properties which govern differences in anti-microbial potency between the AvBDs 
have yet to be fully elucidated. Interestingly, however, data from the AvBD1 studies 
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indicated that the single substitution of H (‘NYH’: Line X) to Y (‘NYY’: Line Z) 
dramatically reduced the anti-microbial effectiveness of the peptide against all bacterial 
species examined. As part of the initial bioinformatic investigations of the AvBDs, a 
number of positively selected sites (PSS), amino acid positions which mutate at a higher 
rate than would be expected under neutral evolution, were identified (Lynn et al., 2004). 
For AvBD1, positions corresponding to SNP 2 (Y/S) and SNP 3 (Y/H) were identified as 
PSS (Lynn et al., 2004), and the anti-microbial data from this study demonstrates that 
these sites are important in determining activity. The functional importance of these 
putative PSS was further demonstrated by another study, which engineered mutant forms 
of AvBD8 and assessed their antimicrobial potencies (Higgs et al., 2007). A comparison 
of two AvBD8 variants showed that substituting valine for arginine at a PSS in the C-
terminal of AvBD8 conferred a specific and potent activity against E. coli but not other 
bacteria, whereas an isoleucine to arginine substitution at a non-PSS position in the N-
terminal did not enhance activity against E. coli (Higgs et al., 2007). Both these AvBD8 
variants had the same charge (+2.7), as did the AvBD1 variants tested for this study (+7.7 
to +7.8), highlighting that the specific amino acid, which is present at a PSS and not 
necessarily the cationicity of the peptide, is important. Further support for the evolution 
of anti-microbial specificity comes from a study which identified a SNP 
(arginine/isoleucine), in the great-tit gene encoding AvBD7 (Hellgren et al., 2010). In 
Hellgren’s  study, the two SNP variants were both potent against E. coli, but only the 
isoleucine allelic form strongly inhibited S. aureus despite this peptide having lower 
charge (+3.7 versus +4.7) (Hellgren et al., 2010). In contrast the anti-microbial data 
detailed in this chapter indicated that changes in the AvBD1 SNPs do not direct killing 
activities against specific species, but instead alter the activity of the encoded peptides 
against a broad spectrum of bacteria. 
 
Two studies utilising GST-tagged AvBD peptides, have demonstrated the anti-microbial 
activity of chicken AvBD10, goose AvBD10 (82% amino acid homology) and quail 
AvBD10 (84% amino acid homology) (Wang et al., 2010,;Ma et al., 2012b). The anti-
microbial assay data for chicken AvBD10 from this study revealed bacterial inhibition 
against E. coli, E. faecalis, B. viscericola and L. johnsonii, although not complete 
bacterial killing; and no activity was detected against B. dorei using a radial diffusion 
assay. Interestingly, cecropin the positive control peptide also failed to produce a clearing 
zone, hinting that that Bacteroides spp. isolates may be more resistant to anti-microbial 
peptides than the other bacteria tested, and possibly linked to Bacteroides spp. functioning 
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as a gut commensals. When AvBD10 was compared to AvBD1 ‘NYH’ using an E. coli 
colony counting assay under low nutrient conditions (PBS), it was apparent that AvBD1 
had far higher anti-microbial activity than AvBD10 (Figure 6.18). Similarly under high 
nutrient conditions (10% LB media), AvBD10 was able to inhibit E. coli growth but even 
at the highest concentration utilised (10μM), AvBD10 could not induce the complete 
inhibition that was observed for all three AvBD1 variants (Figure 6.19). This suggests 
that the anti-bacterial mechanisms of AvBD1 and 10 are different with AvBD1 more 
appropriately classed as bactericidal and AvBD10 as bacteriostatic. Examination of the 
AvBD primary sequences reveals that AvBD10 alongside AvBD8, 12, and 14, do not 
contain a C- terminal tryptophan. It has been reported the tryptophan residues are 
important in membrane disruption due to their hydrophobic nature and human β-defensin-
3 studies have shown that replacing tryptophan residues can decrease the anti-microbial 
activity of the peptide (Kluver et al., 2005). Similar observations have been reported in 
relation to the antibiotic agent L-K6 (Bi et al., 2013). Thus, it is possible that AvBD1, in 
part due to its C terminal tryptophan, may be more able to disrupt the bacterial membrane 
than AvBD10. 
 
It is proposed that positive residues on AMPs are attracted to, and bind, negatively 
charged phospholipids present in bacterial cell walls and this initial binding is a crucial 
step prior to membrane disruption (Zasloff, 2002). Therefore, there is some support for 
the hypothesis that an increase in cationic charge increases antimicrobial potency 
(Bessalle et al., 1992; Matsuzaki et al., 1997; Higgs et al., 2007). AvBD8 shares 
similarities with AvBD10 in that it is expressed at high levels in liver and is a weakly 
charged peptide (Higgs et al., 2005). However, modified versions of the AvBD8 peptide 
in which two native amino acids (isoleucine and valine) are substituted for arginines not 
only confers an increased charge (+2.7 vs. +0.7), but is associated with improved bacterial 
killing relative to the original mature peptide (Higgs et al., 2007). These data support a 
role for cationicity as an important determinant of anti-microbial activity and, considering 
the charge discrepancies as outlined in Table 6.1, may be one of the key reasons for the 
AMA differences observed between AvBD1 ‘NYH’ and 10 (Figure 6.19). However, not 
all studies support this theory. For example, in geese, recombinant AvBD10 was shown 
to have higher bactericidal activity than both AvBD2 and AvBD5, which is perhaps 
surprising as, like in chicken, AvBD10 is a relatively uncharged peptide (Ma et al., 
2012b).  
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The large range of cationic charges found in the 14 AvBDs (Table 1.1) coupled to the 
differences in the location of expression (Table 1.3, pg 31) may help group the AvBDs 
into those which are more likely to have a primary role against bacterial invasion and 
those which primarily exert novel non-killing immune functions. In regards to sites of 
action outside of the gut, previous studies have indicated that AvBD1 does not appear to 
play a role in kidney and liver function (Table 1.3). Although this thesis did find 
expression levels in the kidney and liver that were similar to the gut tissues at Day 0, 
expression decreased significantly by Day 7 (Figure 4.7). Instead, AvBD1 expression was 
maintained in the caecal tonsil after 7 days (Figure 4.7), suggesting a role for modulating 
the innate immune response in the gut. This was supported by data from the current 
chapter which revealed that AvBD1 has potent activity against bacterial genera that are 
normally resident in the small intestine, namely Lactobacillus spp., and the large intestine, 
namely Bacteroides spp., whereas AvBD10 was only weakly bacteriocidal against these 
commensals. It is reasonable, therefore, to suggest that AvBD1 may be more important 
than AvBD10 in shaping the composition of the gut microbiota from hatch and protecting 
against harmful exogenous pathogens. In contrast to AvBD1, at hatch AvBD10 was 
expressed at far higher levels in the kidney and liver than in the gut and, unlike AvBD1, 
remained high throughout the sampling period (Figure 4.19). Due to this unusual 
expression pattern in tissues not usually in contact with bacteria, AvBD10 was assessed 
for cell proliferation and wound healing function. Although these results were 
inconclusive, further exploration of wound healing ability is warranted, particularly as 
studies have also shown that AvBD10 but not AvBD1 is expressed in chicken skin (Table 
1.3). Although this thesis has been  primarily concerned with gut health, skin-associated 
problems such as hock burn and pododermatitis are damaging to bird welfare (Buijs et 
al., 2009; Estevez, 2007) and as such, skin-expressed AvBDs such as 3, 9, 10 and 11 
(Table 1.3) may be potential targets to select for birds that are robust to skin problems.  
 
The majority of investigations into the novel properties of host defense peptides have 
focussed on the human beta-defensins and the cathelicidin hCAP-18/LL-37. Human beta-
defensins 1 – 4 have been shown, to varying degrees, to act as chemoattractants (Yang et 
al., 1999; Wu et al., 2003), up-regulators (Jin et al., 2010) and suppressors of pro-
inflammatory cytokines (Semple et al., 2010), and inducers of cell migration, and wound 
healing (Otte et al., 2008; Vongsa et al., 2009). Few studies have been undertaken in 
relation to the AvBDs though one study has shown that chemotaxis of B and T cell 
splenocytes is stimulated by duck AvBD2 (85% sequence homology to chicken) (Soman 
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et al., 2009a; Soman et al., 2009b). In this study cell proliferation was examined using 
Cell-Titre Blue assays but these failed to show any effects of either AvBD1 or 10 (Figure 
6.20). The positive control for this assay was human fibroblast growth factor (FGF) which 
shares 84% homology with chicken FGF. However, no significant effects of the positive 
control were observed perhaps suggesting human FGF is not specific to the CHCC-OU2 
cells. Cell proliferation, measured by BrDU incorporation, could not be demonstrated in 
human intestinal epithelial cells incubated with hBD2 (Otte et al., 2008), but the authors 
did show that hBD2 treatment enhanced HT-29 cell migration in an in vitro wound 
healing model. Figure 6.21 demonstrated that incubation of CHCC-OU2 cells with 
AvBD10 at 0.1nM resulted in higher mean wound healing than control wells at all 
imaging time-points, but this did not reach statistical significance. Nonetheless, the results 
shown in Figure 6.20 were tantalizing and these data probably justify further 
experimentation. The hBD2 study utilized concentrations of 1 and 5µg/ml, which 
correspond to 200nM and 1µM, so it is possible that the AvBD10 concentrations used, at 
0.1 – 1nM, were too dilute to support an effect. Yet as the data actually indicated that the 
lower concentrations of AvBD10 were inducing wound healing, it would probably be 
worthwhile to also examine wound healing at concentrations from 0.05nM to 1µM. Gut 
epithelial wound healing is likely to be an important facet in prevalent GI diseases such 
as necrotic enteritis and coccidiossis due their associated lesions. Therefore, it is possible 
that at damaged epithelial surfaces, AvBDs may serve dual functions, combining anti-
microbial activity and supporting wound healing. It has been demonstrated for hBD3 that 
an intact defensin secondary structure is important for its chemotaxis, compared to its 
antimicrobial, properties (Wu et al., 2003) and therefore, it is possible that a folded 
structure is important for wound healing. The recombinant AvBD10 produced in this 
study has not been confirmed as containing the cysteine-cysteine bonding typical of β-
defensins, which may also be required to observe an optimal effect.  
 
The data outlined in this chapter has shown that natural allelic variation within AvBD1 
can have a profound effect on the antimicrobial function of the encoded peptides, at least 
in vitro.  Although the potential in vivo effects of such peptides are difficult to quantify 
the variations are associated with genetic lines of birds that differ in their gut microbial 
colonization patterns and susceptibility to enteric disease, suggesting that the peptides 
may play a role in the establishment of the gut microbiota. In addition to differential tissue 
expression (Chapters 4 and 5), AvBD1 and 10, also exhibit different AMAs against gut 
bacterial isolates, with AvBD1 associated with bacterial killing compared to the 
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bacteriostatic properties of AvBD10. The charge and primary amino acid sequence of 
AvBD10, particularly the lack of a C-terminal tryptophan,  suggested other physiological 
functions for AvBD10, including wound healing, however these could not be confirmed 
in this study.  
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7  Final Discussion 
 
Bird health and hence welfare is a major focus for those involved in intensive poultry 
production and a particular concern is the increased incidence and impact of pathogenic 
diseases that affect the bird gastrointestinal tract. These diseases include coccidiosisis 
(Chapman, 2014), and necrotic enteritis (Timbermont et al., 2011), as well as the  less 
well-defined syndromes characterised by non-specific enteritis such as dysbacteriosis 
(Teirlynck et al., 2011) and malabsorption syndrome (Zekarias et al., 2005). Since 
prophylactic antibiotics in feed are now outlawed in the E.U., effective strategies to halt 
and/or reverse the prevalence of such syndromes are still lacking (Dibner and Richards, 
2005). Moreover the development of such strategies actually requires further knowledge 
and understanding of the bird gut defences. To help address this, the studies described in 
this thesis aimed to explore potential relationships between a specific bacterial challenge, 
the gut innate AvBD response and gut health in two commercial poultry Lines, X and Y.  
 
The deterioration in gut health described in the trials reported in Chapters 3 and 4 was 
facilitated by exposing birds to two bacterial species, namely Bacteroides dorei (BD) and 
Barnesiella viscericola (BV), isolated from birds suffering ‘dysbacteriosis’. For both 
Trials 1 and 2 the patterns of gut health deterioration were consistent with the highest gut 
health scores i.e. the worst gut health, characterized by increased watery gut contents and 
gut thinning (poor tone), observed in older birds. These clinical symptoms were typical 
of the syndrome ‘dysbacteriosis’ (Teirlynck et al., 2011), which is associated with shifts 
in the microbiome and small intestinal microbial overgrowth (Bailey, 2010). In support, 
jejunal gut scrape data from both farm trials illustrated a trend for gut scrapes from birds 
with abnormal gut health to support higher in vitro bacterial growth. These data provided 
further evidence that the poor gut health was a ‘dysbacteriosis-like’ condition 
characterised by intestinal microbial over-growth.  
 
Trial 1 attempted to explore if actual shifts in the gut microbiota were associated with the 
‘dysbacteriosis’ phenotype. To achieve this Line X and Y birds were challenged with 
either B/BV, Lactobacillus johnsonii (LJ) or a mix (B/BV + LJ), and gut health 
assessments performed.  As discussed, the B/BV challenged birds had worse gut health, 
while the LJ challenged birds exhibited better gut health, than the water control birds and 
this was consistent for both lines, X and Y. Lactobacillus spp., such as LJ, function as 
probiotics and have been investigated in vivo for their potential immunomodulatory 
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properties in preventing enteric disease (Nava et al., 2005). Samples from the bird trials 
were not assessed for inflammatory markers but the in vitro challenge model, using 
CHCC-OU2 cells, demonstrated that Bacteroides dorei induced significantly higher pro-
inflammatory cytokine expression than LJ. If these findings were replicated in vivo in the 
newly-hatched chicks, then it could be argued that the B/BV challenged birds suffered 
more inflammation induced damaged or an up-surge in inflammation that was not 
properly resolved, resulting in a persistent inflammatory state. Yet despite the challenges 
clearly affecting gut health directly, this was not reflected by the ‘global’ caecal and ileal 
microbiome data as no consistent shifts in measurable microbial species were revealed. 
However, the studies did reveal that the age of the bird at which Bacteroides spp. 
predominate in the caeca may be an important factor in gut health; indeed, high 
abundances of Bacteroides spp. were associated with better gut health in older birds (3 - 
4 week old) and worse gut health in young birds (4-days old). These data suggest that 
Bacteroides spp. can exert both beneficial and damaging effects that appear dependent on 
the maturity of the gut. Traditionally, B and BV spp. are considered as gut commensals, 
but observations made during the studies reported in this thesis, indicate that in young 
birds they can function as opportunistic pathogens. Hence it can be argued that the 
hierarchy of gut colonisation is important and exposure of very young birds to high 
numbers of a particular bacterial species including B & BV, through environmental 
exposure including litter and/or drinking water, may impact negatively on the epithelial 
defences and hence the physiology of the bird gut.  Aside from the microbiome data, it 
was interesting to note that there were clear differences in galactose content in the gut 
scrapes of the X and Y bird lines, with galactose associated particularly with  the Line X 
mucosa of young birds (4 day-old). The origin of the galactose was presumably the grain 
based diet, fed to both lines, and although no further investigative analyses were 
performed to help explain these observations, future studies could explore the gut sugar 
content in the digesta in relation to gut epithelial transport mechanisms, the gut microbiota 
and gut health.  
 
Line X birds are an important part of the Aviagen Ltd. breeding programme but compared 
to some of the other commercial breeding lines there was a perceived issue of sub-optimal 
gut health (Aviagen Ltd.). In Trial 1, the use of a simple gut health scoring system, 
developed by Aviagen Ltd. enabled the perceived differences in gut health between Lines 
X and Y, to be quantitated, and the data confirmed that Line X birds had an increased 
susceptibility to gut health deterioration, particularly following challenge with B/BV. 
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Therefore, Trial 1 indicated the importance of bird genetics in the immune response to 
environmental, and particularly, a B/BV weighted challenge. Line X birds can be 
considered a ‘dybacteriosis’-susceptible line whereas Line Y is not. In a mouse model of 
inflammatory bowel disease it was shown that gavage with Bacteroides spp. induced 
significant pathology in genetically-susceptible mice, but had no effect in non-susceptible 
mice (Bloom et al., 2011). Interestingly, challenge with Enterobacteriaceae, which are 
usually enriched in IBD, produced no pathology in either of the mice genotypes despite 
colonising the hind gut. Therefore, Bloom et al., (2011) have shown that the host-response 
to specific species such as Bacteroides is governed by genotype, which is critical in 
inducing the diseased state, rather than an altered susceptibility to colonisation of IBD 
enriched-species.  Similarly, the microbiome data presented in Chapter 3 did not indicate 
large shifts in the microbiome between Line X and Y and Bacteroides spp. colonisation 
was found at some stage following challenge in both lines. Perhaps then, Bacteroides spp. 
is neither intrinsically ‘bad’ or ‘good’ and induces a different response dependent on 
whether the gut colonisation occurs in Line X and Y birds. Interestingly, the IBD-
susceptible mice utilised in the study by Bloom et al. (2011), had defects in TGF-β and 
IL-10 signalling and further studies are required to ascertain if such disparities in 
expression and signalling pathways are also found in Line X and Y birds.   
 
To further explore the innate immune response in the Line X birds, Trial 2 was performed 
(Chapter 4) to evaluate gut AvBD gene expression, a reflection of the innate defences, in 
these birds following BD/BV challenge. While admittedly the gut AvBD expression 
values within sampled groups were variable, bird age was shown to be important in AvBD 
expression with high constitutive levels detected immediately following hatch, supporting 
the importance of the encoded peptides in the innate protection of the gut. In the 7 day-
old birds however, AvBD1 expression was consistently lower in the B/BV challenged 
group than the control, indicating that B/BV species caused AvBD down-regulation, and 
hence exposed the gut to microbial associated damage. These in vivo findings were 
supported by the in vitro data that supported down-regulation of AvBD1 expression in 
response to a B/BV challenge even at a low multiplicity of infection (MOI < 1). To 
ascertain if this AvBD suppression was associated with gut health status, further analyses 
were performed. Birds with inflamed guts had, on average, lower AvBD1 and 10 
expression than healthy birds and, crucially, ranking the challenged birds for expression 
in each GI tissue revealed that birds that were able to maintain relatively high AvBD1 
expression, despite B/BV challenge, exhibited better gut health than birds with low 
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expression. In contrast to AvBD1, no conclusive link between AvBD10 and gut health 
could be confirmed. None-the-less in vivo data from this study showed that AvBD10 is 
present throughout the GI tract of Line X birds and is also subject to regulation via 
bacterial challenge, and therefore, presumably plays a role in the gut defences.  
 
It is acknowledged that this project focussed on AvBD1 and 10 expression, and analyses 
of other defensins needs to be performed to provide information on whether all or just a 
selection of the responses can be linked to bird gut health. A potential aim is to use AvBD 
expression as a biomarker to predict bird gut health. However, an obvious limitation of 
using AvBD tissue expression as a ‘predictive gut health biomarker’ is that the analyses 
requires tissue and hence bird sacrifice, which means individual birds, particularly those 
with extremely high constitutive expression at hatch, cannot be followed longitudinally 
i.e. throughout their life-span. However, AvBD expression in peripheral blood leukocytes 
(PBLs) has been shown to be responsive to oral challenges with S. typhimurium and C. 
jejuni (Meade et al., 2009b). If, therefore, AvBD expression in PBLs from individual 
birds following B/BV challenge links to gut health, this would allow individual birds to 
be followed from hatch to slaughter. Such studies are yet to be performed.  
 
Overall these data strongly suggested that in birds with relatively high AvBD expression, 
the innate defences were functioning and were able to respond and control the microbial 
challenge, which helped to protect the GI tract from microbial assault. The link between 
innate immune gene expression and resistance to gut pathogens has already been 
demonstrated by recognition of Salmonella-resistant bird lines that exhibit increased 
AvBD (Derache et al., 2009a) and cytokine/chemokine levels (Swaggerty et al., 2009). 
Moreover, this knowledge has been utilised in a small-scale breeding trial that produced 
progeny with enhanced expression of pro-inflammatory mediators (IL-6, CXCLi2, and 
CCLi2), that have improved resistance to Salmonella spp. colonisation (Swaggerty et al., 
2014).  It should be possible, therefore, to identify individual birds with higher than 
average constitutive AvBD expression, and through knowledge of parental breeding 
stocks begin to genetically selected for birds with a ‘dysbacteriosis’-resistant phenotype. 
However, as an alternative to genetic selection, improving the GI health status of broiler 
flocks may be possible by boosting endogenous AvBD expression through, for example, 
using butyrate-supplemented feed (Sunkara et al., 2011) or by adding AMPs directly to 
feed (van Dijk et al., 2011). Realistically, the large-scale routine use of chicken AMPs 
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such as the AvBDs and cathelicidins is likely to be limited by production costs, although 
pilot scale bacterial fermentation methods are being developed (Bommarius et al., 2010). 
 
Chapter 6 outlined the small scale production of recombinant AvBD10 which revealed 
that AvBD10 had antimicrobial activity against an array of chicken gut isolates, except 
interestingly Bacteroides spp., which again may help explain the success of Bacteroides 
as an opportunistic pathogen in young birds. Previous work had identified the presence 
of three coding SNPs in the AvBD1 gene and based on the prevalence of these alleles in 
Line X, Y and a further line with robust gut health, Z, three variants of AvBD1 peptide 
were synthesised. The ‘NYH’ (Line X) peptide was, consistently, the most potent form 
against all the gut bacterial isolates tested in vitro. Although in vivo the effects of the 
expressed ‘NYH’ peptide are unknown, one could postulate that its increased AMA could 
in fact impact on and alter the gut microbiota. Interestingly it has been shown that the 
introduction of human alpha-defensin HD5 into the mouse gut alters the microbiota 
resulting in losses of Firmicutes such as Clostridia, Bacilli and segmented filamentous 
bacteria, and increases in Bacteroidetes (Salzman et al., 2010).  In addition to anti-
microbial properties, AvBD10, due to its elevated gene expression in kidney and liver 
tissues, was investigated for novel physiological functions, not associated with bacterial-
host interactions. Preliminary experimental data hinted at AvBD10 involvement in wound 
healing, as has been shown for human β-defensin 2 (hBD2) (Otte et al., 2008) and hBD3 
(Kiatsurayanon et al., 2014), but confirmation necessitates further experiments utilising 
higher concentrations of defensin peptide.  
 
As set out in the aims of this thesis, the data has demonstrated that bacterial challenges 
can be both beneficial (LJ) and detrimental to gut health (B/BV). Furthermore, gut health 
outcome following bacterial exposure has been shown to be strongly influenced by host 
genetics particularly in the response to the initial B/BV challenge and possibly the 
subsequent immune-tolerance of such species during gut colonisation. Within the 
‘dysbacteriosis’-susceptible line (Line X), high AvBD expression was shown to be 
associated with better gut health supporting the inclusion of the innate immune genes as 
part of the selective breeding process. Future work will evaluate the expression of the 
remaining AvBDs throughout the GI tract and confirm the association with gut health. 
The opportunity of identifying birds with uniquely high GI AvBD expression is of 
commercial interest to poultry breeders such as Aviagen Ltd. as such birds may have huge 
potential as candidates to select for a healthy gut phenotype. 
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Appendix A 
 
 
 
 
 
Gut Health Assessment Guide 
 
The aim of this guide is to provide a quick and simple method of assessing gut health in the 
field without the need for any in depth analyses. The basic principle is to assess the tone of 
the gut wall, the colour of the gut surface and the consistency of the contents. By 
characterising these aspects of the gut at different ages of bird one can judge how well the 
gut is developing and whether it is under any challenge. The scoring system is based on a 
scale of 0, 1 and 2 where ‘0’ is normal, ‘1’ is mildly abnormal and ‘2’ is severely abnormal. 
 
Gut Tone 
 
In normal circumstances when the gut wall is cut into the tissues will fold back 
immediately onto themselves to form rolls. 
 
Score 0  
On cutting into the gut the walls immediately curl back 
 
 
 
 
 
 
Curling back 
 of gut wall 
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Score 1 
 
The gut curls back on itself as above but it does not occur immediately and there is 
a delay (more than 2 seconds) in the wall moving. 
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Score 2  
The gut wall fails to curl back on itself 
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Failure of gut 
wall to fold 
back on itself 
 
Colour of the gut surface (Redness) 
 
Score 0  
In normal circumstances the gut wall should be a pale pink colour. 
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Gut surface 
is pale pink 
colour 
 
 
 
 
 
 
 
 
 
 
 
Bailey 2012 
 
Dr Richard A. Bailey 2012 
 
260 
 
 
  
Score 1 
 
This indicates a mild irritation/inflammation in the gut. This is characterised by the 
surface of the gut wall having a deeper pink colour. 
 
 
 
 
 
Gut surface is a 
deeper pink colour 
with patches of 
darker pink 
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Score 2  
Gut surface is a very dark pink or red colour indicating severe inflammation. 
 
 
 
 
 
 
Severe reddening 
of gut surface 
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Consistency of contents (Watery contents) 
 
Score 0 
 
In normal circumstances as the digesta passes through the gut water is absorbed 
resulting in a faecal pellet. Thus in each region of gut the consistency should be different 
with the duodenum being the wettest and the ileum being the driest – the key point here 
is that the contents at each region should be homogenous in consistency. 
 
 
 
 
 
 
Duodenum normally 
the contents should be 
like watery porridge 
but uniform 
 
 
 
Jejunal contents should 
be drier than the 
duodenal contents 
getting darker in colour 
 
 
 
Contents at the start of 
the ileum should be 
drier and darker than 
the jejunal contents 
with a faecal like bolus 
forming towards the 
end of the ileum 
 
Bailey 2012 
 
On cutting into the duodenum it is normal for the contents to spill out however in the 
jejunum and ileum the contents should generally hold together when you cut into the gut. 
 
 
Score 1 
 
When cutting into the gut if the contents that are present are not uniform in consistency, 
i.e. a separation of water and solids, then it implies that the contents are abnormal. 
 
 
 
 
 
 
 
 
 
 
Dr Richard A. Bailey 2012 
 
262 
 
 
  
 
 
 
 
 
 
 
 
Duodenum showing a 
solid fraction and a water 
fraction 
 
 
 
Jejunal contents 
leaking out with a mix 
of water and solids 
 
 
 
Ileal contents are 
glistening with moisture 
 
 
 
Bolus starting to form 
towards the end of the 
ileum but contents still 
quite soft. 
 
 
 
 
Bailey 2012 
 
 
Score 2 
 
This is when on cutting into the small intestine there is predominately fluid and very little 
solid present which leaks out straight away. In the lower ileum the contents are 
generally very soft with little bolus formation. 
 
Lots of fluid 
which leaks out 
on cutting – very 
little solid 
content with no 
bolus formation 
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Mucus production 
 
Mucus production in the gut is a normal phenomenon as it aids the passage of food 
through the intestine and forms a protective barrier on the mucosal surface. However in 
cases of infection and irritation excess mucus can be produced. As a rule of thumb if you 
can easily see mucus on the gut surface then it is excessive production. 
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Caecal Health 
 
The caeca should contain a dark viscous material with no gas bubbles. Normal caecal contents 
will generally slowly ooze out of a cut in the caecal wall. During an enteric upset it is common for 
the caecal contents to become watery, light in colour and contain gas bubbles. During a caecal 
upset when the caecal wall is cut the contents will empty very quickly 
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Normal Abnormal  
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Other gut lesions/issues 
 
Gizzard erosion 
 
The inner surface of the gizzard should be continuous with no breaks. In case of gizzard 
erosion clear breaks can be seen: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mark on the form a Yes or No if they are present 
 
Coccidiosis  
Lesions can be seen in the small intestine or the caeca. Make a note if any lesions 
seen and where. 
 
Feed passage 
 
The ingesta in the ileum and colon should not contain any whole feed. If present 
record on form. 
 
 
 
 
Feed passage 
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Appendix B 
 
Vaccination protocols for chicks at the Aviagen, sib-testing farm, Scotland, U.K. 
 
Name of 
vaccine 
Age 
administered 
(days) 
Disease  Manufacturer 
Paracox 5 0 coccidiosis Intervet,Schering 
Plough Animal 
Health 
Corporation 
Bursine 2 18/19 Infectious 
Bursal Disease 
Fort Dodge 
MA5 
 
22 Infectious 
bronchitis   
Intervet, 
Schering Plough 
Animal Health 
Corporation 
HB1 22 Newcastle 
Disease 
Lohmann Animal 
Health 
 
 
 
 
 
 
 
 
 
 
